{
  "doc_id": "6",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "糖尿病肾病防治专家共识(2014年版)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病肾病防治专家共识(2014年版)",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            }
          ],
          "sentence_en": "Expert consensus on the prevention and treatment of diabetic nephropathy (2014 edition)"
        }
      ],
      "paragraph_en": "Expert consensus on the prevention and treatment of diabetic nephropathy (2014 edition)"
    },
    {
      "paragraph_id": "1",
      "paragraph": "糖尿病肾病是糖尿病最主要的微血管并发症之一，是目前引起终末期肾病(end-stage renal disease，ESRD)的首要原因。国外研究资料显示，20年以上病程的糖尿病肾病患者发展为ESRD的发生率为40.8/1000人年，需要进行透析或移植等肾脏替代治疗。我国糖尿病肾病的患病率亦呈快速增长趋势，2009至2012年我国2型糖尿病患者的糖尿病肾病患病率在社区患者中为30%~50%，在住院患者中为40%左右。糖尿病肾病起病隐匿，一旦进入大量蛋白尿期后，进展至ESRD的速度大约为其他肾脏病变的14倍，因此早期诊断、预防与延缓糖尿病肾病的发生发展对提高糖尿病患者存活率，改善其生活质量具有重要意义。为规范糖尿病肾病的诊断和治疗，中华医学会糖尿病学分会微血管并发症学组组织国内的内分泌和肾内科领域专家共同制定本共识。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病肾病是糖尿病最主要的微血管并发症之一，是目前引起终末期肾病(end-stage renal disease，ESRD)的首要原因。国外研究资料显示，20年以上病程的糖尿病肾病患者发展为ESRD的发生率为40.8/1000人年，需要进行透析或移植等肾脏替代治疗。我国糖尿病肾病的患病率亦呈快速增长趋势，2009至2012年我国2型糖尿病患者的糖尿病肾病患病率在社区患者中为30%~50%，在住院患者中为40%左右。糖尿病肾病起病隐匿，一旦进入大量蛋白尿期后，进展至ESRD的速度大约为其他肾脏病变的14倍，因此早期诊断、预防与延缓糖尿病肾病的发生发展对提高糖尿病患者存活率，改善其生活质量具有重要意义。为规范糖尿病肾病的诊断和治疗，中华医学会糖尿病学分会微血管并发症学组组织国内的内分泌和肾内科领域专家共同制定本共识。",
          "start_idx": 0,
          "end_idx": 361,
          "entities": [
            {
              "entity_id": "T2",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T3",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T4",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T5",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T6",
              "entity": "终末期肾病(end-stage renal disease，ESRD)",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 62,
              "entity_en": "End-stage renal disease (ESRD)"
            },
            {
              "entity_id": "T7",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T8",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 30,
              "end_idx": 31,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T9",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T10",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 89,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T11",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "ESRD"
            },
            {
              "entity_id": "T12",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 120,
              "end_idx": 122,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T13",
              "entity": "移植",
              "entity_type": "Operation",
              "start_idx": 123,
              "end_idx": 125,
              "entity_en": "transplant"
            },
            {
              "entity_id": "T14",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 140,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T15",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 138,
              "end_idx": 139,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T16",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 165,
              "end_idx": 170,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T17",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 165,
              "end_idx": 167,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T18",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 178,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T19",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 176,
              "end_idx": 177,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T20",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 209,
              "end_idx": 214,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T21",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 212,
              "end_idx": 213,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T22",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 234,
              "end_idx": 238,
              "entity_en": "ESRD"
            },
            {
              "entity_id": "T23",
              "entity": "肾脏病变",
              "entity_type": "Disease",
              "start_idx": 246,
              "end_idx": 250,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T24",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 246,
              "end_idx": 248,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T25",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 267,
              "end_idx": 272,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T26",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 270,
              "end_idx": 271,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T27",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 280,
              "end_idx": 283,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T28",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 306,
              "end_idx": 311,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T29",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 309,
              "end_idx": 310,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T30",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 323,
              "end_idx": 326,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T31",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 329,
              "end_idx": 332,
              "entity_en": "Microvascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T3",
              "tail_entity_id": "T2"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R2",
              "head_entity_id": "T5",
              "tail_entity_id": "T4"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T7",
              "tail_entity_id": "T6"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R4",
              "head_entity_id": "T8",
              "tail_entity_id": "T6"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R5",
              "head_entity_id": "T10",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R6",
              "head_entity_id": "T12",
              "tail_entity_id": "T11"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R7",
              "head_entity_id": "T13",
              "tail_entity_id": "T11"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R8",
              "head_entity_id": "T15",
              "tail_entity_id": "T14"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T17",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R10",
              "head_entity_id": "T19",
              "tail_entity_id": "T18"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R11",
              "head_entity_id": "T21",
              "tail_entity_id": "T20"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R12",
              "head_entity_id": "T24",
              "tail_entity_id": "T23"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R13",
              "head_entity_id": "T26",
              "tail_entity_id": "T25"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R14",
              "head_entity_id": "T29",
              "tail_entity_id": "T28"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R15",
              "head_entity_id": "T31",
              "tail_entity_id": "T30"
            }
          ],
          "sentence_en": "Diabetic nephropathy is one of the most important microvascular complications of diabetes and is currently the leading cause of end-stage renal disease (ESRD). Foreign research data show that the incidence of ESRD in patients with diabetic nephropathy for more than 20 years is 40.8/1000 person-years, requiring renal replacement therapy such as dialysis or transplantation. The prevalence of diabetic nephropathy in my country is also increasing rapidly. From 2009 to 2012, the prevalence of diabetic nephropathy in patients with type 2 diabetes in my country was 30% to 50% in community patients and about 40% in hospitalized patients. Diabetic nephropathy has an insidious onset. Once it enters the massive proteinuria stage, the rate of progression to ESRD is about 14 times that of other renal diseases. Therefore, early diagnosis, prevention and delay of the occurrence and development of diabetic nephropathy are of great significance to improving the survival rate of diabetic patients and their quality of life. In order to standardize the diagnosis and treatment of diabetic nephropathy, the Microvascular Complications Group of the Diabetes Branch of the Chinese Medical Association organized domestic experts in the fields of endocrinology and nephrology to jointly formulate this consensus."
        }
      ],
      "paragraph_en": "Diabetic nephropathy is one of the most important microvascular complications of diabetes and is currently the leading cause of end-stage renal disease (ESRD). Foreign research data show that the incidence of ESRD in patients with diabetic nephropathy for more than 20 years is 40.8/1000 person-years, requiring renal replacement therapy such as dialysis or transplantation. The prevalence of diabetic nephropathy in my country is also increasing rapidly. From 2009 to 2012, the prevalence of diabetic nephropathy in patients with type 2 diabetes in my country was 30% to 50% in community patients and about 40% in hospitalized patients. Diabetic nephropathy has an insidious onset. Once it enters the massive proteinuria stage, the rate of progression to ESRD is about 14 times that of other renal diseases. Therefore, early diagnosis, prevention and delay of the occurrence and development of diabetic nephropathy are of great significance to improving the survival rate of diabetic patients and their quality of life. In order to standardize the diagnosis and treatment of diabetic nephropathy, the Microvascular Complications Group of the Diabetes Branch of the Chinese Medical Association organized domestic experts in the fields of endocrinology and nephrology to jointly formulate this consensus."
    },
    {
      "paragraph_id": "2",
      "paragraph": "一、糖尿病肾病的定义与诊断",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、糖尿病肾病的定义与诊断",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T32",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T33",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 6,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R16",
              "head_entity_id": "T33",
              "tail_entity_id": "T32"
            }
          ],
          "sentence_en": "1. Definition and diagnosis of diabetic nephropathy"
        }
      ],
      "paragraph_en": "1. Definition and diagnosis of diabetic nephropathy"
    },
    {
      "paragraph_id": "3",
      "paragraph": "糖尿病肾病是由糖尿病引起的肾脏损伤，以往用DN(diabetic nephropathy)表示，2007年美国肾脏病基金会(NKF)制定了肾脏病生存质量指导指南，简称NKF/KDOQI。该指南建议用DKD(diabetic kidney disease)取代DN。2014年美国糖尿病协会(ADA)与NKF达成共识，认为DKD是指由糖尿病引起的慢性肾病，主要包括肾小球滤过率(GFR)低于60ml·min-1·1.73m-2或尿白蛋白/肌酐比值(ACR)高于30mg/g持续超过3个月。糖尿病性肾小球肾病(diabetic glomerulopathy)专指经肾脏活检证实的由糖尿病引起的肾小球病变。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病肾病是由糖尿病引起的肾脏损伤，以往用DN(diabetic nephropathy)表示，2007年美国肾脏病基金会(NKF)制定了肾脏病生存质量指导指南，简称NKF/KDOQI。该指南建议用DKD(diabetic kidney disease)取代DN。2014年美国糖尿病协会(ADA)与NKF达成共识，认为DKD是指由糖尿病引起的慢性肾病，主要包括肾小球滤过率(GFR)低于60ml·min-1·1.73m-2或尿白蛋白/肌酐比值(ACR)高于30mg/g持续超过3个月。糖尿病性肾小球肾病(diabetic glomerulopathy)专指经肾脏活检证实的由糖尿病引起的肾小球病变。",
          "start_idx": 0,
          "end_idx": 300,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T35",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T36",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T37",
              "entity": "肾脏损伤",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Kidney damage"
            },
            {
              "entity_id": "T38",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T39",
              "entity": "DN(diabetic nephropathy)",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 45,
              "entity_en": "DN (diabetic nephropathy)"
            },
            {
              "entity_id": "T40",
              "entity": "肾脏病",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 72,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T41",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 71,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T42",
              "entity": "DKD(diabetic kidney disease)",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 127,
              "entity_en": "DKD (diabetic kidney disease)"
            },
            {
              "entity_id": "T43",
              "entity": "DN",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 131,
              "entity_en": "DN"
            },
            {
              "entity_id": "T44",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 142,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T45",
              "entity": "DKD",
              "entity_type": "Disease",
              "start_idx": 160,
              "end_idx": 163,
              "entity_en": "DKD"
            },
            {
              "entity_id": "T46",
              "entity": "糖尿病",
              "entity_type": "Reason",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T47",
              "entity": "慢性肾病",
              "entity_type": "Disease",
              "start_idx": 172,
              "end_idx": 176,
              "entity_en": "Chronic kidney disease"
            },
            {
              "entity_id": "T48",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 172,
              "end_idx": 174,
              "entity_en": "Chronic"
            },
            {
              "entity_id": "T49",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 174,
              "end_idx": 175,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T50",
              "entity": "肾小球滤过率(GFR)",
              "entity_type": "Test_items",
              "start_idx": 181,
              "end_idx": 192,
              "entity_en": "Glomerular filtration rate (GFR)"
            },
            {
              "entity_id": "T51",
              "entity": "低于60ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 192,
              "end_idx": 212,
              "entity_en": "Less than 60ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T52",
              "entity": "尿白蛋白/肌酐比值(ACR)",
              "entity_type": "Test_items",
              "start_idx": 213,
              "end_idx": 227,
              "entity_en": "Urine albumin/creatinine ratio (ACR)"
            },
            {
              "entity_id": "T53",
              "entity": "高于30mg/g",
              "entity_type": "Test_Value",
              "start_idx": 227,
              "end_idx": 235,
              "entity_en": "Higher than 30mg/g"
            },
            {
              "entity_id": "T54",
              "entity": "糖尿病性肾小球肾病(diabetic glomerulopathy)",
              "entity_type": "Disease",
              "start_idx": 243,
              "end_idx": 277,
              "entity_en": "Diabetic glomerulopathy"
            },
            {
              "entity_id": "T55",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 247,
              "end_idx": 250,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T56",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 250,
              "end_idx": 251,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T57",
              "entity": "糖尿病",
              "entity_type": "Reason",
              "start_idx": 288,
              "end_idx": 291,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T58",
              "entity": "肾小球病变",
              "entity_type": "Disease",
              "start_idx": 294,
              "end_idx": 299,
              "entity_en": "Glomerular lesions"
            },
            {
              "entity_id": "T59",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 294,
              "end_idx": 297,
              "entity_en": "Glomerulus"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R17",
              "head_entity_id": "T35",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R18",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R19",
              "head_entity_id": "T41",
              "tail_entity_id": "T40"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R20",
              "head_entity_id": "T46",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R21",
              "head_entity_id": "T50",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R22",
              "head_entity_id": "T52",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R23",
              "head_entity_id": "T48",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R24",
              "head_entity_id": "T49",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R25",
              "head_entity_id": "T55",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R26",
              "head_entity_id": "T56",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R27",
              "head_entity_id": "T57",
              "tail_entity_id": "T58"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R28",
              "head_entity_id": "T59",
              "tail_entity_id": "T58"
            }
          ],
          "sentence_en": "Diabetic nephropathy is kidney damage caused by diabetes. It was previously represented by DN (diabetic nephropathy). In 2007, the National Kidney Foundation (NKF) developed a guideline for quality of life in kidney disease, referred to as NKF/KDOQI. The guideline recommends replacing DN with DKD (diabetic kidney disease). In 2014, the American Diabetes Association (ADA) and NKF reached a consensus that DKD refers to chronic kidney disease caused by diabetes, mainly including a glomerular filtration rate (GFR) lower than 60ml·min-1·1.73m-2 or a urine albumin/creatinine ratio (ACR) higher than 30mg/g for more than 3 months. Diabetic glomerulopathy refers specifically to glomerular lesions caused by diabetes confirmed by kidney biopsy."
        }
      ],
      "paragraph_en": "Diabetic nephropathy is kidney damage caused by diabetes. It was previously represented by DN (diabetic nephropathy). In 2007, the National Kidney Foundation (NKF) developed a guideline for quality of life in kidney disease, referred to as NKF/KDOQI. The guideline recommends replacing DN with DKD (diabetic kidney disease). In 2014, the American Diabetes Association (ADA) and NKF reached a consensus that DKD refers to chronic kidney disease caused by diabetes, mainly including a glomerular filtration rate (GFR) lower than 60ml·min-1·1.73m-2 or a urine albumin/creatinine ratio (ACR) higher than 30mg/g for more than 3 months. Diabetic glomerulopathy refers specifically to glomerular lesions caused by diabetes confirmed by kidney biopsy."
    },
    {
      "paragraph_id": "4",
      "paragraph": "糖尿病肾病的诊断分为病理诊断和临床诊断。肾脏病理被认为是诊断金标准。糖尿病主要引起肾小球病变，表现为肾小球系膜增生、基底膜增厚和K-W(Kimmelstiel-Wilson)结节等，是病理诊断的主要依据。糖尿病还可引起肾小管间质、肾微血管病变，如肾间质纤维化、肾小管萎缩、出球动脉透明变性或肾微血管硬化等，这些改变亦可由其他病因引起，在诊断时仅作为辅助指标。目前糖尿病肾病临床诊断的依据有尿白蛋白和糖尿病视网膜病变。糖尿病肾病早期可表现为尿白蛋白阴性，症状不明显，易被忽略，但目前仍缺乏比尿微量白蛋白更可靠敏感的糖尿病肾病早期检测指标。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病肾病的诊断分为病理诊断和临床诊断。肾脏病理被认为是诊断金标准。糖尿病主要引起肾小球病变，表现为肾小球系膜增生、基底膜增厚和K-W(Kimmelstiel-Wilson)结节等，是病理诊断的主要依据。糖尿病还可引起肾小管间质、肾微血管病变，如肾间质纤维化、肾小管萎缩、出球动脉透明变性或肾微血管硬化等，这些改变亦可由其他病因引起，在诊断时仅作为辅助指标。目前糖尿病肾病临床诊断的依据有尿白蛋白和糖尿病视网膜病变。糖尿病肾病早期可表现为尿白蛋白阴性，症状不明显，易被忽略，但目前仍缺乏比尿微量白蛋白更可靠敏感的糖尿病肾病早期检测指标。",
          "start_idx": 0,
          "end_idx": 268,
          "entities": [
            {
              "entity_id": "T60",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T61",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T62",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T63",
              "entity": "肾小球病变",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "Glomerular lesions"
            },
            {
              "entity_id": "T64",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 41,
              "end_idx": 44,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T65",
              "entity": "肾小球系膜增生",
              "entity_type": "Pathogenesis",
              "start_idx": 50,
              "end_idx": 57,
              "entity_en": "Glomerular mesangial proliferation"
            },
            {
              "entity_id": "T66",
              "entity": "基底膜增厚",
              "entity_type": "Pathogenesis",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Basement membrane thickening"
            },
            {
              "entity_id": "T67",
              "entity": "K-W(Kimmelstiel-Wilson)结节",
              "entity_type": "Pathogenesis",
              "start_idx": 64,
              "end_idx": 89,
              "entity_en": "K-W (Kimmelstiel-Wilson) nodules"
            },
            {
              "entity_id": "T68",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 181,
              "end_idx": 186,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T69",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 185,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T70",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 194,
              "end_idx": 198,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T71",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 199,
              "end_idx": 207,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T72",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 202,
              "end_idx": 205,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T73",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 208,
              "end_idx": 213,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T74",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 211,
              "end_idx": 212,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T75",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 219,
              "end_idx": 223,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T76",
              "entity": "阴性",
              "entity_type": "Test_Value",
              "start_idx": 223,
              "end_idx": 225,
              "entity_en": "Negative"
            },
            {
              "entity_id": "T77",
              "entity": "尿微量白蛋白",
              "entity_type": "Test_items",
              "start_idx": 244,
              "end_idx": 250,
              "entity_en": "Urine microalbumin"
            },
            {
              "entity_id": "T78",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 256,
              "end_idx": 261,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T79",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 259,
              "end_idx": 260,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T80",
              "entity": "糖尿病",
              "entity_type": "Reason",
              "start_idx": 102,
              "end_idx": 105,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T81",
              "entity": "肾小管间质、肾微血管病变",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 121,
              "entity_en": "Tubulointerstitial and renal microvascular diseases"
            },
            {
              "entity_id": "T82",
              "entity": "肾微血管",
              "entity_type": "Anatomy",
              "start_idx": 115,
              "end_idx": 119,
              "entity_en": "Renal microvessels"
            },
            {
              "entity_id": "T83",
              "entity": "肾间质纤维化",
              "entity_type": "Disease",
              "start_idx": 123,
              "end_idx": 129,
              "entity_en": "Renal interstitial fibrosis"
            },
            {
              "entity_id": "T84",
              "entity": "肾小管萎缩",
              "entity_type": "Disease",
              "start_idx": 130,
              "end_idx": 135,
              "entity_en": "Tubular atrophy"
            },
            {
              "entity_id": "T85",
              "entity": "肾小管",
              "entity_type": "Anatomy",
              "start_idx": 130,
              "end_idx": 133,
              "entity_en": "Renal tubules"
            },
            {
              "entity_id": "T86",
              "entity": "肾间质",
              "entity_type": "Anatomy",
              "start_idx": 123,
              "end_idx": 126,
              "entity_en": "Renal interstitium"
            },
            {
              "entity_id": "T87",
              "entity": "肾小管间质",
              "entity_type": "Anatomy",
              "start_idx": 109,
              "end_idx": 114,
              "entity_en": "Tubulointerstitium"
            },
            {
              "entity_id": "T88",
              "entity": "出球动脉透明变性",
              "entity_type": "Disease",
              "start_idx": 136,
              "end_idx": 144,
              "entity_en": "Hyalinization of afferent artery"
            },
            {
              "entity_id": "T89",
              "entity": "肾微血管硬化",
              "entity_type": "Disease",
              "start_idx": 145,
              "end_idx": 151,
              "entity_en": "Renal microvascular sclerosis"
            },
            {
              "entity_id": "T90",
              "entity": "肾微血管",
              "entity_type": "Anatomy",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "Renal microvessels"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R29",
              "head_entity_id": "T61",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R30",
              "head_entity_id": "T64",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R31",
              "head_entity_id": "T65",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R32",
              "head_entity_id": "T66",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R33",
              "head_entity_id": "T67",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R34",
              "head_entity_id": "T69",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R35",
              "head_entity_id": "T70",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R36",
              "head_entity_id": "T72",
              "tail_entity_id": "T71"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R37",
              "head_entity_id": "T74",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R38",
              "head_entity_id": "T75",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R39",
              "head_entity_id": "T77",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R40",
              "head_entity_id": "T79",
              "tail_entity_id": "T78"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R41",
              "head_entity_id": "T80",
              "tail_entity_id": "T81"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R42",
              "head_entity_id": "T80",
              "tail_entity_id": "T83"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R43",
              "head_entity_id": "T80",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R44",
              "head_entity_id": "T80",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R45",
              "head_entity_id": "T80",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R46",
              "head_entity_id": "T87",
              "tail_entity_id": "T81"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R47",
              "head_entity_id": "T82",
              "tail_entity_id": "T81"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R48",
              "head_entity_id": "T86",
              "tail_entity_id": "T83"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R49",
              "head_entity_id": "T85",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R50",
              "head_entity_id": "T90",
              "tail_entity_id": "T89"
            }
          ],
          "sentence_en": "The diagnosis of diabetic nephropathy is divided into pathological diagnosis and clinical diagnosis. Renal pathology is considered the gold standard for diagnosis. Diabetes mainly causes glomerular lesions, manifested as glomerular mesangial proliferation, basement membrane thickening and K-W (Kimmelstiel-Wilson) nodules, etc., which are the main basis for pathological diagnosis. Diabetes can also cause tubulointerstitial and renal microvascular lesions, such as renal interstitial fibrosis, tubular atrophy, hyalinization of the efferent artery or renal microvascular sclerosis, etc. These changes can also be caused by other causes and are only used as auxiliary indicators during diagnosis. At present, the basis for the clinical diagnosis of diabetic nephropathy is urine albumin and diabetic retinopathy. In the early stage of diabetic nephropathy, it can be manifested as negative urine albumin, with no obvious symptoms and easy to be ignored, but there is still a lack of more reliable and sensitive early detection indicators for diabetic nephropathy than urine microalbumin."
        }
      ],
      "paragraph_en": "The diagnosis of diabetic nephropathy is divided into pathological diagnosis and clinical diagnosis. Renal pathology is considered the gold standard for diagnosis. Diabetes mainly causes glomerular lesions, manifested as glomerular mesangial proliferation, basement membrane thickening and K-W (Kimmelstiel-Wilson) nodules, etc., which are the main basis for pathological diagnosis. Diabetes can also cause tubulointerstitial and renal microvascular lesions, such as renal interstitial fibrosis, tubular atrophy, hyalinization of the efferent artery or renal microvascular sclerosis, etc. These changes can also be caused by other causes and are only used as auxiliary indicators during diagnosis. At present, the basis for the clinical diagnosis of diabetic nephropathy is urine albumin and diabetic retinopathy. In the early stage of diabetic nephropathy, it can be manifested as negative urine albumin, with no obvious symptoms and easy to be ignored, but there is still a lack of more reliable and sensitive early detection indicators for diabetic nephropathy than urine microalbumin."
    },
    {
      "paragraph_id": "5",
      "paragraph": "(一)糖尿病肾病临床诊断依据",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)糖尿病肾病临床诊断依据",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T91",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T92",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 6,
              "end_idx": 7,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R51",
              "head_entity_id": "T92",
              "tail_entity_id": "T91"
            }
          ],
          "sentence_en": "1. Clinical diagnosis basis of diabetic nephropathy"
        }
      ],
      "paragraph_en": "1. Clinical diagnosis basis of diabetic nephropathy"
    },
    {
      "paragraph_id": "6",
      "paragraph": "1.尿白蛋白：微量白蛋白尿是糖尿病肾病早期的临床表现，也是诊断糖尿病肾病的主要依据。其评价指标为尿白蛋白排泄率(UAE/AER)或ACR。个体间UAE的差异系数接近40%，与之相比ACR更加稳定且检测方法方便，只需要检测单次随机晨尿即可，故推荐使用ACR。尿白蛋白排泄异常的定义见表1，因尿白蛋白排泄受影响因素较多，需在3-6个月内复查，3次结果中至少2次超过临界值，并且排除影响因素如24h内剧烈运动、感染、发热、充血性心力衰竭、明显高血糖、怀孕、明显高血压、尿路感染，可作出诊断。然而，尿白蛋白对诊断2型糖尿病肾病的特异性不足，对预测病情的转归也存在局限性。长期观察结果发现，微量白蛋白尿的患者在10年中仅有30%~45%转变为大量白蛋白尿，有30%转变为尿白蛋白阴性，该现象在2型糖尿病患者中更为显著。因此，尿白蛋白作为诊断依据时需进行长期随访、多次检测，结果重复时方可做出判定，且需排除其他可引起白蛋白尿的病因。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.尿白蛋白：微量白蛋白尿是糖尿病肾病早期的临床表现，也是诊断糖尿病肾病的主要依据。其评价指标为尿白蛋白排泄率(UAE/AER)或ACR。个体间UAE的差异系数接近40%，与之相比ACR更加稳定且检测方法方便，只需要检测单次随机晨尿即可，故推荐使用ACR。尿白蛋白排泄异常的定义见表1，因尿白蛋白排泄受影响因素较多，需在3-6个月内复查，3次结果中至少2次超过临界值，并且排除影响因素如24h内剧烈运动、感染、发热、充血性心力衰竭、明显高血糖、怀孕、明显高血压、尿路感染，可作出诊断。然而，尿白蛋白对诊断2型糖尿病肾病的特异性不足，对预测病情的转归也存在局限性。",
          "start_idx": 0,
          "end_idx": 281,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T94",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T95",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T96",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T97",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 18,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T98",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T99",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 34,
              "end_idx": 35,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T100",
              "entity": "尿白蛋白排泄率(UAE/AER)",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 64,
              "entity_en": "Urine albumin excretion rate (UAE/AER)"
            },
            {
              "entity_id": "T101",
              "entity": "ACR",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "ACR"
            },
            {
              "entity_id": "T102",
              "entity": "UAE",
              "entity_type": "Test_items",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "UAE"
            },
            {
              "entity_id": "T103",
              "entity": "ACR",
              "entity_type": "Test_items",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "ACR"
            },
            {
              "entity_id": "T104",
              "entity": "ACR",
              "entity_type": "Test_items",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "ACR"
            },
            {
              "entity_id": "T105",
              "entity": "尿白蛋白排泄异常",
              "entity_type": "Symptom",
              "start_idx": 128,
              "end_idx": 136,
              "entity_en": "Abnormal urinary albumin excretion"
            },
            {
              "entity_id": "T106",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 144,
              "end_idx": 148,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T107",
              "entity": "超过临界值",
              "entity_type": "Test_Value",
              "start_idx": 178,
              "end_idx": 183,
              "entity_en": "Exceeding critical value"
            },
            {
              "entity_id": "T108",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 202,
              "end_idx": 204,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T109",
              "entity": "发热",
              "entity_type": "Disease",
              "start_idx": 205,
              "end_idx": 207,
              "entity_en": "fever"
            },
            {
              "entity_id": "T110",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 208,
              "end_idx": 215,
              "entity_en": "Congestive heart failure"
            },
            {
              "entity_id": "T111",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 211,
              "end_idx": 212,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T112",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 218,
              "end_idx": 221,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T113",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 227,
              "end_idx": 230,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T114",
              "entity": "尿路感染",
              "entity_type": "Disease",
              "start_idx": 231,
              "end_idx": 235,
              "entity_en": "Urinary tract infection"
            },
            {
              "entity_id": "T115",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 245,
              "end_idx": 249,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T116",
              "entity": "2型糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 252,
              "end_idx": 259,
              "entity_en": "Type 2 diabetic nephropathy"
            },
            {
              "entity_id": "T117",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 252,
              "end_idx": 254,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T118",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 257,
              "end_idx": 258,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T129",
              "entity": "充血性",
              "entity_type": "Class",
              "start_idx": 208,
              "end_idx": 211,
              "entity_en": "Congestive"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R52",
              "head_entity_id": "T95",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R53",
              "head_entity_id": "T97",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R54",
              "head_entity_id": "T99",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R55",
              "head_entity_id": "T100",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R56",
              "head_entity_id": "T101",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R57",
              "head_entity_id": "T129",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R58",
              "head_entity_id": "T111",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R59",
              "head_entity_id": "T115",
              "tail_entity_id": "T116"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R60",
              "head_entity_id": "T117",
              "tail_entity_id": "T116"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R61",
              "head_entity_id": "T118",
              "tail_entity_id": "T116"
            }
          ],
          "sentence_en": "1. Urinary albumin: Microalbuminuria is an early clinical manifestation of diabetic nephropathy and the main basis for diagnosing diabetic nephropathy. Its evaluation index is urinary albumin excretion rate (UAE/AER) or ACR. The coefficient of variation of UAE between individuals is close to 40%. Compared with it, ACR is more stable and convenient to detect. It only needs to detect a single random morning urine, so ACR is recommended. The definition of abnormal urinary albumin excretion is shown in Table 1. Because urinary albumin excretion is affected by many factors, it needs to be rechecked within 3-6 months. At least 2 of the 3 results exceed the critical value, and the influencing factors such as strenuous exercise within 24 hours, infection, fever, congestive heart failure, obvious hyperglycemia, pregnancy, obvious hypertension, and urinary tract infection are excluded. However, urinary albumin is not specific enough for diagnosing type 2 diabetic nephropathy and has limitations in predicting the outcome of the disease."
        },
        {
          "sentence_id": "1",
          "sentence": "长期观察结果发现，微量白蛋白尿的患者在10年中仅有30%~45%转变为大量白蛋白尿，有30%转变为尿白蛋白阴性，该现象在2型糖尿病患者中更为显著。",
          "start_idx": 281,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T119",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T120",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T121",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T122",
              "entity": "大量",
              "entity_type": "Level",
              "start_idx": 35,
              "end_idx": 37,
              "entity_en": "Large"
            },
            {
              "entity_id": "T123",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T124",
              "entity": "阴性",
              "entity_type": "Test_Value",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "Negative"
            },
            {
              "entity_id": "T125",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 65,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T126",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 60,
              "end_idx": 62,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R62",
              "head_entity_id": "T123",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R63",
              "head_entity_id": "T126",
              "tail_entity_id": "T125"
            }
          ],
          "sentence_en": "Long-term observation results showed that only 30% to 45% of patients with microalbuminuria developed macroalbuminuria in 10 years, and 30% developed negative urine albumin. This phenomenon was more significant in patients with type 2 diabetes."
        },
        {
          "sentence_id": "2",
          "sentence": "因此，尿白蛋白作为诊断依据时需进行长期随访、多次检测，结果重复时方可做出判定，且需排除其他可引起白蛋白尿的病因。",
          "start_idx": 354,
          "end_idx": 410,
          "entities": [
            {
              "entity_id": "T127",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T128",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Albuminuria"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R64",
              "head_entity_id": "T127",
              "tail_entity_id": "T128"
            }
          ],
          "sentence_en": "Therefore, when urinary albumin is used as a basis for diagnosis, long-term follow-up and multiple tests are required. A judgment can only be made when the results are repeated, and other causes of albuminuria must be excluded."
        }
      ],
      "paragraph_en": "1. Urinary albumin: Microalbuminuria is an early clinical manifestation of diabetic nephropathy and the main basis for diagnosing diabetic nephropathy. Its evaluation index is urinary albumin excretion rate (UAE/AER) or ACR. The coefficient of variation of UAE between individuals is close to 40%. Compared with it, ACR is more stable and convenient to detect. It only needs to detect a single random morning urine, so ACR is recommended. The definition of abnormal urinary albumin excretion is shown in Table 1. Because urinary albumin excretion is affected by many factors, it needs to be rechecked within 3-6 months. At least 2 of the 3 results exceed the critical value, and the influencing factors such as strenuous exercise within 24 hours, infection, fever, congestive heart failure, obvious hyperglycemia, pregnancy, obvious hypertension, and urinary tract infection are excluded. However, urinary albumin is not specific enough for diagnosing type 2 diabetic nephropathy and has limitations in predicting the outcome of the disease. Long-term observations have found that only 30% to 45% of patients with microalbuminuria develop macroalbuminuria in 10 years, and 30% develop negative urine albumin. This phenomenon is more significant in patients with type 2 diabetes. Therefore, long-term follow-up and multiple tests are required when urine albumin is used as a diagnostic basis. A judgment can only be made when the results are repeated, and other causes of albuminuria must be excluded."
    },
    {
      "paragraph_id": "7",
      "paragraph": "2.糖尿病视网膜病变：糖尿病视网膜病变常早于糖尿病肾病发生，大部分糖尿病肾病患者患有糖尿病视网膜病变，但在透析的糖尿病肾病患者中，糖尿病视网膜病变的发病率反而减少，糖尿病视网膜病变被NKF/KDOQI指南作为2型糖尿病患者糖尿病肾病的诊断依据之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.糖尿病视网膜病变：糖尿病视网膜病变常早于糖尿病肾病发生，大部分糖尿病肾病患者患有糖尿病视网膜病变，但在透析的糖尿病肾病患者中，糖尿病视网膜病变的发病率反而减少，糖尿病视网膜病变被NKF/KDOQI指南作为2型糖尿病患者糖尿病肾病的诊断依据之一。",
          "start_idx": 0,
          "end_idx": 124,
          "entities": [
            {
              "entity_id": "T130",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 10,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T131",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T132",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T133",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T134",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T135",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T136",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 36,
              "end_idx": 37,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T137",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 50,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T138",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T139",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T140",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 61,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T141",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 60,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T142",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 73,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T143",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 68,
              "end_idx": 71,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T144",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 82,
              "end_idx": 90,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T145",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T146",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 109,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T147",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 104,
              "end_idx": 106,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T148",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T149",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 114,
              "end_idx": 115,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T150",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 19,
              "entity_en": "Diabetic retinopathy"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R65",
              "head_entity_id": "T131",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R66",
              "head_entity_id": "T132",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R67",
              "head_entity_id": "T134",
              "tail_entity_id": "T133"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R68",
              "head_entity_id": "T136",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R69",
              "head_entity_id": "T138",
              "tail_entity_id": "T137"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R70",
              "head_entity_id": "T139",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R71",
              "head_entity_id": "T141",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T143",
              "tail_entity_id": "T142"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T145",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R74",
              "head_entity_id": "T147",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R75",
              "head_entity_id": "T149",
              "tail_entity_id": "T148"
            }
          ],
          "sentence_en": "2. Diabetic retinopathy: Diabetic retinopathy often occurs earlier than diabetic nephropathy. Most patients with diabetic nephropathy suffer from diabetic retinopathy. However, the incidence of diabetic retinopathy is reduced in diabetic nephropathy patients on dialysis. Diabetic retinopathy is used as one of the diagnostic bases for diabetic nephropathy in patients with type 2 diabetes in the NKF/KDOQI guidelines."
        }
      ],
      "paragraph_en": "2. Diabetic retinopathy: Diabetic retinopathy often occurs earlier than diabetic nephropathy. Most patients with diabetic nephropathy suffer from diabetic retinopathy. However, the incidence of diabetic retinopathy is reduced in diabetic nephropathy patients on dialysis. Diabetic retinopathy is used as one of the diagnostic bases for diabetic nephropathy in patients with type 2 diabetes in the NKF/KDOQI guidelines."
    },
    {
      "paragraph_id": "8",
      "paragraph": "2007年NKF指南荟萃大量研究后指出，在大量白蛋白尿者中，糖尿病视网膜病变对糖尿病性肾小球肾病的阳性预测值为67%~100%，阴性预测值为20%~84%，灵敏度为26%~85%，特异度为13%~100%；在微量白蛋白尿者中，阳性预测值为45%左右，但阴性预测值接近100%，灵敏度为100%，特异度为46%~62%。Meta分析结果表明糖尿病视网膜病变预测2型糖尿病肾病的灵敏度为0.65(95%CI：0.62~0.68)，特异度为0.75(95%CI：0.73~0.78)，阳性为0.72(95%CI：0.68~0.75)，阴性预测值为0.69(95%CI：0.67~0.72)，提示糖尿病视网膜病变是2型糖尿病肾病诊断和筛查的有用指标。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2007年NKF指南荟萃大量研究后指出，在大量白蛋白尿者中，糖尿病视网膜病变对糖尿病性肾小球肾病的阳性预测值为67%~100%，阴性预测值为20%~84%，灵敏度为26%~85%，特异度为13%~100%；在微量白蛋白尿者中，阳性预测值为45%左右，但阴性预测值接近100%，灵敏度为100%，特异度为46%~62%。Meta分析结果表明糖尿病视网膜病变预测2型糖尿病肾病的灵敏度为0.65(95%CI：0.62~0.68)，特异度为0.75(95%CI：0.73~0.78)，阳性为0.72(95%CI：0.68~0.75)，阴性预测值为0.69(95%CI：0.67~0.72)，提示糖尿病视网膜病变是2型糖尿病肾病诊断和筛查的有用指标。",
          "start_idx": 0,
          "end_idx": 321,
          "entities": [
            {
              "entity_id": "T151",
              "entity": "大量",
              "entity_type": "Level",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "Large"
            },
            {
              "entity_id": "T152",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T153",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 38,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T154",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T155",
              "entity": "糖尿病性肾小球肾病",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 48,
              "entity_en": "Diabetic Glomerulonephropathy"
            },
            {
              "entity_id": "T156",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T157",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 46,
              "end_idx": 47,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T158",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 104,
              "end_idx": 106,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T159",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T160",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 169,
              "end_idx": 177,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T161",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 172,
              "end_idx": 175,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T162",
              "entity": "2型糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 179,
              "end_idx": 186,
              "entity_en": "Type 2 diabetic nephropathy"
            },
            {
              "entity_id": "T163",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 179,
              "end_idx": 181,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T164",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 185,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T165",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 294,
              "end_idx": 302,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T166",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 297,
              "end_idx": 300,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T167",
              "entity": "2型糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 303,
              "end_idx": 310,
              "entity_en": "Type 2 diabetic nephropathy"
            },
            {
              "entity_id": "T168",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 303,
              "end_idx": 305,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T169",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 308,
              "end_idx": 309,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R76",
              "head_entity_id": "T154",
              "tail_entity_id": "T153"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R77",
              "head_entity_id": "T156",
              "tail_entity_id": "T155"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R78",
              "head_entity_id": "T157",
              "tail_entity_id": "T155"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R79",
              "head_entity_id": "T161",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T164",
              "tail_entity_id": "T162"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T163",
              "tail_entity_id": "T162"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R82",
              "head_entity_id": "T166",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R83",
              "head_entity_id": "T168",
              "tail_entity_id": "T167"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R84",
              "head_entity_id": "T169",
              "tail_entity_id": "T167"
            }
          ],
          "sentence_en": "The 2007 NKF guidelines, after reviewing a large number of studies, pointed out that in patients with macroalbuminuria, the positive predictive value of diabetic retinopathy for diabetic glomerulonephropathy was 67%~100%, the negative predictive value was 20%~84%, the sensitivity was 26%~85%, and the specificity was 13%~100%; in patients with microalbuminuria, the positive predictive value was about 45%, but the negative predictive value was close to 100%, the sensitivity was 100%, and the specificity was 46%~62%. The results of meta-analysis showed that the sensitivity of diabetic retinopathy in predicting type 2 diabetic nephropathy was 0.65 (95%CI: 0.62-0.68), the specificity was 0.75 (95%CI: 0.73-0.78), the positive value was 0.72 (95%CI: 0.68-0.75), and the negative predictive value was 0.69 (95%CI: 0.67-0.72), indicating that diabetic retinopathy is a useful indicator for the diagnosis and screening of type 2 diabetic nephropathy."
        }
      ],
      "paragraph_en": "The 2007 NKF guidelines, after reviewing a large number of studies, pointed out that in patients with macroalbuminuria, the positive predictive value of diabetic retinopathy for diabetic glomerulonephropathy was 67%~100%, the negative predictive value was 20%~84%, the sensitivity was 26%~85%, and the specificity was 13%~100%; in patients with microalbuminuria, the positive predictive value was about 45%, but the negative predictive value was close to 100%, the sensitivity was 100%, and the specificity was 46%~62%. The results of meta-analysis showed that the sensitivity of diabetic retinopathy in predicting type 2 diabetic nephropathy was 0.65 (95%CI: 0.62-0.68), the specificity was 0.75 (95%CI: 0.73-0.78), the positive value was 0.72 (95%CI: 0.68-0.75), and the negative predictive value was 0.69 (95%CI: 0.67-0.72), indicating that diabetic retinopathy is a useful indicator for the diagnosis and screening of type 2 diabetic nephropathy."
    },
    {
      "paragraph_id": "9",
      "paragraph": "近来，发现一些因子对糖尿病肾病的诊断有价值，如转化生长因子β1(TGF-β1)、免疫球蛋白G(IgG)、转铁蛋白(TRF)、细胞外基质(ECM)、肾损伤分子1(Kim-1)及中性粒细胞明胶酶相关脂质运载蛋白(NGAL)。利用糖尿病肾病的患者血清蛋白质指纹图谱的比较中筛选到22个上调、24个下调的蛋白质或多肽，并建立诊断决策树模型，盲法验证模型的敏感性90.9%，特异性89.3%。上述检测方法被认为比微量白蛋白尿能更早地发现糖尿病肾病，可能作为糖尿病肾病早期诊断的工具，但其可靠性、特异性、敏感性仍需更多研究证实，目前尚未作为诊断依据。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "近来，发现一些因子对糖尿病肾病的诊断有价值，如转化生长因子β1(TGF-β1)、免疫球蛋白G(IgG)、转铁蛋白(TRF)、细胞外基质(ECM)、肾损伤分子1(Kim-1)及中性粒细胞明胶酶相关脂质运载蛋白(NGAL)。利用糖尿病肾病的患者血清蛋白质指纹图谱的比较中筛选到22个上调、24个下调的蛋白质或多肽，并建立诊断决策树模型，盲法验证模型的敏感性90.9%，特异性89.3%。",
          "start_idx": 0,
          "end_idx": 191,
          "entities": [
            {
              "entity_id": "T170",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T171",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 14,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T172",
              "entity": "转化生长因子β1(TGF-β1)",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 39,
              "entity_en": "Transforming Growth Factor Beta 1 (TGF-β1)"
            },
            {
              "entity_id": "T173",
              "entity": "免疫球蛋白G(IgG)",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 51,
              "entity_en": "Immunoglobulin G (IgG)"
            },
            {
              "entity_id": "T174",
              "entity": "转铁蛋白(TRF)",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 61,
              "entity_en": "Transferrin (TRF)"
            },
            {
              "entity_id": "T175",
              "entity": "细胞外基质(ECM)",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 72,
              "entity_en": "Extracellular Matrix (ECM)"
            },
            {
              "entity_id": "T176",
              "entity": "肾损伤分子1(Kim-1)",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 86,
              "entity_en": "Kidney injury molecule 1 (Kim-1)"
            },
            {
              "entity_id": "T177",
              "entity": "中性粒细胞明胶酶",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 95,
              "entity_en": "Neutrophil gelatinase"
            },
            {
              "entity_id": "T178",
              "entity": "脂质运载蛋白(NGAL)",
              "entity_type": "Test_items",
              "start_idx": 97,
              "end_idx": 109,
              "entity_en": "NGAL"
            },
            {
              "entity_id": "T179",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 117,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T180",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 115,
              "end_idx": 116,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T181",
              "entity": "血清蛋白质",
              "entity_type": "Test_items",
              "start_idx": 120,
              "end_idx": 125,
              "entity_en": "Serum Protein"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R85",
              "head_entity_id": "T171",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R86",
              "head_entity_id": "T172",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R87",
              "head_entity_id": "T173",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R88",
              "head_entity_id": "T174",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R89",
              "head_entity_id": "T175",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R90",
              "head_entity_id": "T176",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R91",
              "head_entity_id": "T177",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R92",
              "head_entity_id": "T178",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R93",
              "head_entity_id": "T181",
              "tail_entity_id": "T179"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R94",
              "head_entity_id": "T180",
              "tail_entity_id": "T179"
            }
          ],
          "sentence_en": "Recently, some factors have been found to be valuable for the diagnosis of diabetic nephropathy, such as transforming growth factor β1 (TGF-β1), immunoglobulin G (IgG), transferrin (TRF), extracellular matrix (ECM), kidney injury molecule 1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL). By comparing the serum protein fingerprints of patients with diabetic nephropathy, 22 up-regulated and 24 down-regulated proteins or peptides were screened, and a diagnostic decision tree model was established. The blind validation model had a sensitivity of 90.9% and a specificity of 89.3%."
        },
        {
          "sentence_id": "1",
          "sentence": "上述检测方法被认为比微量白蛋白尿能更早地发现糖尿病肾病，可能作为糖尿病肾病早期诊断的工具，但其可靠性、特异性、敏感性仍需更多研究证实，目前尚未作为诊断依据。",
          "start_idx": 191,
          "end_idx": 269,
          "entities": [
            {
              "entity_id": "T182",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T183",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T184",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T185",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T186",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T187",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 36,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R95",
              "head_entity_id": "T185",
              "tail_entity_id": "T184"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R96",
              "head_entity_id": "T187",
              "tail_entity_id": "T186"
            }
          ],
          "sentence_en": "The above detection method is believed to be able to detect diabetic nephropathy earlier than microalbuminuria and may be used as a tool for early diagnosis of diabetic nephropathy. However, its reliability, specificity and sensitivity still need to be confirmed by more research and it has not yet been used as a basis for diagnosis."
        }
      ],
      "paragraph_en": "Recently, some factors have been found to be valuable for the diagnosis of diabetic nephropathy, such as transforming growth factor β1 (TGF-β1), immunoglobulin G (IgG), transferrin (TRF), extracellular matrix (ECM), kidney injury molecule 1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL). By comparing the serum protein fingerprints of patients with diabetic nephropathy, 22 up-regulated and 24 down-regulated proteins or peptides were screened, and a diagnostic decision tree model was established. The blind validation model had a sensitivity of 90.9% and a specificity of 89.3%. The above detection method is believed to be able to detect diabetic nephropathy earlier than microalbuminuria and may be used as a tool for early diagnosis of diabetic nephropathy, but its reliability, specificity and sensitivity still need to be confirmed by more studies and have not yet been used as a basis for diagnosis."
    },
    {
      "paragraph_id": "10",
      "paragraph": "(二)糖尿病肾病的筛查和肾功能评价",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)糖尿病肾病的筛查和肾功能评价",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T188",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T189",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 6,
              "end_idx": 7,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T190",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "Renal function"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R97",
              "head_entity_id": "T189",
              "tail_entity_id": "T188"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R98",
              "head_entity_id": "T190",
              "tail_entity_id": "T188"
            }
          ],
          "sentence_en": "2. Screening for diabetic nephropathy and evaluation of renal function"
        }
      ],
      "paragraph_en": "2. Screening for diabetic nephropathy and evaluation of renal function"
    },
    {
      "paragraph_id": "11",
      "paragraph": "肾功能改变是糖尿病肾病的重要表现，反映肾功能的主要指标是GFR，根据GFR和其他肾脏损伤证据可进行慢性肾病(CKD)的分期(表2)。横断面调查结果显示，部分糖尿病患者无尿白蛋白排泄异常，但已经存在GFR下降，提示尿白蛋白阴性者也可能存在肾病，GFR可作为糖尿病肾病的诊断依据之一。GFR的评估方法分为外源性标志物的肾清除率测定法(如同位素稀释质谱法)和内源性标志物估算法。后者更经济实用，更适合于临床应用。估算GFR最常用的指标是血清肌酐，基于血清肌酐的肾小球滤过率的常用计算公式有CG(Cockcrofl-Gauh)公式和肾脏饮食修正公式(MDRD)，2009年又提出了CKD-EPI公式，被认为比CG公式和MDRD公式能更准确地估算2型糖尿病患者的GFR，但存在争议。本共识推荐使用2006年我国预估肾小球滤过率(eGFR)协作组制定的适用于中国人的改良MDRD公式：eGFR(ml·min-1·1.73m-2)=175x血清肌酐(SCr)·1.234×年龄-0.179(如果是女性×0.79)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "肾功能改变是糖尿病肾病的重要表现，反映肾功能的主要指标是GFR，根据GFR和其他肾脏损伤证据可进行慢性肾病(CKD)的分期(表2)。横断面调查结果显示，部分糖尿病患者无尿白蛋白排泄异常，但已经存在GFR下降，提示尿白蛋白阴性者也可能存在肾病，GFR可作为糖尿病肾病的诊断依据之一。",
          "start_idx": 0,
          "end_idx": 140,
          "entities": [
            {
              "entity_id": "T191",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T192",
              "entity": "改变",
              "entity_type": "Test_Value",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "Change"
            },
            {
              "entity_id": "T193",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T194",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 10,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T195",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T196",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T197",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T198",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T199",
              "entity": "慢性肾病(CKD)",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 58,
              "entity_en": "Chronic Kidney Disease (CKD)"
            },
            {
              "entity_id": "T200",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "Chronic"
            },
            {
              "entity_id": "T201",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 51,
              "end_idx": 52,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T202",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 81,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T203",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T204",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 101,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T205",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "decline"
            },
            {
              "entity_id": "T206",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T207",
              "entity": "阴性",
              "entity_type": "Test_Value",
              "start_idx": 110,
              "end_idx": 112,
              "entity_en": "Negative"
            },
            {
              "entity_id": "T208",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T209",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 118,
              "end_idx": 119,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T210",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T211",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 132,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T212",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 130,
              "end_idx": 131,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R99",
              "head_entity_id": "T191",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R100",
              "head_entity_id": "T195",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R101",
              "head_entity_id": "T194",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R102",
              "head_entity_id": "T196",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R103",
              "head_entity_id": "T197",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R104",
              "head_entity_id": "T198",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R105",
              "head_entity_id": "T201",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R106",
              "head_entity_id": "T200",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R107",
              "head_entity_id": "T203",
              "tail_entity_id": "T202"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R108",
              "head_entity_id": "T204",
              "tail_entity_id": "T202"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R109",
              "head_entity_id": "T206",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R110",
              "head_entity_id": "T209",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R111",
              "head_entity_id": "T210",
              "tail_entity_id": "T211"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R112",
              "head_entity_id": "T212",
              "tail_entity_id": "T211"
            }
          ],
          "sentence_en": "Changes in renal function are an important manifestation of diabetic nephropathy. The main indicator of renal function is GFR. Chronic kidney disease (CKD) can be staged based on GFR and other evidence of renal damage (Table 2). Cross-sectional survey results show that some diabetic patients have no abnormal urinary albumin excretion, but have a decreased GFR, suggesting that those with negative urine albumin may also have kidney disease. GFR can be used as one of the diagnostic bases for diabetic nephropathy."
        },
        {
          "sentence_id": "1",
          "sentence": "GFR的评估方法分为外源性标志物的肾清除率测定法(如同位素稀释质谱法)和内源性标志物估算法。",
          "start_idx": 140,
          "end_idx": 186,
          "entities": [
            {
              "entity_id": "T213",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T214",
              "entity": "肾清除率",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Renal clearance"
            }
          ],
          "relations": [],
          "sentence_en": "GFR assessment methods include exogenous marker renal clearance measurement (such as isotope dilution mass spectrometry) and endogenous marker estimation."
        },
        {
          "sentence_id": "2",
          "sentence": "后者更经济实用，更适合于临床应用。",
          "start_idx": 186,
          "end_idx": 203,
          "entities": [],
          "relations": [],
          "sentence_en": "The latter is more economical and practical and more suitable for clinical application."
        },
        {
          "sentence_id": "3",
          "sentence": "估算GFR最常用的指标是血清肌酐，基于血清肌酐的肾小球滤过率的常用计算公式有CG(Cockcrofl-Gauh)公式和肾脏饮食修正公式(MDRD)，2009年又提出了CKD-EPI公式，被认为比CG公式和MDRD公式能更准确地估算2型糖尿病患者的GFR，但存在争议。",
          "start_idx": 203,
          "end_idx": 336,
          "entities": [
            {
              "entity_id": "T215",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T216",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T217",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T218",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 30,
              "entity_en": "Glomerular filtration rate"
            },
            {
              "entity_id": "T222",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T223",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T224",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 123,
              "end_idx": 126,
              "entity_en": "GFR"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R113",
              "head_entity_id": "T223",
              "tail_entity_id": "T222"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R114",
              "head_entity_id": "T224",
              "tail_entity_id": "T222"
            }
          ],
          "sentence_en": "The most commonly used indicator for estimating GFR is serum creatinine. Common calculation formulas for glomerular filtration rate based on serum creatinine include the CG (Cockcrofl-Gauh) formula and the Modification of Renal Diet (MDRD) formula. In 2009, the CKD-EPI formula was proposed, which is considered to be more accurate than the CG formula and MDRD formula in estimating the GFR of patients with type 2 diabetes, but there is controversy."
        },
        {
          "sentence_id": "4",
          "sentence": "本共识推荐使用2006年我国预估肾小球滤过率(eGFR)协作组制定的适用于中国人的改良MDRD公式：eGFR(ml·min-1·1.73m-2)=175x血清肌酐(SCr)·1.234×年龄-0.179(如果是女性×0.79)。",
          "start_idx": 336,
          "end_idx": 450,
          "entities": [
            {
              "entity_id": "T219",
              "entity": "肾小球滤过率(eGFR)",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 28,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T220",
              "entity": "血清肌酐(SCr)",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 86,
              "entity_en": "Serum creatinine (SCr)"
            },
            {
              "entity_id": "T221",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "eGFR"
            }
          ],
          "relations": [],
          "sentence_en": "This consensus recommends the use of the modified MDRD formula suitable for Chinese people developed by the Chinese estimated glomerular filtration rate (eGFR) collaboration group in 2006: eGFR (ml·min-1·1.73m-2) = 175x serum creatinine (SCr)·1.234×age-0.179 (if female×0.79)."
        }
      ],
      "paragraph_en": "Changes in renal function are an important manifestation of diabetic nephropathy. The main indicator of renal function is GFR. Chronic kidney disease (CKD) can be staged based on GFR and other evidence of kidney damage (Table 2). Cross-sectional survey results show that some diabetic patients have no abnormal urinary albumin excretion, but have a decreased GFR, suggesting that those with negative urine albumin may also have kidney disease. GFR can be used as one of the diagnostic bases for diabetic nephropathy. GFR assessment methods are divided into exogenous marker renal clearance determination method (such as isotope dilution mass spectrometry) and endogenous marker estimation method. The latter is more economical and practical and more suitable for clinical application. The most commonly used indicator for estimating GFR is serum creatinine. The commonly used calculation formulas for glomerular filtration rate based on serum creatinine are the CG (Cockcrofl-Gauh) formula and the modified renal diet formula (MDRD). In 2009, the CKD-EPI formula was proposed, which is considered to be more accurate than the CG formula and the MDRD formula in estimating the GFR of patients with type 2 diabetes, but there is controversy. This consensus recommends the use of the modified MDRD formula suitable for Chinese people developed by the Chinese estimated glomerular filtration rate (eGFR) collaboration group in 2006: eGFR (ml·min-1·1.73m-2) = 175x serum creatinine (SCr)·1.234×age-0.179 (if female×0.79)."
    },
    {
      "paragraph_id": "12",
      "paragraph": "血清肌本酐在估算GFR中存在灵敏度不足，受个体肌肉量、蛋白质摄入、体内代谢水平、溶血、脂血等因素干扰等局限性。近年来，胱抑素C(CysC)被认为在预测2型糖尿病肾病进展为ESRD的作用上比血清肌酐更好，CysC是由有核细胞以恒速产生的，可自由滤过，被肾小管上皮细胞重吸收和细胞内降解，但不会被肾小管上皮细胞分泌，可更准确地反映肾功能，但其检测的准确性尚未得到保障。一些学者提出了基于CysC的eGFR计算公式和CKD分期。目前有研究提出，联合使用血清肌酐与CysC公式比单独使用基于其中一项指标的公式更好。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "血清肌本酐在估算GFR中存在灵敏度不足，受个体肌肉量、蛋白质摄入、体内代谢水平、溶血、脂血等因素干扰等局限性。近年来，胱抑素C(CysC)被认为在预测2型糖尿病肾病进展为ESRD的作用上比血清肌酐更好，CysC是由有核细胞以恒速产生的，可自由滤过，被肾小管上皮细胞重吸收和细胞内降解，但不会被肾小管上皮细胞分泌，可更准确地反映肾功能，但其检测的准确性尚未得到保障。一些学者提出了基于CysC的eGFR计算公式和CKD分期。",
          "start_idx": 0,
          "end_idx": 211,
          "entities": [
            {
              "entity_id": "T225",
              "entity": "血清肌本酐",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T226",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T227",
              "entity": "溶血",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "Hemolysis"
            },
            {
              "entity_id": "T228",
              "entity": "胱抑素C(CysC)",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 69,
              "entity_en": "Cystatin C (CysC)"
            },
            {
              "entity_id": "T229",
              "entity": "2型糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 82,
              "entity_en": "Type 2 diabetic nephropathy"
            },
            {
              "entity_id": "T230",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T231",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 80,
              "end_idx": 81,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T232",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 89,
              "entity_en": "ESRD"
            },
            {
              "entity_id": "T233",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 98,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T234",
              "entity": "CysC",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "CxC"
            },
            {
              "entity_id": "T235",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T236",
              "entity": "CysC",
              "entity_type": "Test_items",
              "start_idx": 191,
              "end_idx": 195,
              "entity_en": "CxC"
            },
            {
              "entity_id": "T237",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 196,
              "end_idx": 200,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T238",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 205,
              "end_idx": 208,
              "entity_en": "CKD"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R115",
              "head_entity_id": "T225",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R116",
              "head_entity_id": "T226",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R117",
              "head_entity_id": "T228",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R118",
              "head_entity_id": "T230",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R119",
              "head_entity_id": "T231",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R120",
              "head_entity_id": "T233",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R121",
              "head_entity_id": "T234",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R122",
              "head_entity_id": "T236",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R123",
              "head_entity_id": "T237",
              "tail_entity_id": "T238"
            }
          ],
          "sentence_en": "Serum creatinine has limited sensitivity in estimating GFR and is affected by factors such as individual muscle mass, protein intake, metabolic level in the body, hemolysis, and lipemia. In recent years, cystatin C (CysC) is considered to be better than serum creatinine in predicting the progression of type 2 diabetic nephropathy to ESRD. CysC is produced by nucleated cells at a constant rate, can be filtered freely, reabsorbed by renal tubular epithelial cells, and degraded intracellularly, but will not be secreted by renal tubular epithelial cells. It can more accurately reflect renal function, but the accuracy of its detection has not yet been guaranteed. Some scholars have proposed eGFR calculation formulas and CKD staging based on CysC."
        },
        {
          "sentence_id": "1",
          "sentence": "目前有研究提出，联合使用血清肌酐与CysC公式比单独使用基于其中一项指标的公式更好。",
          "start_idx": 211,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T239",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T240",
              "entity": "CysC",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "CxC"
            }
          ],
          "relations": [],
          "sentence_en": "Current studies have suggested that the combined use of serum creatinine and CysC formulas is better than using a formula based on either indicator alone."
        }
      ],
      "paragraph_en": "Serum creatinine has limitations such as insufficient sensitivity in estimating GFR and interference from factors such as individual muscle mass, protein intake, in vivo metabolic level, hemolysis, and lipemia. In recent years, cystatin C (CysC) is considered to be better than serum creatinine in predicting the progression of type 2 diabetic nephropathy to ESRD. CysC is produced by nucleated cells at a constant rate, can be filtered freely, reabsorbed by renal tubular epithelial cells, and degraded intracellularly, but will not be secreted by renal tubular epithelial cells. It can more accurately reflect renal function, but the accuracy of its detection has not yet been guaranteed. Some scholars have proposed eGFR calculation formulas and CKD staging based on CysC. At present, some studies have suggested that the combined use of serum creatinine and CysC formulas is better than using formulas based on one of the indicators alone."
    },
    {
      "paragraph_id": "13",
      "paragraph": "由于尿白蛋白和GFR对糖尿病肾病的重要性，对这两项的检测是目前糖尿病肾病的筛检项目，一旦确诊糖尿病，应每年都进行筛检：(1)所有2型糖尿病患者应从确诊时和1型糖尿病患者病程超过5年时每年检查1次以评估UAE/AER。(2)所有成人糖尿病患者，不管UAE/AER如何，每年应至少检查1次血清肌酐，并用血清肌酐估计GFR。如果有CKD，需进行分期。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于尿白蛋白和GFR对糖尿病肾病的重要性，对这两项的检测是目前糖尿病肾病的筛检项目，一旦确诊糖尿病，应每年都进行筛检：(1)所有2型糖尿病患者应从确诊时和1型糖尿病患者病程超过5年时每年检查1次以评估UAE/AER。(2)所有成人糖尿病患者，不管UAE/AER如何，每年应至少检查1次血清肌酐，并用血清肌酐估计GFR。",
          "start_idx": 0,
          "end_idx": 159,
          "entities": [
            {
              "entity_id": "T241",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T242",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T243",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T244",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 15,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T245",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T246",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 34,
              "end_idx": 35,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T247",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T248",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 69,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T249",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T250",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 77,
              "end_idx": 82,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T251",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T252",
              "entity": "UAE/AER",
              "entity_type": "Test_items",
              "start_idx": 100,
              "end_idx": 107,
              "entity_en": "UAE/AER"
            },
            {
              "entity_id": "T253",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T254",
              "entity": "UAE/AER",
              "entity_type": "Test_items",
              "start_idx": 123,
              "end_idx": 130,
              "entity_en": "UAE/AER"
            },
            {
              "entity_id": "T255",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 142,
              "end_idx": 146,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T256",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 149,
              "end_idx": 153,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T258",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 155,
              "end_idx": 158,
              "entity_en": "GFR"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R124",
              "head_entity_id": "T241",
              "tail_entity_id": "T243"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R125",
              "head_entity_id": "T242",
              "tail_entity_id": "T243"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R126",
              "head_entity_id": "T244",
              "tail_entity_id": "T243"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R127",
              "head_entity_id": "T246",
              "tail_entity_id": "T245"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R128",
              "head_entity_id": "T249",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R129",
              "head_entity_id": "T251",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R130",
              "head_entity_id": "T252",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R131",
              "head_entity_id": "T254",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R132",
              "head_entity_id": "T255",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R133",
              "head_entity_id": "T256",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R134",
              "head_entity_id": "T258",
              "tail_entity_id": "T253"
            }
          ],
          "sentence_en": "Due to the importance of urinary albumin and GFR in diabetic nephropathy, the detection of these two items is currently a screening item for diabetic nephropathy. Once diabetes is diagnosed, screening should be performed annually: (1) All patients with type 2 diabetes should be examined once a year from the time of diagnosis and patients with type 1 diabetes who have had the disease for more than 5 years to assess UAE/AER. (2) All adult patients with diabetes, regardless of UAE/AER, should have their serum creatinine checked at least once a year and their GFR estimated using serum creatinine."
        },
        {
          "sentence_id": "1",
          "sentence": "如果有CKD，需进行分期。",
          "start_idx": 159,
          "end_idx": 172,
          "entities": [
            {
              "entity_id": "T257",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "If CKD is present, it needs to be staged."
        }
      ],
      "paragraph_en": "Due to the importance of urinary albumin and GFR to diabetic nephropathy, the detection of these two items is currently a screening item for diabetic nephropathy. Once diabetes is diagnosed, screening should be performed annually: (1) All patients with type 2 diabetes should be examined once a year from the time of diagnosis and patients with type 1 diabetes who have had the disease for more than 5 years to assess UAE/AER. (2) All adult patients with diabetes, regardless of UAE/AER, should have their serum creatinine checked at least once a year and their GFR estimated using serum creatinine. If CKD is present, staging is required."
    },
    {
      "paragraph_id": "14",
      "paragraph": "(三)糖尿病肾病临床诊断标准",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)糖尿病肾病临床诊断标准",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T259",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T260",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 6,
              "end_idx": 7,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R135",
              "head_entity_id": "T260",
              "tail_entity_id": "T259"
            }
          ],
          "sentence_en": "3. Clinical diagnostic criteria for diabetic nephropathy"
        }
      ],
      "paragraph_en": "3. Clinical diagnostic criteria for diabetic nephropathy"
    },
    {
      "paragraph_id": "15",
      "paragraph": "糖尿病肾病的国外诊断标准有美国肾脏基金会(NKF)肾脏病预后质量倡议(K/DOQI)指南标准(2007年)和英国国民医疗服务(NHS)标准(2010年)。我国目前仍无统一的糖尿病肾病诊断标准，本共识推荐采用表3诊断标准，符合任何一项者可考虑为糖尿病肾脏病变(适用于1型及2型糖尿病)：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病肾病的国外诊断标准有美国肾脏基金会(NKF)肾脏病预后质量倡议(K/DOQI)指南标准(2007年)和英国国民医疗服务(NHS)标准(2010年)。我国目前仍无统一的糖尿病肾病诊断标准，本共识推荐采用表3诊断标准，符合任何一项者可考虑为糖尿病肾脏病变(适用于1型及2型糖尿病)：",
          "start_idx": 0,
          "end_idx": 142,
          "entities": [
            {
              "entity_id": "T261",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T262",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T263",
              "entity": "肾脏病",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T264",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T265",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 91,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T266",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 89,
              "end_idx": 90,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T267",
              "entity": "糖尿病肾脏病变",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 128,
              "entity_en": "Diabetic Nephropathy"
            },
            {
              "entity_id": "T268",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 124,
              "end_idx": 126,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T269",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 140,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T270",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 135,
              "end_idx": 137,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R136",
              "head_entity_id": "T262",
              "tail_entity_id": "T261"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R137",
              "head_entity_id": "T264",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R138",
              "head_entity_id": "T266",
              "tail_entity_id": "T265"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R139",
              "head_entity_id": "T270",
              "tail_entity_id": "T269"
            }
          ],
          "sentence_en": "The foreign diagnostic criteria for diabetic nephropathy include the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines (2007) and the UK National Health Service (NHS) standards (2010). my country currently does not have a unified diagnostic standard for diabetic nephropathy. This consensus recommends the use of the diagnostic criteria in Table 3. Patients who meet any of the criteria can be considered to have diabetic nephropathy (applicable to type 1 and type 2 diabetes):"
        }
      ],
      "paragraph_en": "The foreign diagnostic criteria for diabetic nephropathy include the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines (2007) and the UK National Health Service (NHS) standards (2010). my country currently does not have a unified diagnostic standard for diabetic nephropathy. This consensus recommends the use of the diagnostic criteria in Table 3. Patients who meet any of the criteria can be considered to have diabetic nephropathy (applicable to type 1 and type 2 diabetes):"
    },
    {
      "paragraph_id": "16",
      "paragraph": "诊断时，出现以下情况之一的应考虑其CKD是由其他原因引起的：(1)无糖尿病视网膜病变；(2)GFR较低或迅速下降；(3)蛋白尿急剧增多或有肾病综合征；(4)顽固性高血压；(5)尿沉渣活动表现；(6)其他系统性疾病的症状或体征；(7)血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体拮抗剂(ARB)类药物开始治疗后2~3个月内肾小球滤过率下降超过30%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "诊断时，出现以下情况之一的应考虑其CKD是由其他原因引起的：(1)无糖尿病视网膜病变；(2)GFR较低或迅速下降；(3)蛋白尿急剧增多或有肾病综合征；(4)顽固性高血压；(5)尿沉渣活动表现；(6)其他系统性疾病的症状或体征；(7)血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体拮抗剂(ARB)类药物开始治疗后2~3个月内肾小球滤过率下降超过30%。",
          "start_idx": 0,
          "end_idx": 179,
          "entities": [
            {
              "entity_id": "T271",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T272",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 42,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T273",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T274",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T275",
              "entity": "较低",
              "entity_type": "Test_Value",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "Lower"
            },
            {
              "entity_id": "T276",
              "entity": "迅速下降",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Rapid decline"
            },
            {
              "entity_id": "T277",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T278",
              "entity": "肾病综合征",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 74,
              "entity_en": "Nephrotic syndrome"
            },
            {
              "entity_id": "T279",
              "entity": "顽固性高血压",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 84,
              "entity_en": "Resistant hypertension"
            },
            {
              "entity_id": "T280",
              "entity": "顽固性",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 81,
              "entity_en": "Stubbornness"
            },
            {
              "entity_id": "T281",
              "entity": "尿沉渣",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "Urine sediment"
            },
            {
              "entity_id": "T282",
              "entity": "血管紧张素转换酶抑制剂(ACEI)",
              "entity_type": "Drug",
              "start_idx": 116,
              "end_idx": 133,
              "entity_en": "Angiotensin-converting enzyme inhibitors (ACEIs)"
            },
            {
              "entity_id": "T283",
              "entity": "血管紧张素II受体拮抗剂(ARB)类药物",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 154,
              "entity_en": "Angiotensin II receptor blockers (ARBs)"
            },
            {
              "entity_id": "T284",
              "entity": "2~3个月",
              "entity_type": "Duration",
              "start_idx": 159,
              "end_idx": 164,
              "entity_en": "2~3 months"
            },
            {
              "entity_id": "T285",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 165,
              "end_idx": 171,
              "entity_en": "Glomerular filtration rate"
            },
            {
              "entity_id": "T286",
              "entity": "下降超过30%",
              "entity_type": "Test_Value",
              "start_idx": 171,
              "end_idx": 178,
              "entity_en": "Down more than 30%"
            },
            {
              "entity_id": "T287",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R140",
              "head_entity_id": "T273",
              "tail_entity_id": "T272"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R141",
              "head_entity_id": "T287",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R142",
              "head_entity_id": "T280",
              "tail_entity_id": "T279"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R143",
              "head_entity_id": "T284",
              "tail_entity_id": "T282"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R144",
              "head_entity_id": "T284",
              "tail_entity_id": "T283"
            }
          ],
          "sentence_en": "At the time of diagnosis, if any of the following conditions are present, CKD should be considered to be caused by other causes: (1) no diabetic retinopathy; (2) low or rapidly declining GFR; (3) a sharp increase in proteinuria or nephrotic syndrome; (4) refractory hypertension; (5) signs of active urine sediment; (6) symptoms or signs of other systemic diseases; (7) a decrease in glomerular filtration rate of more than 30% within 2 to 3 months after starting treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)."
        }
      ],
      "paragraph_en": "At the time of diagnosis, if any of the following conditions are present, CKD should be considered to be caused by other causes: (1) no diabetic retinopathy; (2) low or rapidly declining GFR; (3) a sharp increase in proteinuria or nephrotic syndrome; (4) refractory hypertension; (5) signs of active urine sediment; (6) symptoms or signs of other systemic diseases; (7) a decrease in glomerular filtration rate of more than 30% within 2 to 3 months after starting treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)."
    },
    {
      "paragraph_id": "17",
      "paragraph": "根据NKF-K/DOQI指南、NHS等标准，强调白蛋白尿是2型糖尿病肾脏病变诊断的必要依据，但不能涵盖正常白蛋白尿的糖尿病肾病，忽略了GFR的诊断价值。考虑到ADA指南建议每年检测CKD，本共识提出糖尿病视网膜病变并CKD任何一期的诊断标准，避免遗漏那些白蛋白尿正常但eGFR下降的糖尿病肾病。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "根据NKF-K/DOQI指南、NHS等标准，强调白蛋白尿是2型糖尿病肾脏病变诊断的必要依据，但不能涵盖正常白蛋白尿的糖尿病肾病，忽略了GFR的诊断价值。考虑到ADA指南建议每年检测CKD，本共识提出糖尿病视网膜病变并CKD任何一期的诊断标准，避免遗漏那些白蛋白尿正常但eGFR下降的糖尿病肾病。",
          "start_idx": 0,
          "end_idx": 147,
          "entities": [
            {
              "entity_id": "T288",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T289",
              "entity": "2型糖尿病肾脏病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 37,
              "entity_en": "Type 2 diabetic nephropathy"
            },
            {
              "entity_id": "T290",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T291",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T292",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T293",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T294",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 62,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T295",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 67,
              "end_idx": 70,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T296",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T297",
              "entity": "糖尿病视网膜病变",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 107,
              "entity_en": "Diabetic retinopathy"
            },
            {
              "entity_id": "T298",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 105,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T299",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 108,
              "end_idx": 111,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T300",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T301",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T302",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 138,
              "end_idx": 140,
              "entity_en": "decline"
            },
            {
              "entity_id": "T303",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 141,
              "end_idx": 146,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T304",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 144,
              "end_idx": 145,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R145",
              "head_entity_id": "T290",
              "tail_entity_id": "T289"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R146",
              "head_entity_id": "T291",
              "tail_entity_id": "T289"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T294",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R148",
              "head_entity_id": "T295",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R149",
              "head_entity_id": "T298",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R150",
              "head_entity_id": "T301",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R151",
              "head_entity_id": "T301",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R152",
              "head_entity_id": "T304",
              "tail_entity_id": "T303"
            }
          ],
          "sentence_en": "According to the NKF-K/DOQI guidelines, NHS and other standards, albuminuria is emphasized as a necessary basis for the diagnosis of type 2 diabetic nephropathy, but it does not cover diabetic nephropathy with normal albuminuria, ignoring the diagnostic value of GFR. Considering that the ADA guidelines recommend annual testing of CKD, this consensus proposes the diagnostic criteria for diabetic retinopathy and any stage of CKD to avoid missing those diabetic nephropathy with normal albuminuria but decreased eGFR."
        }
      ],
      "paragraph_en": "According to the NKF-K/DOQI guidelines, NHS and other standards, albuminuria is emphasized as a necessary basis for the diagnosis of type 2 diabetic nephropathy, but it does not cover diabetic nephropathy with normal albuminuria, ignoring the diagnostic value of GFR. Considering that the ADA guidelines recommend annual testing of CKD, this consensus proposes the diagnostic criteria for diabetic retinopathy and any stage of CKD to avoid missing those diabetic nephropathy with normal albuminuria but decreased eGFR."
    },
    {
      "paragraph_id": "18",
      "paragraph": "(四)糖尿病肾病的临床分期和病理分级",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)糖尿病肾病的临床分期和病理分级",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [
            {
              "entity_id": "T305",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T306",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 6,
              "end_idx": 7,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R153",
              "head_entity_id": "T306",
              "tail_entity_id": "T305"
            }
          ],
          "sentence_en": "4. Clinical staging and pathological grading of diabetic nephropathy"
        }
      ],
      "paragraph_en": "4. Clinical staging and pathological grading of diabetic nephropathy"
    },
    {
      "paragraph_id": "19",
      "paragraph": "1987年Mogensen建议，根据糖尿病肾病的病理生理特点和演变过程，将1型糖尿病患者的糖尿病肾病分为5期。I期：急性肾小球高滤过期，肾小球入球小动脉扩张，肾小球内压增加，GFR升高，伴或不伴肾体积增大；II期：正常白蛋白尿期，UAE正常(<20μg/min或<30mg/24h)(如休息时)，或呈间歇性微量白蛋白尿(如运动后、应激状态)，病理检查可发现肾小球基底膜轻度增厚；Ⅲ期：早期糖尿病肾病期(UAE 20~200μg/min或30~300mg/24h)，以持续性微量白蛋白尿为标志，病理检查肾小球基底膜(GBM)增厚及系膜进一步增宽；IV期：临床(显性)糖尿病肾病期，进展性显性白蛋白尿，部分可进展为肾病综合征，病理检查肾小球病变更重，如肾小球硬化，灶性肾小管萎缩及间质纤维化；V期：肾衰竭期。2型糖尿病患者的糖尿病肾病可参考以上标准分期。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1987年Mogensen建议，根据糖尿病肾病的病理生理特点和演变过程，将1型糖尿病患者的糖尿病肾病分为5期。I期：急性肾小球高滤过期，肾小球入球小动脉扩张，肾小球内压增加，GFR升高，伴或不伴肾体积增大；II期：正常白蛋白尿期，UAE正常(<20μg/min或<30mg/24h)(如休息时)，或呈间歇性微量白蛋白尿(如运动后、应激状态)，病理检查可发现肾小球基底膜轻度增厚；Ⅲ期：早期糖尿病肾病期(UAE 20~200μg/min或30~300mg/24h)，以持续性微量白蛋白尿为标志，病理检查肾小球基底膜(GBM)增厚及系膜进一步增宽；IV期：临床(显性)糖尿病肾病期，进展性显性白蛋白尿，部分可进展为肾病综合征，病理检查肾小球病变更重，如肾小球硬化，灶性肾小管萎缩及间质纤维化；V期：肾衰竭期。",
          "start_idx": 0,
          "end_idx": 352,
          "entities": [
            {
              "entity_id": "T307",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T308",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 21,
              "end_idx": 22,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T309",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T310",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T311",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T312",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 49,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T313",
              "entity": "急性肾小球高滤过期",
              "entity_type": "Class",
              "start_idx": 58,
              "end_idx": 67,
              "entity_en": "Acute glomerular hyperfiltration phase"
            },
            {
              "entity_id": "T314",
              "entity": "肾小球入球小动脉扩张",
              "entity_type": "Pathogenesis",
              "start_idx": 68,
              "end_idx": 78,
              "entity_en": "Dilation of glomerular afferent arterioles"
            },
            {
              "entity_id": "T315",
              "entity": "肾小球内压增加",
              "entity_type": "Pathogenesis",
              "start_idx": 79,
              "end_idx": 86,
              "entity_en": "Increased intraglomerular pressure"
            },
            {
              "entity_id": "T316",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 90,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T317",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T318",
              "entity": "肾体积增大",
              "entity_type": "Pathogenesis",
              "start_idx": 97,
              "end_idx": 102,
              "entity_en": "Increased kidney size"
            },
            {
              "entity_id": "T319",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 113,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T320",
              "entity": "UAE",
              "entity_type": "Test_items",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "UAE"
            },
            {
              "entity_id": "T321",
              "entity": "正常(<20μg/min或<30mg/24h)",
              "entity_type": "Test_Value",
              "start_idx": 118,
              "end_idx": 141,
              "entity_en": "Normal (<20 μg/min or <30 mg/24 h)"
            },
            {
              "entity_id": "T322",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T323",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T326",
              "entity": "肾小球基底膜轻度增厚",
              "entity_type": "Pathogenesis",
              "start_idx": 178,
              "end_idx": 188,
              "entity_en": "Mild thickening of glomerular basement membrane"
            },
            {
              "entity_id": "T327",
              "entity": "UAE",
              "entity_type": "Test_items",
              "start_idx": 201,
              "end_idx": 204,
              "entity_en": "UAE"
            },
            {
              "entity_id": "T328",
              "entity": "20~200μg/min",
              "entity_type": "Test_Value",
              "start_idx": 205,
              "end_idx": 217,
              "entity_en": "20~200μg/min"
            },
            {
              "entity_id": "T329",
              "entity": "30~300mg/24h",
              "entity_type": "Test_Value",
              "start_idx": 218,
              "end_idx": 230,
              "entity_en": "30-300 mg/24 hours"
            },
            {
              "entity_id": "T330",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 236,
              "end_idx": 238,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T331",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 238,
              "end_idx": 242,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T332",
              "entity": "肾小球基底膜(GBM)增厚",
              "entity_type": "Pathogenesis",
              "start_idx": 250,
              "end_idx": 263,
              "entity_en": "Glomerular basement membrane (GBM) thickening"
            },
            {
              "entity_id": "T333",
              "entity": "系膜进一步增宽",
              "entity_type": "Pathogenesis",
              "start_idx": 264,
              "end_idx": 271,
              "entity_en": "Further widening of the mesangium"
            },
            {
              "entity_id": "T334",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 282,
              "end_idx": 287,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T335",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 285,
              "end_idx": 286,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T336",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 294,
              "end_idx": 298,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T337",
              "entity": "肾病综合征",
              "entity_type": "Disease",
              "start_idx": 305,
              "end_idx": 310,
              "entity_en": "Nephrotic syndrome"
            },
            {
              "entity_id": "T338",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 305,
              "end_idx": 306,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T339",
              "entity": "肾小球病变",
              "entity_type": "Disease",
              "start_idx": 315,
              "end_idx": 320,
              "entity_en": "Glomerular lesions"
            },
            {
              "entity_id": "T340",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 315,
              "end_idx": 318,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T341",
              "entity": "肾小球硬化",
              "entity_type": "Pathogenesis",
              "start_idx": 324,
              "end_idx": 329,
              "entity_en": "Glomerulosclerosis"
            },
            {
              "entity_id": "T342",
              "entity": "灶性肾小管萎缩",
              "entity_type": "Pathogenesis",
              "start_idx": 330,
              "end_idx": 337,
              "entity_en": "Focal tubular atrophy"
            },
            {
              "entity_id": "T343",
              "entity": "间质纤维化",
              "entity_type": "Pathogenesis",
              "start_idx": 338,
              "end_idx": 343,
              "entity_en": "Interstitial fibrosis"
            },
            {
              "entity_id": "T344",
              "entity": "肾衰竭",
              "entity_type": "Disease",
              "start_idx": 347,
              "end_idx": 350,
              "entity_en": "Kidney failure"
            },
            {
              "entity_id": "T345",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 347,
              "end_idx": 348,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T348",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 194,
              "end_idx": 199,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T349",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 197,
              "end_idx": 198,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R154",
              "head_entity_id": "T308",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R155",
              "head_entity_id": "T310",
              "tail_entity_id": "T309"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R156",
              "head_entity_id": "T312",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R157",
              "head_entity_id": "T320",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R159",
              "head_entity_id": "T327",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R160",
              "head_entity_id": "T335",
              "tail_entity_id": "T334"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R161",
              "head_entity_id": "T338",
              "tail_entity_id": "T337"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R162",
              "head_entity_id": "T340",
              "tail_entity_id": "T339"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R163",
              "head_entity_id": "T341",
              "tail_entity_id": "T339"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R164",
              "head_entity_id": "T342",
              "tail_entity_id": "T339"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R165",
              "head_entity_id": "T343",
              "tail_entity_id": "T339"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R166",
              "head_entity_id": "T345",
              "tail_entity_id": "T344"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R168",
              "head_entity_id": "T349",
              "tail_entity_id": "T348"
            }
          ],
          "sentence_en": "In 1987, Mogensen suggested that diabetic nephropathy in patients with type 1 diabetes be divided into five stages based on the pathophysiological characteristics and evolution of diabetic nephropathy. Stage I: acute glomerular hyperfiltration stage, with dilation of glomerular afferent arterioles, increased intraglomerular pressure, and elevated GFR, with or without an increase in kidney volume; Stage II: normoalbuminuria stage, with normal UAE (<20 μg/min or <30 mg/24 h) (such as at rest), or intermittent microalbuminuria (such as after exercise, stress state), and pathological examination may reveal mild thickening of the glomerular basement membrane; Stage III: early diabetic nephropathy stage (UAE 20~200 μg/min or 30~300 mg/24 h), marked by persistent microalbuminuria, and pathological examination shows thickening of the glomerular basement membrane (GBM) and further widening of the mesangium; Stage IV: clinical (overt) diabetic nephropathy stage, with progressive overt albuminuria, some of which may progress to nephrotic syndrome, and pathological examination shows more severe glomerular lesions, such as glomerular sclerosis, focal tubular atrophy and interstitial fibrosis; Stage V: renal failure stage."
        },
        {
          "sentence_id": "1",
          "sentence": "2型糖尿病患者的糖尿病肾病可参考以上标准分期。",
          "start_idx": 352,
          "end_idx": 375,
          "entities": [
            {
              "entity_id": "T324",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T325",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T346",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T347",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 12,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R158",
              "head_entity_id": "T325",
              "tail_entity_id": "T324"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R167",
              "head_entity_id": "T347",
              "tail_entity_id": "T346"
            }
          ],
          "sentence_en": "The diabetic nephropathy in patients with type 2 diabetes can refer to the above standard staging."
        }
      ],
      "paragraph_en": "In 1987, Mogensen suggested that diabetic nephropathy in patients with type 1 diabetes be divided into five stages based on the pathophysiological characteristics and evolution of diabetic nephropathy. Stage I: acute glomerular hyperfiltration stage, with dilation of glomerular afferent arterioles, increased intraglomerular pressure, and elevated GFR, with or without an increase in kidney volume; Stage II: normoalbuminuria stage, with normal UAE (<20 μg/min or <30 mg/24 h) (such as at rest), or intermittent microalbuminuria (such as after exercise, stress state), and pathological examination may reveal mild thickening of the glomerular basement membrane; Stage III: early diabetic nephropathy stage (UAE 20~200 μg/min or 30~300 mg/24 h), marked by persistent microalbuminuria, and pathological examination shows thickening of the glomerular basement membrane (GBM) and further widening of the mesangium; Stage IV: clinical (overt) diabetic nephropathy stage, with progressive overt albuminuria, some of which may progress to nephrotic syndrome, and pathological examination shows more severe glomerular lesions, such as glomerular sclerosis, focal tubular atrophy and interstitial fibrosis; Stage V: renal failure stage. The diabetic nephropathy in patients with type 2 diabetes can refer to the above standard staging."
    },
    {
      "paragraph_id": "20",
      "paragraph": "病理活检被认为是糖尿病肾病诊断的金标准，不能依据临床病史排除其他肾脏疾病时，需考虑进行肾穿刺以确诊。2010年，肾脏病理学会研究委员会首次提出了糖尿病肾病病理分级标准，在1型和2型糖尿病患者中均适用。根据肾脏组织光镜、电镜及免疫荧光染色的改变对肾小球损害和肾小管/肾血管损伤分别进行分级、分度。肾小球损伤分为4级：Ⅰ级：GBM增厚；Ⅱa级：轻度系膜增生；Ⅱb级：重度系膜增生；Ⅲ级：一个以上结节性硬化(K-W结节)；Ⅳ级：晚期糖尿病肾小球硬化。肾小管间质用间质纤维化和肾小管萎缩、间质炎症的程度评分，肾血管损伤按血管透明变性和大血管硬化的程度评分。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "病理活检被认为是糖尿病肾病诊断的金标准，不能依据临床病史排除其他肾脏疾病时，需考虑进行肾穿刺以确诊。2010年，肾脏病理学会研究委员会首次提出了糖尿病肾病病理分级标准，在1型和2型糖尿病患者中均适用。根据肾脏组织光镜、电镜及免疫荧光染色的改变对肾小球损害和肾小管/肾血管损伤分别进行分级、分度。肾小球损伤分为4级：Ⅰ级：GBM增厚；Ⅱa级：轻度系膜增生；Ⅱb级：重度系膜增生；Ⅲ级：一个以上结节性硬化(K-W结节)；Ⅳ级：晚期糖尿病肾小球硬化。肾小管间质用间质纤维化和肾小管萎缩、间质炎症的程度评分，肾血管损伤按血管透明变性和大血管硬化的程度评分。",
          "start_idx": 0,
          "end_idx": 274,
          "entities": [
            {
              "entity_id": "T350",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T351",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 12,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T352",
              "entity": "肾脏疾病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T353",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T354",
              "entity": "肾穿刺",
              "entity_type": "Test",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "Renal puncture"
            },
            {
              "entity_id": "T355",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 77,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T356",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 76,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T357",
              "entity": "1型和2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 93,
              "entity_en": "Type 1 and type 2 diabetes"
            },
            {
              "entity_id": "T358",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 85,
              "end_idx": 87,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T359",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 88,
              "end_idx": 90,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T360",
              "entity": "肾脏组织光镜",
              "entity_type": "Test",
              "start_idx": 102,
              "end_idx": 108,
              "entity_en": "Renal tissue light microscopy"
            },
            {
              "entity_id": "T361",
              "entity": "电镜及免疫荧光染色",
              "entity_type": "Test",
              "start_idx": 109,
              "end_idx": 118,
              "entity_en": "Electron microscopy and immunofluorescence staining"
            },
            {
              "entity_id": "T362",
              "entity": "肾小球损害",
              "entity_type": "Disease",
              "start_idx": 122,
              "end_idx": 127,
              "entity_en": "Glomerular damage"
            },
            {
              "entity_id": "T363",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 122,
              "end_idx": 125,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T364",
              "entity": "肾小管/肾血管损伤",
              "entity_type": "Disease",
              "start_idx": 128,
              "end_idx": 137,
              "entity_en": "Renal tubular/renal vascular damage"
            },
            {
              "entity_id": "T365",
              "entity": "肾小管",
              "entity_type": "Anatomy",
              "start_idx": 128,
              "end_idx": 131,
              "entity_en": "Renal tubules"
            },
            {
              "entity_id": "T366",
              "entity": "肾血管",
              "entity_type": "Anatomy",
              "start_idx": 132,
              "end_idx": 135,
              "entity_en": "Renal blood vessels"
            },
            {
              "entity_id": "T367",
              "entity": "肾小球损伤",
              "entity_type": "Disease",
              "start_idx": 147,
              "end_idx": 152,
              "entity_en": "Glomerular damage"
            },
            {
              "entity_id": "T368",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 147,
              "end_idx": 150,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T369",
              "entity": "Ⅰ级",
              "entity_type": "Class",
              "start_idx": 157,
              "end_idx": 159,
              "entity_en": "Level I"
            },
            {
              "entity_id": "T370",
              "entity": "Ⅱa级",
              "entity_type": "Class",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "Grade IIa"
            },
            {
              "entity_id": "T371",
              "entity": "Ⅱb级",
              "entity_type": "Class",
              "start_idx": 177,
              "end_idx": 180,
              "entity_en": "Grade IIb"
            },
            {
              "entity_id": "T372",
              "entity": "Ⅲ级",
              "entity_type": "Class",
              "start_idx": 188,
              "end_idx": 190,
              "entity_en": "Grade III"
            },
            {
              "entity_id": "T373",
              "entity": "Ⅳ级",
              "entity_type": "Class",
              "start_idx": 208,
              "end_idx": 210,
              "entity_en": "Level IV"
            },
            {
              "entity_id": "T374",
              "entity": "GBM增厚",
              "entity_type": "Pathogenesis",
              "start_idx": 160,
              "end_idx": 165,
              "entity_en": "GBM thickening"
            },
            {
              "entity_id": "T375",
              "entity": "轻度系膜增生",
              "entity_type": "Pathogenesis",
              "start_idx": 170,
              "end_idx": 176,
              "entity_en": "Mild mesangial hyperplasia"
            },
            {
              "entity_id": "T376",
              "entity": "重度系膜增生",
              "entity_type": "Pathogenesis",
              "start_idx": 181,
              "end_idx": 187,
              "entity_en": "Severe mesangial proliferation"
            },
            {
              "entity_id": "T377",
              "entity": "一个以上结节性硬化(K-W结节)",
              "entity_type": "Pathogenesis",
              "start_idx": 191,
              "end_idx": 207,
              "entity_en": "More than one tuberous sclerosis (K-W nodule)"
            },
            {
              "entity_id": "T378",
              "entity": "晚期糖尿病肾小球硬化",
              "entity_type": "Pathogenesis",
              "start_idx": 211,
              "end_idx": 221,
              "entity_en": "Advanced diabetic glomerulosclerosis"
            },
            {
              "entity_id": "T379",
              "entity": "肾小管间质",
              "entity_type": "Anatomy",
              "start_idx": 222,
              "end_idx": 227,
              "entity_en": "Tubulointerstitium"
            },
            {
              "entity_id": "T380",
              "entity": "间质纤维化",
              "entity_type": "Pathogenesis",
              "start_idx": 228,
              "end_idx": 233,
              "entity_en": "Interstitial fibrosis"
            },
            {
              "entity_id": "T381",
              "entity": "肾小管萎缩",
              "entity_type": "Pathogenesis",
              "start_idx": 234,
              "end_idx": 239,
              "entity_en": "Tubular atrophy"
            },
            {
              "entity_id": "T382",
              "entity": "间质炎症",
              "entity_type": "Pathogenesis",
              "start_idx": 240,
              "end_idx": 244,
              "entity_en": "Interstitial inflammation"
            },
            {
              "entity_id": "T383",
              "entity": "肾血管损伤",
              "entity_type": "Disease",
              "start_idx": 250,
              "end_idx": 255,
              "entity_en": "Renal vascular injury"
            },
            {
              "entity_id": "T384",
              "entity": "肾血管",
              "entity_type": "Anatomy",
              "start_idx": 250,
              "end_idx": 253,
              "entity_en": "Renal blood vessels"
            },
            {
              "entity_id": "T385",
              "entity": "血管透明变性",
              "entity_type": "Pathogenesis",
              "start_idx": 256,
              "end_idx": 262,
              "entity_en": "Vascular hyalinosis"
            },
            {
              "entity_id": "T386",
              "entity": "大血管硬化",
              "entity_type": "Pathogenesis",
              "start_idx": 263,
              "end_idx": 268,
              "entity_en": "Large vessel sclerosis"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R169",
              "head_entity_id": "T351",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R170",
              "head_entity_id": "T354",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R171",
              "head_entity_id": "T353",
              "tail_entity_id": "T352"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R172",
              "head_entity_id": "T354",
              "tail_entity_id": "T352"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R173",
              "head_entity_id": "T356",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R174",
              "head_entity_id": "T358",
              "tail_entity_id": "T357"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R175",
              "head_entity_id": "T359",
              "tail_entity_id": "T357"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R176",
              "head_entity_id": "T360",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R177",
              "head_entity_id": "T360",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R178",
              "head_entity_id": "T361",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R179",
              "head_entity_id": "T361",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R180",
              "head_entity_id": "T363",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R181",
              "head_entity_id": "T365",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R182",
              "head_entity_id": "T366",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R183",
              "head_entity_id": "T369",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R184",
              "head_entity_id": "T371",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R185",
              "head_entity_id": "T372",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R186",
              "head_entity_id": "T373",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R187",
              "head_entity_id": "T374",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R188",
              "head_entity_id": "T375",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R189",
              "head_entity_id": "T376",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R190",
              "head_entity_id": "T377",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R191",
              "head_entity_id": "T378",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R192",
              "head_entity_id": "T368",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R193",
              "head_entity_id": "T384",
              "tail_entity_id": "T383"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R194",
              "head_entity_id": "T385",
              "tail_entity_id": "T383"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R195",
              "head_entity_id": "T386",
              "tail_entity_id": "T383"
            }
          ],
          "sentence_en": "Pathological biopsy is considered the gold standard for the diagnosis of diabetic nephropathy. When other kidney diseases cannot be excluded based on clinical history, renal puncture should be considered for diagnosis. In 2010, the Renal Pathology Society Research Committee first proposed the pathological grading standard for diabetic nephropathy, which is applicable to patients with type 1 and type 2 diabetes. Glomerular damage and tubular/renal vascular damage are graded and graded according to the changes in renal tissue light microscopy, electron microscopy and immunofluorescence staining. Glomerular damage is divided into 4 grades: Grade I: GBM thickening; Grade IIa: mild mesangial proliferation; Grade IIb: severe mesangial proliferation; Grade III: more than one tuberous sclerosis (K-W nodule); Grade IV: advanced diabetic glomerulosclerosis. The tubulointerstitium is scored by the degree of interstitial fibrosis, tubular atrophy, and interstitial inflammation, and renal vascular damage is scored by the degree of vascular hyalinization and large vessel sclerosis."
        }
      ],
      "paragraph_en": "Pathological biopsy is considered the gold standard for the diagnosis of diabetic nephropathy. When other kidney diseases cannot be excluded based on clinical history, renal puncture should be considered for diagnosis. In 2010, the Renal Pathology Society Research Committee first proposed the pathological grading standard for diabetic nephropathy, which is applicable to patients with type 1 and type 2 diabetes. Glomerular damage and tubular/renal vascular damage are graded and graded according to the changes in renal tissue light microscopy, electron microscopy and immunofluorescence staining. Glomerular damage is divided into 4 grades: Grade I: GBM thickening; Grade IIa: mild mesangial proliferation; Grade IIb: severe mesangial proliferation; Grade III: more than one tuberous sclerosis (K-W nodule); Grade IV: advanced diabetic glomerulosclerosis. The tubulointerstitium is scored by the degree of interstitial fibrosis, tubular atrophy, and interstitial inflammation, and renal vascular damage is scored by the degree of vascular hyalinization and large vessel sclerosis."
    },
    {
      "paragraph_id": "21",
      "paragraph": "二、糖尿病肾病的防治",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、糖尿病肾病的防治",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T387",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T388",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 6,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R196",
              "head_entity_id": "T388",
              "tail_entity_id": "T387"
            }
          ],
          "sentence_en": "2. Prevention and treatment of diabetic nephropathy"
        }
      ],
      "paragraph_en": "2. Prevention and treatment of diabetic nephropathy"
    },
    {
      "paragraph_id": "22",
      "paragraph": "糖尿病肾病的防治分为三个阶段。第一阶段为糖尿病肾病的预防，对重点人群进行糖尿病筛查，发现糖耐量受损或空腹血糖受损的患者，采取改变生活方式、控制血糖等措施，预防糖尿病及糖尿病肾病的发生。第二阶段为糖尿病肾病早期治疗，出现微量白蛋白尿的糖尿病患者，予以糖尿病肾病治疗，减少或延缓大量蛋白尿的发生。第三阶段为预防或延缓肾功能不全的发生或进展，治疗并发症，出现肾功能不全者考虑肾脏替代治疗。糖尿病肾病的治疗以控制血糖、控制血压、减少尿蛋白为主，还包括生活方式干预、纠正脂质代谢紊乱、治疗肾功能不全的并发症、透析治疗等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病肾病的防治分为三个阶段。第一阶段为糖尿病肾病的预防，对重点人群进行糖尿病筛查，发现糖耐量受损或空腹血糖受损的患者，采取改变生活方式、控制血糖等措施，预防糖尿病及糖尿病肾病的发生。第二阶段为糖尿病肾病早期治疗，出现微量白蛋白尿的糖尿病患者，予以糖尿病肾病治疗，减少或延缓大量蛋白尿的发生。第三阶段为预防或延缓肾功能不全的发生或进展，治疗并发症，出现肾功能不全者考虑肾脏替代治疗。糖尿病肾病的治疗以控制血糖、控制血压、减少尿蛋白为主，还包括生活方式干预、纠正脂质代谢紊乱、治疗肾功能不全的并发症、透析治疗等。",
          "start_idx": 0,
          "end_idx": 255,
          "entities": [
            {
              "entity_id": "T389",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T390",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T391",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T392",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 23,
              "end_idx": 24,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T393",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T394",
              "entity": "糖耐量受损",
              "entity_type": "Pathogenesis",
              "start_idx": 44,
              "end_idx": 49,
              "entity_en": "Impaired glucose tolerance"
            },
            {
              "entity_id": "T395",
              "entity": "空腹血糖受损",
              "entity_type": "Pathogenesis",
              "start_idx": 50,
              "end_idx": 56,
              "entity_en": "Impaired fasting glucose"
            },
            {
              "entity_id": "T396",
              "entity": "改变生活方式",
              "entity_type": "Treatment",
              "start_idx": 62,
              "end_idx": 68,
              "entity_en": "Lifestyle changes"
            },
            {
              "entity_id": "T397",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T398",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 82,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T399",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 88,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T400",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 86,
              "end_idx": 87,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T401",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 102,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T402",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 100,
              "end_idx": 101,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T403",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 109,
              "end_idx": 111,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T404",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T405",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 116,
              "end_idx": 119,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T406",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 124,
              "end_idx": 129,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T407",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 127,
              "end_idx": 128,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T408",
              "entity": "大量",
              "entity_type": "Level",
              "start_idx": 137,
              "end_idx": 139,
              "entity_en": "Large"
            },
            {
              "entity_id": "T409",
              "entity": "蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 139,
              "end_idx": 142,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T410",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 156,
              "end_idx": 161,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T411",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 156,
              "end_idx": 157,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T412",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 176,
              "end_idx": 181,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T413",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 176,
              "end_idx": 177,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T414",
              "entity": "肾脏替代治疗",
              "entity_type": "Treatment",
              "start_idx": 184,
              "end_idx": 190,
              "entity_en": "Renal replacement therapy"
            },
            {
              "entity_id": "T415",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 191,
              "end_idx": 196,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T416",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 194,
              "end_idx": 195,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T417",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 207,
              "end_idx": 209,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T418",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 202,
              "end_idx": 204,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T419",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 212,
              "end_idx": 215,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T420",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 221,
              "end_idx": 227,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T421",
              "entity": "脂质代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 230,
              "end_idx": 236,
              "entity_en": "Lipid metabolism disorders"
            },
            {
              "entity_id": "T422",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 239,
              "end_idx": 244,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T423",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 239,
              "end_idx": 240,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T424",
              "entity": "透析治疗",
              "entity_type": "Treatment",
              "start_idx": 249,
              "end_idx": 253,
              "entity_en": "Dialysis treatment"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R197",
              "head_entity_id": "T390",
              "tail_entity_id": "T389"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R198",
              "head_entity_id": "T392",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R199",
              "head_entity_id": "T394",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R200",
              "head_entity_id": "T395",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R201",
              "head_entity_id": "T396",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R202",
              "head_entity_id": "T397",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R203",
              "head_entity_id": "T400",
              "tail_entity_id": "T399"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R204",
              "head_entity_id": "T402",
              "tail_entity_id": "T401"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R205",
              "head_entity_id": "T407",
              "tail_entity_id": "T406"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R206",
              "head_entity_id": "T411",
              "tail_entity_id": "T410"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R207",
              "head_entity_id": "T413",
              "tail_entity_id": "T412"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R208",
              "head_entity_id": "T414",
              "tail_entity_id": "T412"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R209",
              "head_entity_id": "T416",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R210",
              "head_entity_id": "T418",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R211",
              "head_entity_id": "T419",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R212",
              "head_entity_id": "T417",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R213",
              "head_entity_id": "T420",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R214",
              "head_entity_id": "T424",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R215",
              "head_entity_id": "T423",
              "tail_entity_id": "T422"
            }
          ],
          "sentence_en": "The prevention and treatment of diabetic nephropathy is divided into three stages. The first stage is the prevention of diabetic nephropathy. Diabetes screening is performed on key populations. Patients with impaired glucose tolerance or impaired fasting blood sugar are found, and measures such as changing lifestyles and controlling blood sugar are taken to prevent the occurrence of diabetes and diabetic nephropathy. The second stage is the early treatment of diabetic nephropathy. Diabetic patients with microalbuminuria are given diabetic nephropathy treatment to reduce or delay the occurrence of massive proteinuria. The third stage is to prevent or delay the occurrence or progression of renal insufficiency and treat complications. Renal replacement therapy is considered for those with renal insufficiency. The treatment of diabetic nephropathy focuses on controlling blood sugar, controlling blood pressure, and reducing urinary protein. It also includes lifestyle intervention, correction of lipid metabolism disorders, treatment of complications of renal insufficiency, dialysis treatment, etc."
        }
      ],
      "paragraph_en": "The prevention and treatment of diabetic nephropathy is divided into three stages. The first stage is the prevention of diabetic nephropathy. Diabetes screening is performed on key populations. Patients with impaired glucose tolerance or impaired fasting blood sugar are found, and measures such as changing lifestyles and controlling blood sugar are taken to prevent the occurrence of diabetes and diabetic nephropathy. The second stage is the early treatment of diabetic nephropathy. Diabetic patients with microalbuminuria are given diabetic nephropathy treatment to reduce or delay the occurrence of massive proteinuria. The third stage is to prevent or delay the occurrence or progression of renal insufficiency and treat complications. Renal replacement therapy is considered for those with renal insufficiency. The treatment of diabetic nephropathy focuses on controlling blood sugar, controlling blood pressure, and reducing urinary protein. It also includes lifestyle intervention, correction of lipid metabolism disorders, treatment of complications of renal insufficiency, dialysis treatment, etc."
    },
    {
      "paragraph_id": "23",
      "paragraph": "(一)生活方式指导",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)生活方式指导",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T425",
              "entity": "生活方式指导",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Lifestyle guidance"
            }
          ],
          "relations": [],
          "sentence_en": "1. Lifestyle guidance"
        }
      ],
      "paragraph_en": "1. Lifestyle guidance"
    },
    {
      "paragraph_id": "24",
      "paragraph": "改变生活方式包括饮食治疗、运动、戒酒、戒烟、控制体重，有利于减缓糖尿病肾病进展，保护肾功能。近期研究证明控制多种危险因素(降糖、降脂、降压并注意生活干预后)糖尿病肾病发展至肾功能衰竭的比例明显下降，生存率明显增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "改变生活方式包括饮食治疗、运动、戒酒、戒烟、控制体重，有利于减缓糖尿病肾病进展，保护肾功能。近期研究证明控制多种危险因素(降糖、降脂、降压并注意生活干预后)糖尿病肾病发展至肾功能衰竭的比例明显下降，生存率明显增加。",
          "start_idx": 0,
          "end_idx": 107,
          "entities": [
            {
              "entity_id": "T426",
              "entity": "改变生活方式",
              "entity_type": "Treatment",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Lifestyle changes"
            },
            {
              "entity_id": "T427",
              "entity": "饮食治疗",
              "entity_type": "Treatment",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Diet therapy"
            },
            {
              "entity_id": "T428",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "sports"
            },
            {
              "entity_id": "T429",
              "entity": "戒酒",
              "entity_type": "Treatment",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "Stop drinking"
            },
            {
              "entity_id": "T430",
              "entity": "戒烟",
              "entity_type": "Treatment",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "Quitting smoking"
            },
            {
              "entity_id": "T431",
              "entity": "控制体重",
              "entity_type": "Treatment",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Weight control"
            },
            {
              "entity_id": "T432",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T433",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 36,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T434",
              "entity": "生活干预",
              "entity_type": "Treatment",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Lifestyle intervention"
            },
            {
              "entity_id": "T435",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T436",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 81,
              "end_idx": 82,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T437",
              "entity": "肾功能衰竭",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 91,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T438",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 86,
              "end_idx": 87,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R216",
              "head_entity_id": "T426",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R217",
              "head_entity_id": "T427",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R218",
              "head_entity_id": "T428",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R219",
              "head_entity_id": "T429",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R220",
              "head_entity_id": "T430",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R221",
              "head_entity_id": "T431",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R222",
              "head_entity_id": "T433",
              "tail_entity_id": "T432"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R223",
              "head_entity_id": "T434",
              "tail_entity_id": "T435"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R224",
              "head_entity_id": "T436",
              "tail_entity_id": "T435"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R225",
              "head_entity_id": "T438",
              "tail_entity_id": "T437"
            }
          ],
          "sentence_en": "Changing lifestyles, including diet therapy, exercise, quitting drinking and smoking, and controlling weight, can help slow the progression of diabetic nephropathy and protect renal function. Recent studies have shown that controlling multiple risk factors (lowering blood sugar, lipids, and blood pressure, and paying attention to lifestyle intervention) significantly reduces the proportion of diabetic nephropathy developing into renal failure, and significantly increases the survival rate."
        }
      ],
      "paragraph_en": "Changing lifestyles, including diet therapy, exercise, quitting drinking and smoking, and controlling weight, can help slow the progression of diabetic nephropathy and protect renal function. Recent studies have shown that controlling multiple risk factors (lowering blood sugar, lipids, and blood pressure, and paying attention to lifestyle intervention) significantly reduces the proportion of diabetic nephropathy developing into renal failure, and significantly increases the survival rate."
    },
    {
      "paragraph_id": "25",
      "paragraph": "1.医学营养治疗：医学营养治疗应强调饮食结构合理，包括对碳水化合物、蛋白质、脂肪、钠、钾、磷等营养素的管理。每日摄入的总热量应使患者维持接近理想体重，肥胖者可适当减少热量，消瘦者可适当增加热量。高蛋白摄入(超过总热量20%)与轻度肾损伤糖尿病患者中肾功能的下降、糖尿病合并高血压患者中微量白蛋白尿的发展相关联。因此糖尿病肾病患者应避免高蛋白饮食，严格控制蛋白质每日摄入量，不超过总热量的15%，微量白蛋白尿者每千克体重应控制在0.8~1.0g，显性蛋白尿者及肾功能损害者应控制在0.6~0.8g。有随机对照试验的meta分析表明，低蛋白饮食治疗对蛋白尿的控制有益，但对GFR或内生肌酐清除率(Ccr)的改善无显著作用。由于蛋白质的摄入减少，摄入的蛋白质应以生物学效价高的优质蛋白质为主，可从家禽、鱼、大豆及植物蛋白等中获得。有研究表明，ARB/ACEI类药物在低钠饮食下对糖尿病。肾病及心血管疾病的改善作用更明显，但在高钠饮食下则可能存在危害，此应限制钠盐摄入，每日摄入量控制在2000~2400mg，高血压者可配合降压药物治疗。尚无明确证据表明富含纤维的蔬菜的摄入对糖尿病肾病有益。与执业营养师一起完成营养控制目标，可改善糖尿病肾病患者的预后。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.医学营养治疗：医学营养治疗应强调饮食结构合理，包括对碳水化合物、蛋白质、脂肪、钠、钾、磷等营养素的管理。每日摄入的总热量应使患者维持接近理想体重，肥胖者可适当减少热量，消瘦者可适当增加热量。高蛋白摄入(超过总热量20%)与轻度肾损伤糖尿病患者中肾功能的下降、糖尿病合并高血压患者中微量白蛋白尿的发展相关联。因此糖尿病肾病患者应避免高蛋白饮食，严格控制蛋白质每日摄入量，不超过总热量的15%，微量白蛋白尿者每千克体重应控制在0.8~1.0g，显性蛋白尿者及肾功能损害者应控制在0.6~0.8g。有随机对照试验的meta分析表明，低蛋白饮食治疗对蛋白尿的控制有益，但对GFR或内生肌酐清除率(Ccr)的改善无显著作用。由于蛋白质的摄入减少，摄入的蛋白质应以生物学效价高的优质蛋白质为主，可从家禽、鱼、大豆及植物蛋白等中获得。有研究表明，ARB/ACEI类药物在低钠饮食下对糖尿病。肾病及心血管疾病的改善作用更明显，但在高钠饮食下则可能存在危害，此应限制钠盐摄入，每日摄入量控制在2000~2400mg，高血压者可配合降压药物治疗。",
          "start_idx": 0,
          "end_idx": 465,
          "entities": [
            {
              "entity_id": "T439",
              "entity": "医学营养治疗",
              "entity_type": "Treatment",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "Medical Nutrition Therapy"
            },
            {
              "entity_id": "T440",
              "entity": "医学营养治疗",
              "entity_type": "Treatment",
              "start_idx": 9,
              "end_idx": 15,
              "entity_en": "Medical Nutrition Therapy"
            },
            {
              "entity_id": "T441",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T442",
              "entity": "消瘦",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "thin"
            },
            {
              "entity_id": "T443",
              "entity": "高蛋白摄入",
              "entity_type": "Treatment",
              "start_idx": 97,
              "end_idx": 102,
              "entity_en": "High protein intake"
            },
            {
              "entity_id": "T444",
              "entity": "肾损伤",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "Kidney damage"
            },
            {
              "entity_id": "T445",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 115,
              "end_idx": 116,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T446",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T447",
              "entity": "轻度",
              "entity_type": "Class",
              "start_idx": 113,
              "end_idx": 115,
              "entity_en": "Mild"
            },
            {
              "entity_id": "T448",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T449",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 128,
              "end_idx": 130,
              "entity_en": "decline"
            },
            {
              "entity_id": "T450",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T451",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 136,
              "end_idx": 139,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T452",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T453",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 144,
              "end_idx": 148,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T454",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 157,
              "end_idx": 162,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T455",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 160,
              "end_idx": 161,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T456",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 197,
              "end_idx": 199,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T457",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 199,
              "end_idx": 203,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T458",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 227,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T459",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 229,
              "end_idx": 234,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T460",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 229,
              "end_idx": 230,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T461",
              "entity": "低蛋白饮食治疗",
              "entity_type": "Treatment",
              "start_idx": 265,
              "end_idx": 272,
              "entity_en": "Low-protein diet therapy"
            },
            {
              "entity_id": "T462",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 284,
              "end_idx": 287,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T463",
              "entity": "内生肌酐清除率(Ccr)",
              "entity_type": "Test_items",
              "start_idx": 288,
              "end_idx": 300,
              "entity_en": "Endogenous creatinine clearance (Ccr)"
            },
            {
              "entity_id": "T464",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 273,
              "end_idx": 276,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T465",
              "entity": "ARB/ACEI类药物",
              "entity_type": "Drug",
              "start_idx": 368,
              "end_idx": 379,
              "entity_en": "ARB/ACEI drugs"
            },
            {
              "entity_id": "T466",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 386,
              "end_idx": 389,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T467",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 390,
              "end_idx": 392,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T468",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 390,
              "end_idx": 391,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T469",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 393,
              "end_idx": 398,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T470",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 393,
              "end_idx": 396,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T471",
              "entity": "限制钠盐摄入",
              "entity_type": "Treatment",
              "start_idx": 424,
              "end_idx": 430,
              "entity_en": "Limit sodium intake"
            },
            {
              "entity_id": "T472",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 451,
              "end_idx": 454,
              "entity_en": "hypertension"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R226",
              "head_entity_id": "T443",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R227",
              "head_entity_id": "T443",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R228",
              "head_entity_id": "T443",
              "tail_entity_id": "T450"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R229",
              "head_entity_id": "T443",
              "tail_entity_id": "T451"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R230",
              "head_entity_id": "T443",
              "tail_entity_id": "T453"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R231",
              "head_entity_id": "T447",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R232",
              "head_entity_id": "T448",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R233",
              "head_entity_id": "T448",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R234",
              "head_entity_id": "T455",
              "tail_entity_id": "T454"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R235",
              "head_entity_id": "T460",
              "tail_entity_id": "T459"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R236",
              "head_entity_id": "T461",
              "tail_entity_id": "T464"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R237",
              "head_entity_id": "T462",
              "tail_entity_id": "T464"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R238",
              "head_entity_id": "T463",
              "tail_entity_id": "T464"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R239",
              "head_entity_id": "T465",
              "tail_entity_id": "T466"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R240",
              "head_entity_id": "T468",
              "tail_entity_id": "T467"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R241",
              "head_entity_id": "T471",
              "tail_entity_id": "T467"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R242",
              "head_entity_id": "T470",
              "tail_entity_id": "T469"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R243",
              "head_entity_id": "T471",
              "tail_entity_id": "T469"
            }
          ],
          "sentence_en": "1. Medical nutrition therapy: Medical nutrition therapy should emphasize a reasonable diet structure, including the management of nutrients such as carbohydrates, proteins, fats, sodium, potassium, and phosphorus. The total daily calorie intake should keep the patient close to the ideal weight. Obese patients can appropriately reduce calories, and thin patients can appropriately increase calories. High protein intake (more than 20% of total calories) is associated with decreased renal function in diabetic patients with mild renal damage and the development of microalbuminuria in diabetic patients with hypertension. Therefore, patients with diabetic nephropathy should avoid a high-protein diet and strictly control the daily protein intake, not exceeding 15% of total calories. Microalbuminuria should be controlled at 0.8~1.0g per kilogram of body weight, and overt proteinuria and renal impairment should be controlled at 0.6~0.8g. A meta-analysis of randomized controlled trials showed that low-protein diet therapy is beneficial for the control of proteinuria, but has no significant effect on the improvement of GFR or endogenous creatinine clearance (Ccr). Due to the reduction in protein intake, the protein intake should be mainly high-quality protein with high biological efficacy, which can be obtained from poultry, fish, soybeans, and plant proteins. Studies have shown that ARB/ACEI drugs have a more obvious effect on improving diabetes, kidney disease and cardiovascular disease under a low-sodium diet, but may be harmful under a high-sodium diet. Therefore, sodium salt intake should be limited to 2000~2400mg per day. Hypertension patients can be treated with antihypertensive drugs."
        },
        {
          "sentence_id": "1",
          "sentence": "尚无明确证据表明富含纤维的蔬菜的摄入对糖尿病肾病有益。",
          "start_idx": 465,
          "end_idx": 492,
          "entities": [
            {
              "entity_id": "T473",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T474",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 22,
              "end_idx": 23,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R244",
              "head_entity_id": "T474",
              "tail_entity_id": "T473"
            }
          ],
          "sentence_en": "There is no clear evidence that fiber-rich vegetable intake is beneficial for diabetic nephropathy."
        },
        {
          "sentence_id": "2",
          "sentence": "与执业营养师一起完成营养控制目标，可改善糖尿病肾病患者的预后。",
          "start_idx": 492,
          "end_idx": 523,
          "entities": [
            {
              "entity_id": "T475",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T476",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 23,
              "end_idx": 24,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R245",
              "head_entity_id": "T476",
              "tail_entity_id": "T475"
            }
          ],
          "sentence_en": "Achieving nutritional control goals together with a practicing dietitian can improve the prognosis of patients with diabetic nephropathy."
        }
      ],
      "paragraph_en": "1. Medical nutrition therapy: Medical nutrition therapy should emphasize a reasonable diet structure, including the management of nutrients such as carbohydrates, proteins, fats, sodium, potassium, and phosphorus. The total daily calorie intake should keep the patient close to the ideal weight. Obese patients can appropriately reduce calories, and thin patients can appropriately increase calories. High protein intake (more than 20% of total calories) is associated with decreased renal function in diabetic patients with mild renal damage and the development of microalbuminuria in diabetic patients with hypertension. Therefore, patients with diabetic nephropathy should avoid a high-protein diet and strictly control the daily protein intake, not exceeding 15% of total calories. Microalbuminuria should be controlled at 0.8~1.0g per kilogram of body weight, and overt proteinuria and renal impairment should be controlled at 0.6~0.8g. A meta-analysis of randomized controlled trials showed that low-protein diet therapy is beneficial for the control of proteinuria, but has no significant effect on the improvement of GFR or endogenous creatinine clearance (Ccr). Due to the reduction in protein intake, the protein intake should be mainly high-quality protein with high biological value, which can be obtained from poultry, fish, soybeans and plant protein. Studies have shown that ARB/ACEI drugs have a more obvious effect on improving diabetic nephropathy and cardiovascular disease under a low-sodium diet, but may be harmful under a high-sodium diet. Therefore, sodium salt intake should be limited to 2000~2400mg per day. Hypertensive patients can take antihypertensive drugs. There is no clear evidence that the intake of fiber-rich vegetables is beneficial for diabetic nephropathy. Achieving nutritional control goals with a practicing dietitian can improve the prognosis of patients with diabetic nephropathy."
    },
    {
      "paragraph_id": "26",
      "paragraph": "2.运动：体力活动可诱导糖尿病肾病早期的尿蛋白暂时升高，长期规律的运动可通过提高胰岛素敏感性、改善糖耐量，减轻体重，改善脂质代谢，改善内皮功能，控制血糖、血压，，减缓糖尿病及糖尿病肾病的发生发展。糖尿病控制和并发症防治试验(DCCT)的回顾分析却表明运动对1型糖尿病微血管病变的预后无改善作用，但无证据表明运动带来危害，故仍建议1型糖尿病患者运动。FinnDiane研究结果显示，低频率低强度体育锻炼的1型糖尿病患者发生糖尿病肾病的比例更高。因此糖尿病肾病患者运动的频率强度应达到一定的要求。患者每周应至少进行150min以上中等强度的有氧运动(运动时心率达到最高值的50%~70%)，每周至少运动3d，每周至少安排2次对抗性训练。不适当的运动可因胰岛素水平不足诱发酮症，也可因过度耗能诱发低血糖，因而运动强度、持续时间、频率、项目的选择都要个体化，建议糖尿病肾病患者在专业人士的指导下制定合理的运动方案，或参加运动计划，提高依从性，减少运动不良后果的发生。对于进展至ESRD的糖尿病肾病患者，每周2~3次以上的有氧运动、对抗性运动有利于控制血压、减轻炎症、改善生活质量，但证据大多来自小样本试验。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.运动：体力活动可诱导糖尿病肾病早期的尿蛋白暂时升高，长期规律的运动可通过提高胰岛素敏感性、改善糖耐量，减轻体重，改善脂质代谢，改善内皮功能，控制血糖、血压，，减缓糖尿病及糖尿病肾病的发生发展。糖尿病控制和并发症防治试验(DCCT)的回顾分析却表明运动对1型糖尿病微血管病变的预后无改善作用，但无证据表明运动带来危害，故仍建议1型糖尿病患者运动。FinnDiane研究结果显示，低频率低强度体育锻炼的1型糖尿病患者发生糖尿病肾病的比例更高。因此糖尿病肾病患者运动的频率强度应达到一定的要求。患者每周应至少进行150min以上中等强度的有氧运动(运动时心率达到最高值的50%~70%)，每周至少运动3d，每周至少安排2次对抗性训练。不适当的运动可因胰岛素水平不足诱发酮症，也可因过度耗能诱发低血糖，因而运动强度、持续时间、频率、项目的选择都要个体化，建议糖尿病肾病患者在专业人士的指导下制定合理的运动方案，或参加运动计划，提高依从性，减少运动不良后果的发生。对于进展至ESRD的糖尿病肾病患者，每周2~3次以上的有氧运动、对抗性运动有利于控制血压、减轻炎症、改善生活质量，但证据大多来自小样本试验。",
          "start_idx": 0,
          "end_idx": 499,
          "entities": [
            {
              "entity_id": "T477",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "sports"
            },
            {
              "entity_id": "T478",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T479",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 16,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T480",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T481",
              "entity": "暂时升高",
              "entity_type": "Test_Value",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Temporary increase"
            },
            {
              "entity_id": "T482",
              "entity": "长期规律的运动",
              "entity_type": "Treatment",
              "start_idx": 28,
              "end_idx": 35,
              "entity_en": "Long-term regular exercise"
            },
            {
              "entity_id": "T483",
              "entity": "糖耐量",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "Glucose tolerance"
            },
            {
              "entity_id": "T484",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 74,
              "end_idx": 76,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T485",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T486",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T487",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 92,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T488",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 90,
              "end_idx": 91,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T489",
              "entity": "酮症",
              "entity_type": "Disease",
              "start_idx": 333,
              "end_idx": 335,
              "entity_en": "Ketosis"
            },
            {
              "entity_id": "T490",
              "entity": "胰岛素水平不足",
              "entity_type": "Pathogenesis",
              "start_idx": 324,
              "end_idx": 331,
              "entity_en": "Insufficient insulin levels"
            },
            {
              "entity_id": "T491",
              "entity": "不适当的运动",
              "entity_type": "Reason",
              "start_idx": 316,
              "end_idx": 322,
              "entity_en": "Inappropriate exercise"
            },
            {
              "entity_id": "T492",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 345,
              "end_idx": 348,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T493",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 377,
              "end_idx": 382,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T494",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 380,
              "end_idx": 381,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T495",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 434,
              "end_idx": 438,
              "entity_en": "ESRD"
            },
            {
              "entity_id": "T496",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 439,
              "end_idx": 444,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T497",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 442,
              "end_idx": 443,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T498",
              "entity": "每周2~3次以上的有氧运动、对抗性运动",
              "entity_type": "Treatment",
              "start_idx": 447,
              "end_idx": 466,
              "entity_en": "Do aerobic exercise or resistance exercise 2 to 3 times a week"
            },
            {
              "entity_id": "T499",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 471,
              "end_idx": 473,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T500",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 101,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T501",
              "entity": "1型糖尿病微血管病变",
              "entity_type": "Disease",
              "start_idx": 128,
              "end_idx": 138,
              "entity_en": "Type 1 diabetes microangiopathy"
            },
            {
              "entity_id": "T502",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 125,
              "end_idx": 127,
              "entity_en": "sports"
            },
            {
              "entity_id": "T503",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 128,
              "end_idx": 130,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T504",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 133,
              "end_idx": 136,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T505",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 169,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T506",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 164,
              "end_idx": 166,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T507",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 201,
              "end_idx": 206,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T508",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 201,
              "end_idx": 203,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T509",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 210,
              "end_idx": 215,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T510",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 213,
              "end_idx": 214,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T511",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "sports"
            },
            {
              "entity_id": "T512",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 171,
              "end_idx": 173,
              "entity_en": "sports"
            },
            {
              "entity_id": "T513",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 223,
              "end_idx": 228,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T514",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 226,
              "end_idx": 227,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T515",
              "entity": "每周应至少进行150min以上中等强度的有氧运动",
              "entity_type": "Treatment",
              "start_idx": 248,
              "end_idx": 272,
              "entity_en": "At least 150 minutes of moderate-intensity aerobic exercise should be performed every week"
            },
            {
              "entity_id": "T516",
              "entity": "每周至少运动3d",
              "entity_type": "Treatment",
              "start_idx": 293,
              "end_idx": 301,
              "entity_en": "Exercise at least 3 days a week"
            },
            {
              "entity_id": "T517",
              "entity": "每周至少安排2次对抗性训练",
              "entity_type": "Treatment",
              "start_idx": 302,
              "end_idx": 315,
              "entity_en": "Arrange at least 2 confrontational training sessions per week"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R246",
              "head_entity_id": "T479",
              "tail_entity_id": "T478"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R247",
              "head_entity_id": "T480",
              "tail_entity_id": "T478"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R248",
              "head_entity_id": "T483",
              "tail_entity_id": "T478"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R249",
              "head_entity_id": "T484",
              "tail_entity_id": "T478"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R250",
              "head_entity_id": "T482",
              "tail_entity_id": "T478"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R251",
              "head_entity_id": "T485",
              "tail_entity_id": "T478"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R252",
              "head_entity_id": "T491",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R253",
              "head_entity_id": "T490",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R254",
              "head_entity_id": "T491",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R255",
              "head_entity_id": "T494",
              "tail_entity_id": "T493"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R256",
              "head_entity_id": "T498",
              "tail_entity_id": "T495"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R257",
              "head_entity_id": "T499",
              "tail_entity_id": "T495"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R258",
              "head_entity_id": "T498",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R259",
              "head_entity_id": "T497",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R260",
              "head_entity_id": "T499",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R261",
              "head_entity_id": "T502",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R262",
              "head_entity_id": "T503",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R263",
              "head_entity_id": "T504",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R264",
              "head_entity_id": "T506",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R265",
              "head_entity_id": "T512",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R266",
              "head_entity_id": "T508",
              "tail_entity_id": "T507"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R267",
              "head_entity_id": "T510",
              "tail_entity_id": "T509"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R268",
              "head_entity_id": "T514",
              "tail_entity_id": "T513"
            }
          ],
          "sentence_en": "2. Exercise: Physical activity can induce a temporary increase in urine protein in the early stages of diabetic nephropathy. Long-term regular exercise can slow down the development of diabetes and diabetic nephropathy by improving insulin sensitivity, improving glucose tolerance, reducing weight, improving lipid metabolism, improving endothelial function, controlling blood sugar and blood pressure. A retrospective analysis of the Diabetes Control and Complications Trial (DCCT) showed that exercise had no effect on the prognosis of microvascular lesions in type 1 diabetes, but there was no evidence that exercise was harmful, so it is still recommended that patients with type 1 diabetes exercise. The results of the FinnDiane study showed that patients with type 1 diabetes who exercised at low frequency and low intensity had a higher incidence of diabetic nephropathy. Therefore, the frequency and intensity of exercise for patients with diabetic nephropathy should meet certain requirements. Patients should perform at least 150 minutes of moderate-intensity aerobic exercise per week (heart rate reaches 50% to 70% of the maximum value during exercise), exercise at least 3 days per week, and arrange at least 2 confrontational training sessions per week. Inappropriate exercise can induce ketosis due to insufficient insulin levels, or hypoglycemia due to excessive energy consumption. Therefore, the intensity, duration, frequency, and selection of exercise items should be individualized. It is recommended that patients with diabetic nephropathy develop a reasonable exercise plan under the guidance of professionals, or participate in an exercise plan to improve compliance and reduce the occurrence of adverse consequences of exercise. For patients with diabetic nephropathy who have progressed to ESRD, aerobic exercise and confrontational exercise 2 to 3 times a week or more are beneficial for controlling blood pressure, reducing inflammation, and improving quality of life, but most of the evidence comes from small sample trials."
        }
      ],
      "paragraph_en": "2. Exercise: Physical activity can induce a temporary increase in urine protein in the early stages of diabetic nephropathy. Long-term regular exercise can slow down the development of diabetes and diabetic nephropathy by improving insulin sensitivity, improving glucose tolerance, reducing weight, improving lipid metabolism, improving endothelial function, controlling blood sugar and blood pressure. A retrospective analysis of the Diabetes Control and Complications Trial (DCCT) showed that exercise had no effect on the prognosis of microvascular lesions in type 1 diabetes, but there was no evidence that exercise was harmful, so it is still recommended that patients with type 1 diabetes exercise. The results of the FinnDiane study showed that patients with type 1 diabetes who exercised at low frequency and low intensity had a higher incidence of diabetic nephropathy. Therefore, the frequency and intensity of exercise for patients with diabetic nephropathy should meet certain requirements. Patients should perform at least 150 minutes of moderate-intensity aerobic exercise per week (heart rate reaches 50% to 70% of the maximum value during exercise), exercise at least 3 days per week, and arrange at least 2 confrontational training sessions per week. Inappropriate exercise can induce ketosis due to insufficient insulin levels, or hypoglycemia due to excessive energy consumption. Therefore, the intensity, duration, frequency, and selection of exercise items should be individualized. It is recommended that patients with diabetic nephropathy develop a reasonable exercise plan under the guidance of professionals, or participate in an exercise plan to improve compliance and reduce the occurrence of adverse consequences of exercise. For patients with diabetic nephropathy who have progressed to ESRD, aerobic exercise and confrontational exercise 2 to 3 times a week or more are beneficial for controlling blood pressure, reducing inflammation, and improving quality of life, but most of the evidence comes from small sample trials."
    },
    {
      "paragraph_id": "27",
      "paragraph": "3.戒烟：吸烟是糖尿病肾病患者蛋白尿及肾功能进展的危险因素，戒烟或减少吸烟是糖尿病患者预防或控制糖尿病肾病进展的重要措施。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.戒烟：吸烟是糖尿病肾病患者蛋白尿及肾功能进展的危险因素，戒烟或减少吸烟是糖尿病患者预防或控制糖尿病肾病进展的重要措施。",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T518",
              "entity": "戒烟",
              "entity_type": "Treatment",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "Quitting smoking"
            },
            {
              "entity_id": "T519",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T520",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 12,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T521",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T522",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T523",
              "entity": "戒烟或减少吸烟",
              "entity_type": "Treatment",
              "start_idx": 30,
              "end_idx": 37,
              "entity_en": "Quit or reduce smoking"
            },
            {
              "entity_id": "T524",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T525",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 53,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T526",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 51,
              "end_idx": 52,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R269",
              "head_entity_id": "T518",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R270",
              "head_entity_id": "T520",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R271",
              "head_entity_id": "T522",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R272",
              "head_entity_id": "T523",
              "tail_entity_id": "T524"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R273",
              "head_entity_id": "T526",
              "tail_entity_id": "T525"
            }
          ],
          "sentence_en": "3. Quit smoking: Smoking is a risk factor for proteinuria and renal function progression in patients with diabetic nephropathy. Quitting smoking or reducing smoking is an important measure for diabetic patients to prevent or control the progression of diabetic nephropathy."
        }
      ],
      "paragraph_en": "3. Quit smoking: Smoking is a risk factor for proteinuria and renal function progression in patients with diabetic nephropathy. Quitting smoking or reducing smoking is an important measure for diabetic patients to prevent or control the progression of diabetic nephropathy."
    },
    {
      "paragraph_id": "28",
      "paragraph": "(二)控制血糖",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)控制血糖",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T527",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "2. Control blood sugar"
        }
      ],
      "paragraph_en": "2. Control blood sugar"
    },
    {
      "paragraph_id": "29",
      "paragraph": "DCCT及其后续的糖尿病干预和并发症流行病学研究(EDIC)、英国2型糖尿病前瞻性研究(UKPDS)及美国退伍军人合作研究(VAC)分别验证了在1型糖尿病和2型糖尿病患者中，严格控制血糖可减少糖尿病肾病的发生或延缓其病程进展。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DCCT及其后续的糖尿病干预和并发症流行病学研究(EDIC)、英国2型糖尿病前瞻性研究(UKPDS)及美国退伍军人合作研究(VAC)分别验证了在1型糖尿病和2型糖尿病患者中，严格控制血糖可减少糖尿病肾病的发生或延缓其病程进展。",
          "start_idx": 0,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T528",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T529",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T530",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T531",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 77,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T532",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T533",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T534",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T535",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 93,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T536",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 101,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T537",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 99,
              "end_idx": 100,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R274",
              "head_entity_id": "T530",
              "tail_entity_id": "T529"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R275",
              "head_entity_id": "T532",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R276",
              "head_entity_id": "T535",
              "tail_entity_id": "T536"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R277",
              "head_entity_id": "T537",
              "tail_entity_id": "T536"
            }
          ],
          "sentence_en": "The DCCT and its subsequent Epidemiology of Diabetes Interventions and Complications (EDIC), the UK Prospective Study of Type 2 Diabetes (UKPDS), and the US Veterans Cooperative Study (VAC) have respectively verified that strict blood sugar control can reduce the occurrence of diabetic nephropathy or delay its progression in patients with type 1 diabetes and type 2 diabetes."
        }
      ],
      "paragraph_en": "The DCCT and its subsequent Epidemiology of Diabetes Interventions and Complications (EDIC), the United Kingdom Prospective Study of Type 2 Diabetes (UKPDS), and the United States Veterans Cooperative Study (VAC) have respectively verified that strict blood sugar control can reduce the occurrence of diabetic nephropathy or delay its progression in patients with type 1 diabetes and type 2 diabetes."
    },
    {
      "paragraph_id": "30",
      "paragraph": "1.血糖控制目标：糖尿病肾病患者的血糖控制应遵循个体化原则。血糖控制目标：糖化血红蛋白(HbA1c)不超过7%。对中老年患者，HbA1c控制目标适当放宽至不超过7%~9%。由于CKD患者的红细胞寿命缩短，HbA1c可能被低估。在CKD4~5期的患者中，用果糖胺或糖化血清白蛋白反映血糖控制水平更可靠一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.血糖控制目标：糖尿病肾病患者的血糖控制应遵循个体化原则。血糖控制目标：糖化血红蛋白(HbA1c)不超过7%。对中老年患者，HbA1c控制目标适当放宽至不超过7%~9%。由于CKD患者的红细胞寿命缩短，HbA1c可能被低估。在CKD4~5期的患者中，用果糖胺或糖化血清白蛋白反映血糖控制水平更可靠一。",
          "start_idx": 0,
          "end_idx": 151,
          "entities": [
            {
              "entity_id": "T538",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T539",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T540",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T541",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T542",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T543",
              "entity": "糖化血红蛋白(HbA1c)",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 50,
              "entity_en": "Glycated hemoglobin (HbA1c)"
            },
            {
              "entity_id": "T544",
              "entity": "不超过7%",
              "entity_type": "Test_Value",
              "start_idx": 50,
              "end_idx": 55,
              "entity_en": "No more than 7%"
            },
            {
              "entity_id": "T545",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T546",
              "entity": "不超过7%~9%",
              "entity_type": "Test_Value",
              "start_idx": 77,
              "end_idx": 85,
              "entity_en": "No more than 7%~9%"
            },
            {
              "entity_id": "T547",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T548",
              "entity": "红细胞寿命缩短",
              "entity_type": "Pathogenesis",
              "start_idx": 94,
              "end_idx": 101,
              "entity_en": "Shortened red blood cell lifespan"
            },
            {
              "entity_id": "T549",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 102,
              "end_idx": 107,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T550",
              "entity": "CKD4~5期",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 121,
              "entity_en": "CKD stage 4-5"
            },
            {
              "entity_id": "T551",
              "entity": "4~5期",
              "entity_type": "Class",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "4~5th period"
            },
            {
              "entity_id": "T552",
              "entity": "果糖胺",
              "entity_type": "Test_items",
              "start_idx": 127,
              "end_idx": 130,
              "entity_en": "Fructosamine"
            },
            {
              "entity_id": "T553",
              "entity": "糖化血清白蛋白",
              "entity_type": "Test_items",
              "start_idx": 131,
              "end_idx": 138,
              "entity_en": "Glycated serum albumin"
            },
            {
              "entity_id": "T554",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 140,
              "end_idx": 142,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R278",
              "head_entity_id": "T538",
              "tail_entity_id": "T539"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R279",
              "head_entity_id": "T541",
              "tail_entity_id": "T539"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R280",
              "head_entity_id": "T540",
              "tail_entity_id": "T539"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R281",
              "head_entity_id": "T548",
              "tail_entity_id": "T547"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R282",
              "head_entity_id": "T549",
              "tail_entity_id": "T547"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R283",
              "head_entity_id": "T551",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R284",
              "head_entity_id": "T552",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R285",
              "head_entity_id": "T553",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R286",
              "head_entity_id": "T554",
              "tail_entity_id": "T550"
            }
          ],
          "sentence_en": "1. Blood sugar control target: Blood sugar control in patients with diabetic nephropathy should follow the principle of individualization. Blood sugar control target: Glycated hemoglobin (HbA1c) should not exceed 7%. For middle-aged and elderly patients, the HbA1c control target should be appropriately relaxed to no more than 7%~9%. Due to the shortened life span of red blood cells in CKD patients, HbA1c may be underestimated. In patients with CKD stage 4~5, it is more reliable to use fructosamine or glycated serum albumin to reflect the level of blood sugar control."
        }
      ],
      "paragraph_en": "1. Blood sugar control target: Blood sugar control in patients with diabetic nephropathy should follow the principle of individualization. Blood sugar control target: Glycated hemoglobin (HbA1c) should not exceed 7%. For middle-aged and elderly patients, the HbA1c control target should be appropriately relaxed to no more than 7%~9%. Due to the shortened life span of red blood cells in CKD patients, HbA1c may be underestimated. In patients with CKD stage 4~5, it is more reliable to use fructosamine or glycated serum albumin to reflect the level of blood sugar control."
    },
    {
      "paragraph_id": "31",
      "paragraph": "2.抗高血糖药物的选择：包括双胍类、磺脲类、格列奈类、噻唑烷二酮类、α-糖苷酶抑制剂、二肽基肽酶IV(DPP-4)抑制剂、胰高血糖素样肽1(GLP-1)类似物及胰岛素。某些在肾脏代谢或排泄的药物，在糖尿病肾病尤其是肾功能不全的患者中，经肾排泄减少或其活性代谢产物的清除减少，可引起低血糖等不良反应，这些药物在GFR低于60ml·min·-1·1.73m-2时需酌情减量或停药(图1)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.抗高血糖药物的选择：包括双胍类、磺脲类、格列奈类、噻唑烷二酮类、α-糖苷酶抑制剂、二肽基肽酶IV(DPP-4)抑制剂、胰高血糖素样肽1(GLP-1)类似物及胰岛素。某些在肾脏代谢或排泄的药物，在糖尿病肾病尤其是肾功能不全的患者中，经肾排泄减少或其活性代谢产物的清除减少，可引起低血糖等不良反应，这些药物在GFR低于60ml·min·-1·1.73m-2时需酌情减量或停药(图1)。",
          "start_idx": 0,
          "end_idx": 192,
          "entities": [
            {
              "entity_id": "T555",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T556",
              "entity": "双胍类",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "Biguanides"
            },
            {
              "entity_id": "T557",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T558",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T559",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 33,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T560",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 42,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T561",
              "entity": "二肽基肽酶IV(DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 60,
              "entity_en": "Dipeptidyl peptidase IV (DPP-4) inhibitors"
            },
            {
              "entity_id": "T562",
              "entity": "胰高血糖素样肽1(GLP-1)类似物",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 79,
              "entity_en": "Glucagon-like peptide 1 (GLP-1) analogs"
            },
            {
              "entity_id": "T563",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 80,
              "end_idx": 83,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T564",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T565",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 103,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T566",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 112,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T567",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 107,
              "end_idx": 108,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T568",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T569",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 154,
              "end_idx": 157,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T570",
              "entity": "低于60ml·min·-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 157,
              "end_idx": 178,
              "entity_en": "Less than 60ml·min·-1·1.73m-2"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R287",
              "head_entity_id": "T565",
              "tail_entity_id": "T564"
            },
            {
              "relation_type": "ADE_Disease",
              "relation_id": "R288",
              "head_entity_id": "T568",
              "tail_entity_id": "T564"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R289",
              "head_entity_id": "T567",
              "tail_entity_id": "T566"
            }
          ],
          "sentence_en": "2. Choice of anti-hyperglycemic drugs: including biguanides, sulfonylureas, glinides, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) analogs and insulin. Certain drugs metabolized or excreted by the kidneys can cause adverse reactions such as hypoglycemia due to reduced renal excretion or reduced clearance of their active metabolites in patients with diabetic nephropathy, especially those with renal insufficiency. These drugs need to be reduced or discontinued as appropriate when the GFR is lower than 60 ml·min·-1·1.73 m-2 (Figure 1)."
        }
      ],
      "paragraph_en": "2. Choice of anti-hyperglycemic drugs: including biguanides, sulfonylureas, glinides, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) analogs and insulin. Certain drugs metabolized or excreted by the kidneys can cause adverse reactions such as hypoglycemia due to reduced renal excretion or reduced clearance of their active metabolites in patients with diabetic nephropathy, especially those with renal insufficiency. These drugs need to be reduced or discontinued as appropriate when the GFR is lower than 60 ml·min·-1·1.73 m-2 (Figure 1)."
    },
    {
      "paragraph_id": "32",
      "paragraph": "(1)双胍类：目前，二甲双胍被推荐作为2型糖尿病控制血糖的一线用药，首选用于单纯饮食控制或体育锻炼无效的2型糖尿病，尤其适用于肥胖患者，也与胰岛素联合用于1型和2型糖尿病。其主要药理作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖，二甲双胍可以使HbA1c降低1%~2%，并可减轻体重且不增加低血糖风险。UKPDS研究显示，二甲双胍可降低伴有肥胖的2型糖尿病患者的心血管事件和死亡风险。糖尿病结果预防试验(ADOPT)研究显示，二甲双胍可延缓糖尿病患者微量白蛋白尿的进展。二甲双胍不经肝脏代谢，直接以原形经肾脏排泄，当肾功能受损时，易发生二甲双胍和乳酸在体内堆积，增加乳酸性酸中毒风险。因此二甲双胍用于CKD3a期以上的患者时应减少剂量，eGFR<45ml·min-1·1.73m-2时停用。肾功能受损的患者应用二甲双胍时应注意肾功能变化，每年至少检查一次肾功能。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)双胍类：目前，二甲双胍被推荐作为2型糖尿病控制血糖的一线用药，首选用于单纯饮食控制或体育锻炼无效的2型糖尿病，尤其适用于肥胖患者，也与胰岛素联合用于1型和2型糖尿病。其主要药理作用是通过减少肝糖输出和改善外周胰岛素抵抗而降低血糖，二甲双胍可以使HbA1c降低1%~2%，并可减轻体重且不增加低血糖风险。UKPDS研究显示，二甲双胍可降低伴有肥胖的2型糖尿病患者的心血管事件和死亡风险。糖尿病结果预防试验(ADOPT)研究显示，二甲双胍可延缓糖尿病患者微量白蛋白尿的进展。二甲双胍不经肝脏代谢，直接以原形经肾脏排泄，当肾功能受损时，易发生二甲双胍和乳酸在体内堆积，增加乳酸性酸中毒风险。因此二甲双胍用于CKD3a期以上的患者时应减少剂量，eGFR<45ml·min-1·1.73m-2时停用。肾功能受损的患者应用二甲双胍时应注意肾功能变化，每年至少检查一次肾功能。",
          "start_idx": 0,
          "end_idx": 384,
          "entities": [
            {
              "entity_id": "T571",
              "entity": "双胍类",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Biguanides"
            },
            {
              "entity_id": "T572",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T573",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T574",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T575",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T576",
              "entity": "单纯饮食控制",
              "entity_type": "Treatment",
              "start_idx": 38,
              "end_idx": 44,
              "entity_en": "Simple diet control"
            },
            {
              "entity_id": "T577",
              "entity": "体育锻炼",
              "entity_type": "Treatment",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Physical exercise"
            },
            {
              "entity_id": "T578",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T579",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T580",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 65,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T581",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T582",
              "entity": "1型和2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 77,
              "end_idx": 85,
              "entity_en": "Type 1 and type 2 diabetes"
            },
            {
              "entity_id": "T583",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T584",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T585",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 107,
              "end_idx": 112,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T586",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T587",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 122,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T588",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 130,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T589",
              "entity": "降低1%~2%",
              "entity_type": "Test_Value",
              "start_idx": 130,
              "end_idx": 137,
              "entity_en": "Reduce by 1%~2%"
            },
            {
              "entity_id": "T590",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 148,
              "end_idx": 151,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T591",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 168,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T592",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 175,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T593",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 176,
              "end_idx": 181,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T594",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 176,
              "end_idx": 178,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T595",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 184,
              "end_idx": 189,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T596",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 187,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T597",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 195,
              "end_idx": 198,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T598",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 216,
              "end_idx": 220,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T599",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 223,
              "end_idx": 226,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T600",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 228,
              "end_idx": 230,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T601",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 230,
              "end_idx": 234,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T602",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 238,
              "end_idx": 242,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T603",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 271,
              "end_idx": 275,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T604",
              "entity": "乳酸性酸中毒",
              "entity_type": "ADE",
              "start_idx": 286,
              "end_idx": 292,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T605",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 297,
              "end_idx": 301,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T606",
              "entity": "CKD3a期",
              "entity_type": "Disease",
              "start_idx": 303,
              "end_idx": 309,
              "entity_en": "CKD stage 3a"
            },
            {
              "entity_id": "T607",
              "entity": "3a期",
              "entity_type": "Class",
              "start_idx": 306,
              "end_idx": 309,
              "entity_en": "Phase 3a"
            },
            {
              "entity_id": "T608",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 321,
              "end_idx": 325,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T609",
              "entity": "45ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 326,
              "end_idx": 344,
              "entity_en": "45ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T610",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 348,
              "end_idx": 353,
              "entity_en": "Impaired renal function"
            },
            {
              "entity_id": "T611",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 348,
              "end_idx": 349,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T612",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 358,
              "end_idx": 362,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T613",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 380,
              "end_idx": 383,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T614",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 366,
              "end_idx": 369,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T615",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 261,
              "end_idx": 266,
              "entity_en": "Impaired renal function"
            },
            {
              "entity_id": "T616",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 261,
              "end_idx": 262,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R290",
              "head_entity_id": "T572",
              "tail_entity_id": "T573"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R291",
              "head_entity_id": "T572",
              "tail_entity_id": "T580"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R292",
              "head_entity_id": "T572",
              "tail_entity_id": "T582"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R293",
              "head_entity_id": "T574",
              "tail_entity_id": "T573"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R294",
              "head_entity_id": "T575",
              "tail_entity_id": "T573"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R295",
              "head_entity_id": "T576",
              "tail_entity_id": "T578"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R296",
              "head_entity_id": "T577",
              "tail_entity_id": "T578"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R297",
              "head_entity_id": "T579",
              "tail_entity_id": "T578"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R298",
              "head_entity_id": "T581",
              "tail_entity_id": "T582"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R299",
              "head_entity_id": "T583",
              "tail_entity_id": "T582"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R300",
              "head_entity_id": "T584",
              "tail_entity_id": "T582"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R301",
              "head_entity_id": "T591",
              "tail_entity_id": "T592"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R302",
              "head_entity_id": "T591",
              "tail_entity_id": "T593"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R303",
              "head_entity_id": "T594",
              "tail_entity_id": "T593"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R304",
              "head_entity_id": "T596",
              "tail_entity_id": "T595"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R305",
              "head_entity_id": "T598",
              "tail_entity_id": "T599"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R306",
              "head_entity_id": "T602",
              "tail_entity_id": "T615"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R307",
              "head_entity_id": "T604",
              "tail_entity_id": "T602"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R308",
              "head_entity_id": "T605",
              "tail_entity_id": "T606"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R309",
              "head_entity_id": "T607",
              "tail_entity_id": "T606"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R310",
              "head_entity_id": "T608",
              "tail_entity_id": "T606"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R311",
              "head_entity_id": "T611",
              "tail_entity_id": "T610"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R312",
              "head_entity_id": "T612",
              "tail_entity_id": "T610"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R313",
              "head_entity_id": "T614",
              "tail_entity_id": "T610"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R314",
              "head_entity_id": "T613",
              "tail_entity_id": "T610"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R315",
              "head_entity_id": "T616",
              "tail_entity_id": "T615"
            }
          ],
          "sentence_en": "(1) Biguanides: Currently, metformin is recommended as the first-line drug for controlling blood sugar in type 2 diabetes. It is the first choice for type 2 diabetes that is ineffective with simple diet control or physical exercise. It is especially suitable for obese patients. It is also used in combination with insulin for type 1 and type 2 diabetes. Its main pharmacological action is to lower blood sugar by reducing hepatic glucose output and improving peripheral insulin resistance. Metformin can reduce HbA1c by 1%~2%, and can reduce weight without increasing the risk of hypoglycemia. The UKPDS study showed that metformin can reduce the risk of cardiovascular events and death in obese type 2 diabetes patients. The Diabetes Outcome Prevention Trial (ADOPT) study showed that metformin can delay the progression of microalbuminuria in diabetic patients. Metformin is not metabolized by the liver and is directly excreted in its original form by the kidneys. When renal function is impaired, metformin and lactic acid are prone to accumulate in the body, increasing the risk of lactic acidosis. Therefore, the dosage of metformin should be reduced when used in patients with CKD stage 3a or above, and it should be discontinued when eGFR is <45 ml·min-1·1.73 m-2. Patients with impaired renal function should pay attention to changes in renal function when using metformin, and have their renal function checked at least once a year."
        }
      ],
      "paragraph_en": "(1) Biguanides: Currently, metformin is recommended as the first-line drug for controlling blood sugar in type 2 diabetes. It is the first choice for type 2 diabetes that is ineffective with simple diet control or physical exercise. It is especially suitable for obese patients. It is also used in combination with insulin for type 1 and type 2 diabetes. Its main pharmacological action is to lower blood sugar by reducing hepatic glucose output and improving peripheral insulin resistance. Metformin can reduce HbA1c by 1%~2%, and can reduce weight without increasing the risk of hypoglycemia. The UKPDS study showed that metformin can reduce the risk of cardiovascular events and death in obese type 2 diabetes patients. The Diabetes Outcome Prevention Trial (ADOPT) study showed that metformin can delay the progression of microalbuminuria in diabetic patients. Metformin is not metabolized by the liver and is directly excreted in its original form by the kidneys. When renal function is impaired, metformin and lactic acid are prone to accumulate in the body, increasing the risk of lactic acidosis. Therefore, the dosage of metformin should be reduced when used in patients with CKD stage 3a or above, and it should be discontinued when eGFR is <45 ml·min-1·1.73 m-2. Patients with impaired renal function should pay attention to changes in renal function when using metformin, and have their renal function checked at least once a year."
    },
    {
      "paragraph_id": "33",
      "paragraph": "(2)磺脲类：第一代磺脲类药物(如氯磺丙脲、妥拉磺脲、甲苯磺丁脲)的药物原型及其活性代谢产物主要依赖肾脏排泄，应用于CKD患者时半衰期延长，低血糖风险明显增加，因此禁用于该类患者，目前此类药物在临床上已基本被淘汰。第二代磺脲类药物包括格列本脲、格列吡嗪、格列奇特、格列喹酮和格列美脲等。格列本脲和格列美脲的代谢产物仍有降糖活性，尤其是格列本脲的半衰期较长，其活性代谢产物可在CKD患者体内积聚，可能引起严重的低血糖反应，且持续时间可超过24h。因而格列本脲仅可用于CKD1~2期的患者；格列美脲用于CKD3~4期的患者时，应从小剂量开始用药，即起始剂量为每日1mg；由于还未积累关于透析患者的用药经验，在透析患者禁用。格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于前两者。格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5%由肾脏排泄，受肾功能影响较小。因而格列吡嗪、格列齐特和格列喹酮于CKD1~3期患者无需调整剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)磺脲类：第一代磺脲类药物(如氯磺丙脲、妥拉磺脲、甲苯磺丁脲)的药物原型及其活性代谢产物主要依赖肾脏排泄，应用于CKD患者时半衰期延长，低血糖风险明显增加，因此禁用于该类患者，目前此类药物在临床上已基本被淘汰。第二代磺脲类药物包括格列本脲、格列吡嗪、格列奇特、格列喹酮和格列美脲等。格列本脲和格列美脲的代谢产物仍有降糖活性，尤其是格列本脲的半衰期较长，其活性代谢产物可在CKD患者体内积聚，可能引起严重的低血糖反应，且持续时间可超过24h。因而格列本脲仅可用于CKD1~2期的患者；格列美脲用于CKD3~4期的患者时，应从小剂量开始用药，即起始剂量为每日1mg；由于还未积累关于透析患者的用药经验，在透析患者禁用。格列吡嗪和格列齐特的代谢产物均无降糖活性，虽然主要经肾脏排泄，但低血糖风险小于前两者。格列喹酮的代谢产物无降糖作用且大部分从粪便排泄，仅5%由肾脏排泄，受肾功能影响较小。因而格列吡嗪、格列齐特和格列喹酮于CKD1~3期患者无需调整剂量。",
          "start_idx": 0,
          "end_idx": 427,
          "entities": [
            {
              "entity_id": "T617",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T618",
              "entity": "第一代磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 15,
              "entity_en": "First-generation sulfonylureas"
            },
            {
              "entity_id": "T619",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T620",
              "entity": "妥拉磺脲",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Tolazamide"
            },
            {
              "entity_id": "T621",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Tolbutamide"
            },
            {
              "entity_id": "T622",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T623",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T624",
              "entity": "第二代磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 107,
              "end_idx": 115,
              "entity_en": "Second-generation sulfonylureas"
            },
            {
              "entity_id": "T625",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T626",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 122,
              "end_idx": 126,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T627",
              "entity": "格列奇特",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Glicet"
            },
            {
              "entity_id": "T628",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 132,
              "end_idx": 136,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T629",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T630",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 147,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T631",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 148,
              "end_idx": 152,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T632",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 171,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T633",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 190,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T634",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 204,
              "end_idx": 207,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T635",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 224,
              "end_idx": 228,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T636",
              "entity": "CKD1~2期",
              "entity_type": "Disease",
              "start_idx": 232,
              "end_idx": 239,
              "entity_en": "CKD stage 1-2"
            },
            {
              "entity_id": "T637",
              "entity": "1~2期",
              "entity_type": "Class",
              "start_idx": 235,
              "end_idx": 239,
              "entity_en": "Phase 1~2"
            },
            {
              "entity_id": "T638",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 243,
              "end_idx": 247,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T639",
              "entity": "CKD3~4期",
              "entity_type": "Disease",
              "start_idx": 249,
              "end_idx": 256,
              "entity_en": "CKD stage 3-4"
            },
            {
              "entity_id": "T640",
              "entity": "3~4期",
              "entity_type": "Class",
              "start_idx": 252,
              "end_idx": 256,
              "entity_en": "Phase 3~4"
            },
            {
              "entity_id": "T641",
              "entity": "每日1mg",
              "entity_type": "Amount",
              "start_idx": 277,
              "end_idx": 282,
              "entity_en": "1 mg per day"
            },
            {
              "entity_id": "T642",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 291,
              "end_idx": 293,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T643",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 302,
              "end_idx": 304,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T644",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 309,
              "end_idx": 313,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T645",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 314,
              "end_idx": 318,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T646",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 341,
              "end_idx": 344,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T647",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 352,
              "end_idx": 356,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T648",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 396,
              "end_idx": 400,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T649",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 401,
              "end_idx": 405,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T650",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 406,
              "end_idx": 410,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T651",
              "entity": "CKD1~3期",
              "entity_type": "Disease",
              "start_idx": 411,
              "end_idx": 418,
              "entity_en": "CKD stage 1-3"
            },
            {
              "entity_id": "T652",
              "entity": "1~3期",
              "entity_type": "Class",
              "start_idx": 414,
              "end_idx": 418,
              "entity_en": "Phase 1~3"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R316",
              "head_entity_id": "T618",
              "tail_entity_id": "T622"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R317",
              "head_entity_id": "T623",
              "tail_entity_id": "T618"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R318",
              "head_entity_id": "T619",
              "tail_entity_id": "T622"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R319",
              "head_entity_id": "T623",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R320",
              "head_entity_id": "T620",
              "tail_entity_id": "T622"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R321",
              "head_entity_id": "T623",
              "tail_entity_id": "T620"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R322",
              "head_entity_id": "T621",
              "tail_entity_id": "T622"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R323",
              "head_entity_id": "T623",
              "tail_entity_id": "T621"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R324",
              "head_entity_id": "T630",
              "tail_entity_id": "T633"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R325",
              "head_entity_id": "T631",
              "tail_entity_id": "T633"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R326",
              "head_entity_id": "T632",
              "tail_entity_id": "T633"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R327",
              "head_entity_id": "T634",
              "tail_entity_id": "T632"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R328",
              "head_entity_id": "T635",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R329",
              "head_entity_id": "T637",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R330",
              "head_entity_id": "T638",
              "tail_entity_id": "T639"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R331",
              "head_entity_id": "T641",
              "tail_entity_id": "T638"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R332",
              "head_entity_id": "T640",
              "tail_entity_id": "T639"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R333",
              "head_entity_id": "T642",
              "tail_entity_id": "T639"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R334",
              "head_entity_id": "T643",
              "tail_entity_id": "T639"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R335",
              "head_entity_id": "T646",
              "tail_entity_id": "T644"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R336",
              "head_entity_id": "T646",
              "tail_entity_id": "T645"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R337",
              "head_entity_id": "T648",
              "tail_entity_id": "T651"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R338",
              "head_entity_id": "T649",
              "tail_entity_id": "T651"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R339",
              "head_entity_id": "T650",
              "tail_entity_id": "T651"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R340",
              "head_entity_id": "T652",
              "tail_entity_id": "T651"
            }
          ],
          "sentence_en": "(2) Sulfonylureas: The prototype and active metabolites of first-generation sulfonylurea drugs (such as chlorpropamide, tolazamide, and tolbutamide) are mainly excreted by the kidneys. When used in CKD patients, their half-life is prolonged and the risk of hypoglycemia is significantly increased. Therefore, they are contraindicated in such patients. Currently, such drugs have been basically eliminated in clinical practice. Second-generation sulfonylurea drugs include glibenclamide, glipizide, gliclazide, gliquidone, and glimepiride. The metabolites of glibenclamide and glimepiride still have hypoglycemic activity, especially glibenclamide, which has a longer half-life. Its active metabolites can accumulate in the body of CKD patients and may cause severe hypoglycemia reactions that may last for more than 24 hours. Therefore, glibenclamide can only be used in patients with CKD stage 1~2; when glimepiride is used in patients with CKD stage 3~4, it should be started at a low dose, that is, the starting dose is 1 mg per day; since there is no experience in the use of dialysis patients, it is contraindicated in dialysis patients. The metabolites of glipizide and gliclazide have no glucose-lowering activity. Although they are mainly excreted through the kidneys, the risk of hypoglycemia is lower than that of the first two. The metabolites of gliclazide have no glucose-lowering effect and are mostly excreted in the feces, with only 5% excreted by the kidneys, which is less affected by renal function. Therefore, there is no need to adjust the dose of glipizide, gliclazide, and gliclazide in patients with CKD stages 1 to 3."
        }
      ],
      "paragraph_en": "(2) Sulfonylureas: The prototype and active metabolites of first-generation sulfonylurea drugs (such as chlorpropamide, tolazamide, and tolbutamide) are mainly excreted by the kidneys. When used in CKD patients, their half-life is prolonged and the risk of hypoglycemia is significantly increased. Therefore, they are contraindicated in such patients. Currently, such drugs have been basically eliminated in clinical practice. Second-generation sulfonylurea drugs include glibenclamide, glipizide, gliclazide, gliquidone, and glimepiride. The metabolites of glibenclamide and glimepiride still have hypoglycemic activity, especially glibenclamide, which has a long half-life. Its active metabolites can accumulate in the body of CKD patients and may cause severe hypoglycemia reactions that may last for more than 24 hours. Therefore, glibenclamide can only be used in patients with CKD stage 1~2; when glimepiride is used in patients with CKD stage 3~4, it should be started at a low dose, that is, the starting dose is 1 mg per day; since there is no experience in the use of dialysis patients, it is contraindicated in dialysis patients. The metabolites of glipizide and gliclazide have no glucose-lowering activity. Although they are mainly excreted through the kidneys, the risk of hypoglycemia is lower than that of the first two. The metabolites of gliclazide have no glucose-lowering effect and are mostly excreted in the feces, with only 5% excreted by the kidneys, which is less affected by renal function. Therefore, there is no need to adjust the dose of glipizide, gliclazide, and gliclazide in patients with CKD stages 1 to 3."
    },
    {
      "paragraph_id": "34",
      "paragraph": "(3)格列奈类：格列奈类药物是非磺脲类胰岛素促泌剂，其具有葡萄糖依赖性，需餐前服用。由于其对基础胰岛素分泌物无明显刺激作用，其引起低血糖的风险和程度较磺脲类药物轻。其他不良反应有过敏反应、胃肠道不适、眼睛异常、肝功能损害等，均较罕见。格列奈类的主要代表药物有那格列奈和瑞格列奈。瑞格列奈及其代谢产物主要经肝脏代谢，仅<8%经肾排泄。瑞格列奈I期临床试验表明，使用瑞格列奈7d后，肾功能正常患者与不同程度的CKD患者相比，血药浓度没有明显差异，提示瑞格列奈在CKD患者体内无蓄积。一项入选281例伴或不伴肾功能不全2型糖尿病患者的多中心研究提示，使用瑞格列奈替换原有降糖治疗，不同程度肾功能不全亚组患者(正常、轻、中、重、极重肾功能损伤)低血糖发生率均低于2%，且瑞格列奈治疗期低血糖发生率与肾功能损伤程度无关。因此瑞格列奈应用于CKD3、4期或肾脏移植、透析者，均无需调整剂量。在Ccr15~50ml·min-1·1.73m-2的糖尿病患者中，那格列奈的生物利用度和半衰期与健康人相比其差别未达到具有临床意义的程度，但随着肾功能的下降，那格列奈的活性代谢产物水平增加。有观点认为那格列奈应用于肾功能不全的糖尿病患者时无需调整剂量，但ADA仍建议CKD4期应从小剂量每次餐前60mg开始。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)格列奈类：格列奈类药物是非磺脲类胰岛素促泌剂，其具有葡萄糖依赖性，需餐前服用。由于其对基础胰岛素分泌物无明显刺激作用，其引起低血糖的风险和程度较磺脲类药物轻。其他不良反应有过敏反应、胃肠道不适、眼睛异常、肝功能损害等，均较罕见。格列奈类的主要代表药物有那格列奈和瑞格列奈。瑞格列奈及其代谢产物主要经肝脏代谢，仅<8%经肾排泄。瑞格列奈I期临床试验表明，使用瑞格列奈7d后，肾功能正常患者与不同程度的CKD患者相比，血药浓度没有明显差异，提示瑞格列奈在CKD患者体内无蓄积。一项入选281例伴或不伴肾功能不全2型糖尿病患者的多中心研究提示，使用瑞格列奈替换原有降糖治疗，不同程度肾功能不全亚组患者(正常、轻、中、重、极重肾功能损伤)低血糖发生率均低于2%，且瑞格列奈治疗期低血糖发生率与肾功能损伤程度无关。因此瑞格列奈应用于CKD3、4期或肾脏移植、透析者，均无需调整剂量。在Ccr15~50ml·min-1·1.73m-2的糖尿病患者中，那格列奈的生物利用度和半衰期与健康人相比其差别未达到具有临床意义的程度，但随着肾功能的下降，那格列奈的活性代谢产物水平增加。有观点认为那格列奈应用于肾功能不全的糖尿病患者时无需调整剂量，但ADA仍建议CKD4期应从小剂量每次餐前60mg开始。",
          "start_idx": 0,
          "end_idx": 543,
          "entities": [
            {
              "entity_id": "T653",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T654",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 14,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T655",
              "entity": "非磺脲类胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 25,
              "entity_en": "Non-sulfonylurea insulin secretagogues"
            },
            {
              "entity_id": "T656",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T657",
              "entity": "磺脲类药",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T658",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Allergic reactions"
            },
            {
              "entity_id": "T659",
              "entity": "胃肠道不适",
              "entity_type": "ADE",
              "start_idx": 94,
              "end_idx": 99,
              "entity_en": "Gastrointestinal discomfort"
            },
            {
              "entity_id": "T660",
              "entity": "眼睛异常",
              "entity_type": "ADE",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "Eye abnormalities"
            },
            {
              "entity_id": "T661",
              "entity": "肝功能损害",
              "entity_type": "ADE",
              "start_idx": 105,
              "end_idx": 110,
              "entity_en": "Liver impairment"
            },
            {
              "entity_id": "T662",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T663",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 133,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T664",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T665",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 143,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T666",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 170,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T667",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 181,
              "end_idx": 185,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T668",
              "entity": "7d",
              "entity_type": "Duration",
              "start_idx": 185,
              "end_idx": 187,
              "entity_en": "7d"
            },
            {
              "entity_id": "T669",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 189,
              "end_idx": 192,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T670",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 202,
              "end_idx": 205,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T671",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 227,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T672",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 228,
              "end_idx": 231,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T673",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 210,
              "end_idx": 214,
              "entity_en": "Blood concentration"
            },
            {
              "entity_id": "T674",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 251,
              "end_idx": 256,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T675",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 251,
              "end_idx": 252,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T676",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 256,
              "end_idx": 261,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T677",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 256,
              "end_idx": 258,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T678",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 274,
              "end_idx": 278,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T679",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 291,
              "end_idx": 296,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T680",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 291,
              "end_idx": 292,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T681",
              "entity": "正常、轻、中、重、极重",
              "entity_type": "Level",
              "start_idx": 301,
              "end_idx": 312,
              "entity_en": "Normal, Mild, Moderate, Severe, Extremely Severe"
            },
            {
              "entity_id": "T682",
              "entity": "肾功能损伤",
              "entity_type": "Disease",
              "start_idx": 312,
              "end_idx": 317,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T683",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 312,
              "end_idx": 313,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T684",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 318,
              "end_idx": 321,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T685",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 331,
              "end_idx": 335,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T686",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 338,
              "end_idx": 341,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T687",
              "entity": "肾功能损伤",
              "entity_type": "Disease",
              "start_idx": 345,
              "end_idx": 350,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T688",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 345,
              "end_idx": 346,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T689",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 357,
              "end_idx": 361,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T690",
              "entity": "CKD3、4期",
              "entity_type": "Disease",
              "start_idx": 364,
              "end_idx": 371,
              "entity_en": "CKD stage 3 and 4"
            },
            {
              "entity_id": "T691",
              "entity": "3、4期",
              "entity_type": "Class",
              "start_idx": 367,
              "end_idx": 371,
              "entity_en": "Phase 3 and 4"
            },
            {
              "entity_id": "T692",
              "entity": "肾脏移植",
              "entity_type": "Operation",
              "start_idx": 372,
              "end_idx": 376,
              "entity_en": "Kidney transplant"
            },
            {
              "entity_id": "T693",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 377,
              "end_idx": 379,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T694",
              "entity": "Ccr",
              "entity_type": "Test_items",
              "start_idx": 390,
              "end_idx": 393,
              "entity_en": "Ccr"
            },
            {
              "entity_id": "T695",
              "entity": "15~50ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 393,
              "end_idx": 414,
              "entity_en": "15~50ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T696",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 415,
              "end_idx": 418,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T697",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 422,
              "end_idx": 426,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T698",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 461,
              "end_idx": 464,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T699",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 468,
              "end_idx": 472,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T700",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 489,
              "end_idx": 493,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T701",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 496,
              "end_idx": 501,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T702",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 496,
              "end_idx": 497,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T703",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 502,
              "end_idx": 505,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T704",
              "entity": "CKD4期",
              "entity_type": "Disease",
              "start_idx": 522,
              "end_idx": 527,
              "entity_en": "CKD stage 4"
            },
            {
              "entity_id": "T705",
              "entity": "4期",
              "entity_type": "Class",
              "start_idx": 525,
              "end_idx": 527,
              "entity_en": "4th phase"
            },
            {
              "entity_id": "T706",
              "entity": "餐前60mg",
              "entity_type": "Amount",
              "start_idx": 534,
              "end_idx": 540,
              "entity_en": "60 mg before meals"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R341",
              "head_entity_id": "T656",
              "tail_entity_id": "T657"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R342",
              "head_entity_id": "T668",
              "tail_entity_id": "T667"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R343",
              "head_entity_id": "T667",
              "tail_entity_id": "T670"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R344",
              "head_entity_id": "T673",
              "tail_entity_id": "T670"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R345",
              "head_entity_id": "T671",
              "tail_entity_id": "T672"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R346",
              "head_entity_id": "T675",
              "tail_entity_id": "T674"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R347",
              "head_entity_id": "T678",
              "tail_entity_id": "T674"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R348",
              "head_entity_id": "T677",
              "tail_entity_id": "T676"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R349",
              "head_entity_id": "T678",
              "tail_entity_id": "T676"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R350",
              "head_entity_id": "T684",
              "tail_entity_id": "T678"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R351",
              "head_entity_id": "T680",
              "tail_entity_id": "T679"
            },
            {
              "relation_type": "ADE_Disease",
              "relation_id": "R352",
              "head_entity_id": "T684",
              "tail_entity_id": "T679"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R353",
              "head_entity_id": "T683",
              "tail_entity_id": "T682"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R354",
              "head_entity_id": "T686",
              "tail_entity_id": "T685"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R355",
              "head_entity_id": "T688",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R356",
              "head_entity_id": "T689",
              "tail_entity_id": "T690"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R357",
              "head_entity_id": "T691",
              "tail_entity_id": "T690"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R358",
              "head_entity_id": "T692",
              "tail_entity_id": "T690"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R359",
              "head_entity_id": "T693",
              "tail_entity_id": "T690"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R360",
              "head_entity_id": "T694",
              "tail_entity_id": "T696"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R361",
              "head_entity_id": "T697",
              "tail_entity_id": "T696"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R362",
              "head_entity_id": "T698",
              "tail_entity_id": "T696"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R363",
              "head_entity_id": "T700",
              "tail_entity_id": "T701"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R364",
              "head_entity_id": "T700",
              "tail_entity_id": "T703"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R365",
              "head_entity_id": "T700",
              "tail_entity_id": "T704"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R366",
              "head_entity_id": "T706",
              "tail_entity_id": "T700"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R367",
              "head_entity_id": "T702",
              "tail_entity_id": "T701"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R368",
              "head_entity_id": "T705",
              "tail_entity_id": "T704"
            }
          ],
          "sentence_en": "(3) Meglitinides: Meglitinides are non-sulfonylurea insulin secretagogues that are glucose-dependent and must be taken before meals. Because they have no significant stimulatory effect on basal insulin secretion, the risk and degree of hypoglycemia they cause are less than those of sulfonylureas. Other adverse reactions include allergic reactions, gastrointestinal discomfort, eye abnormalities, liver damage, etc., which are all relatively rare. The main representatives of meglitinides are nateglinide and repaglinide. Repaglinide and its metabolites are mainly metabolized by the liver, with only <8% excreted by the kidneys. The Phase I clinical trial of repaglinide showed that after 7 days of use of repaglinide, there was no significant difference in blood drug concentration between patients with normal renal function and patients with different degrees of CKD, indicating that repaglinide does not accumulate in CKD patients. A multicenter study of 281 patients with type 2 diabetes with or without renal insufficiency showed that the incidence of hypoglycemia in patients with different degrees of renal insufficiency (normal, mild, moderate, severe, and extremely severe renal impairment) was less than 2% when repaglinide was used to replace the original hypoglycemic treatment, and the incidence of hypoglycemia during repaglinide treatment was not related to the degree of renal impairment. Therefore, no dose adjustment is required for repaglinide in patients with CKD stage 3 and 4 or those undergoing kidney transplantation or dialysis. In diabetic patients with Ccr 15~50ml·min-1·1.73m-2, the bioavailability and half-life of nateglinide are not clinically significant compared with healthy people, but as renal function decreases, the level of active metabolites of nateglinide increases. Some people believe that there is no need to adjust the dose of nateglinide when it is used in diabetic patients with renal insufficiency, but the ADA still recommends that CKD stage 4 should start with a small dose of 60mg before each meal."
        }
      ],
      "paragraph_en": "(3) Meglitinides: Meglitinides are non-sulfonylurea insulin secretagogues that are glucose-dependent and must be taken before meals. Because they have no significant stimulatory effect on basal insulin secretion, the risk and degree of hypoglycemia they cause are less than those of sulfonylureas. Other adverse reactions include allergic reactions, gastrointestinal discomfort, eye abnormalities, liver damage, etc., which are all relatively rare. The main representatives of meglitinides are nateglinide and repaglinide. Repaglinide and its metabolites are mainly metabolized by the liver, with only <8% excreted by the kidneys. The Phase I clinical trial of repaglinide showed that after 7 days of use of repaglinide, there was no significant difference in blood drug concentration between patients with normal renal function and patients with different degrees of CKD, indicating that repaglinide does not accumulate in CKD patients. A multicenter study of 281 patients with type 2 diabetes with or without renal insufficiency showed that the incidence of hypoglycemia in patients with different degrees of renal insufficiency (normal, mild, moderate, severe, and extremely severe renal impairment) was less than 2% when repaglinide was used to replace the original hypoglycemic treatment, and the incidence of hypoglycemia during repaglinide treatment was not related to the degree of renal impairment. Therefore, no dose adjustment is required for repaglinide in patients with CKD stage 3 and 4 or those undergoing kidney transplantation or dialysis. In diabetic patients with Ccr 15~50ml·min-1·1.73m-2, the bioavailability and half-life of nateglinide are not clinically significant compared with healthy people, but as renal function decreases, the level of active metabolites of nateglinide increases. Some people believe that there is no need to adjust the dose of nateglinide when it is used in diabetic patients with renal insufficiency, but the ADA still recommends that CKD stage 4 should start with a small dose of 60mg before each meal."
    },
    {
      "paragraph_id": "35",
      "paragraph": "(4)噻唑烷二酮类：该类药物的常见不良反应是液体潴留，因而对于重度心衰患者应慎用。使用该类药物发生骨折及骨质疏松的风险增加，需慎用于潜在骨疾病的患者(如肾性骨营养不良)，尤其是绝经后女性；其他不良反应包括肝酶升高、体重增加等。该类药物不刺激内源性胰岛素分泌，单独使用低血糖风险低(1%~2%)。该类药物主要代表为吡格列酮和罗格列酮。由于其经过肝脏代谢，吡格列酮用于肾功能不全无需调整剂量；罗格列酮因增加心血管风险的安全性问题引起了国内外的警惕，美国食品药品监督管理局(FDA)和欧洲药品管理局建议在心功能不全和严重骨质疏松患者慎用已限制其使用(图1)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)噻唑烷二酮类：该类药物的常见不良反应是液体潴留，因而对于重度心衰患者应慎用。使用该类药物发生骨折及骨质疏松的风险增加，需慎用于潜在骨疾病的患者(如肾性骨营养不良)，尤其是绝经后女性；其他不良反应包括肝酶升高、体重增加等。该类药物不刺激内源性胰岛素分泌，单独使用低血糖风险低(1%~2%)。该类药物主要代表为吡格列酮和罗格列酮。由于其经过肝脏代谢，吡格列酮用于肾功能不全无需调整剂量；罗格列酮因增加心血管风险的安全性问题引起了国内外的警惕，美国食品药品监督管理局(FDA)和欧洲药品管理局建议在心功能不全和严重骨质疏松患者慎用已限制其使用(图1)。",
          "start_idx": 0,
          "end_idx": 276,
          "entities": [
            {
              "entity_id": "T707",
              "entity": "重度心衰",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "Severe heart failure"
            },
            {
              "entity_id": "T708",
              "entity": "重度",
              "entity_type": "Class",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T709",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 34,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T710",
              "entity": "骨折",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "fracture"
            },
            {
              "entity_id": "T711",
              "entity": "骨质疏松",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Osteoporosis"
            },
            {
              "entity_id": "T712",
              "entity": "骨疾病",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 71,
              "entity_en": "Bone diseases"
            },
            {
              "entity_id": "T713",
              "entity": "骨",
              "entity_type": "Anatomy",
              "start_idx": 68,
              "end_idx": 69,
              "entity_en": "bone"
            },
            {
              "entity_id": "T714",
              "entity": "肾性骨营养不良",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 83,
              "entity_en": "Renal osteodystrophy"
            },
            {
              "entity_id": "T715",
              "entity": "肾性",
              "entity_type": "Class",
              "start_idx": 76,
              "end_idx": 78,
              "entity_en": "Renal"
            },
            {
              "entity_id": "T716",
              "entity": "骨",
              "entity_type": "Anatomy",
              "start_idx": 78,
              "end_idx": 79,
              "entity_en": "bone"
            },
            {
              "entity_id": "T717",
              "entity": "肝酶升高",
              "entity_type": "ADE",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "Elevated liver enzymes"
            },
            {
              "entity_id": "T718",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 107,
              "end_idx": 111,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T719",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 133,
              "end_idx": 136,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T720",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 156,
              "end_idx": 160,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T721",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 161,
              "end_idx": 165,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T722",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 180,
              "entity_en": "Pioglitazone"
            },
            {
              "entity_id": "T723",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 182,
              "end_idx": 187,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T724",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 182,
              "end_idx": 183,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T725",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 194,
              "end_idx": 198,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T726",
              "entity": "心血管风险",
              "entity_type": "Disease",
              "start_idx": 201,
              "end_idx": 206,
              "entity_en": "Cardiovascular risk"
            },
            {
              "entity_id": "T727",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 201,
              "end_idx": 204,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T728",
              "entity": "心功能不全",
              "entity_type": "Disease",
              "start_idx": 249,
              "end_idx": 254,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T729",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 249,
              "end_idx": 250,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T730",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 255,
              "end_idx": 257,
              "entity_en": "serious"
            },
            {
              "entity_id": "T731",
              "entity": "骨质疏松",
              "entity_type": "Disease",
              "start_idx": 257,
              "end_idx": 261,
              "entity_en": "Osteoporosis"
            },
            {
              "entity_id": "T732",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T733",
              "entity": "液体潴留",
              "entity_type": "ADE",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Fluid retention"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R369",
              "head_entity_id": "T732",
              "tail_entity_id": "T707"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R370",
              "head_entity_id": "T708",
              "tail_entity_id": "T707"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R371",
              "head_entity_id": "T709",
              "tail_entity_id": "T707"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R372",
              "head_entity_id": "T713",
              "tail_entity_id": "T712"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R373",
              "head_entity_id": "T716",
              "tail_entity_id": "T714"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R374",
              "head_entity_id": "T715",
              "tail_entity_id": "T714"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R375",
              "head_entity_id": "T722",
              "tail_entity_id": "T723"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R376",
              "head_entity_id": "T724",
              "tail_entity_id": "T723"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R377",
              "head_entity_id": "T725",
              "tail_entity_id": "T726"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R378",
              "head_entity_id": "T729",
              "tail_entity_id": "T728"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R379",
              "head_entity_id": "T733",
              "tail_entity_id": "T732"
            }
          ],
          "sentence_en": "(4) Thiazolidinediones: The common adverse reaction of this class of drugs is fluid retention, so they should be used with caution in patients with severe heart failure. The use of this class of drugs increases the risk of fractures and osteoporosis, and should be used with caution in patients with underlying bone diseases (such as renal osteodystrophy), especially postmenopausal women; other adverse reactions include elevated liver enzymes and weight gain. This class of drugs does not stimulate endogenous insulin secretion, and the risk of hypoglycemia when used alone is low (1%~2%). The main representatives of this class of drugs are pioglitazone and rosiglitazone. Because it is metabolized by the liver, pioglitazone does not require dose adjustment for renal insufficiency; rosiglitazone has aroused domestic and international vigilance due to the safety issue of increased cardiovascular risk. The US Food and Drug Administration (FDA) and the European Medicines Agency recommend that it be used with caution in patients with heart failure and severe osteoporosis, and its use has been restricted (Figure 1)."
        }
      ],
      "paragraph_en": "(4) Thiazolidinediones: The common adverse reaction of this class of drugs is fluid retention, so they should be used with caution in patients with severe heart failure. The use of this class of drugs increases the risk of fractures and osteoporosis, and should be used with caution in patients with underlying bone diseases (such as renal osteodystrophy), especially postmenopausal women; other adverse reactions include elevated liver enzymes and weight gain. This class of drugs does not stimulate endogenous insulin secretion, and the risk of hypoglycemia when used alone is low (1%~2%). The main representatives of this class of drugs are pioglitazone and rosiglitazone. Because it is metabolized by the liver, pioglitazone does not require dose adjustment for renal insufficiency; rosiglitazone has aroused domestic and international vigilance due to the safety issue of increased cardiovascular risk. The US Food and Drug Administration (FDA) and the European Medicines Agency recommend that it be used with caution in patients with heart failure and severe osteoporosis, and its use has been restricted (Figure 1)."
    },
    {
      "paragraph_id": "36",
      "paragraph": "(5)α-糖苷酶抑制剂：α-糖苷酶抑制剂适用于饮食结构以碳水化合物为主且餐后血糖升高的患者，可将HbA1c降低0.5%~0.8%，其主要药理作用是抑制碳水化合物在小肠上段的吸收而降低餐后血糖，不增加体重且有减轻体重的趋势。该类药物口服后被胃肠道吸收不到1%，故全身性不良反应不多见，主要不良反应是胃肠道不适，表现为腹胀、腹泻等，其主要代表药物有阿卡波糖、伏格列波糖等。随肾功能的降低，阿卡波糖及其代谢产物的血药浓度显著增加，Ccr低于25ml·min-1·1.73m-2者禁用。伏格列波糖仅微量被吸收，分布于肠黏膜和肾脏，可用于CKD 1~3期患者，慎用于CKD4~5期患者，不必调整剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)α-糖苷酶抑制剂：α-糖苷酶抑制剂适用于饮食结构以碳水化合物为主且餐后血糖升高的患者，可将HbA1c降低0.5%~0.8%，其主要药理作用是抑制碳水化合物在小肠上段的吸收而降低餐后血糖，不增加体重且有减轻体重的趋势。该类药物口服后被胃肠道吸收不到1%，故全身性不良反应不多见，主要不良反应是胃肠道不适，表现为腹胀、腹泻等，其主要代表药物有阿卡波糖、伏格列波糖等。随肾功能的降低，阿卡波糖及其代谢产物的血药浓度显著增加，Ccr低于25ml·min-1·1.73m-2者禁用。伏格列波糖仅微量被吸收，分布于肠黏膜和肾脏，可用于CKD 1~3期患者，慎用于CKD4~5期患者，不必调整剂量。",
          "start_idx": 0,
          "end_idx": 295,
          "entities": [
            {
              "entity_id": "T734",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 11,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T735",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 20,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T736",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T737",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T738",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 53,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T739",
              "entity": "降低0.5%~0.8%",
              "entity_type": "Test_Value",
              "start_idx": 53,
              "end_idx": 64,
              "entity_en": "Reduce by 0.5%~0.8%"
            },
            {
              "entity_id": "T740",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T741",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "oral"
            },
            {
              "entity_id": "T742",
              "entity": "胃肠道不适",
              "entity_type": "ADE",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "Gastrointestinal discomfort"
            },
            {
              "entity_id": "T743",
              "entity": "腹胀",
              "entity_type": "ADE",
              "start_idx": 157,
              "end_idx": 159,
              "entity_en": "Abdominal bloating"
            },
            {
              "entity_id": "T744",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 160,
              "end_idx": 162,
              "entity_en": "diarrhea"
            },
            {
              "entity_id": "T745",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 176,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T746",
              "entity": "伏格列波糖",
              "entity_type": "Drug",
              "start_idx": 177,
              "end_idx": 182,
              "entity_en": "Voglibose"
            },
            {
              "entity_id": "T747",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 196,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T748",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 203,
              "end_idx": 207,
              "entity_en": "Blood concentration"
            },
            {
              "entity_id": "T749",
              "entity": "Ccr",
              "entity_type": "Test_items",
              "start_idx": 212,
              "end_idx": 215,
              "entity_en": "Ccr"
            },
            {
              "entity_id": "T750",
              "entity": "低于25ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 215,
              "end_idx": 235,
              "entity_en": "Less than 25ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T751",
              "entity": "伏格列波糖",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 244,
              "entity_en": "Voglibose"
            },
            {
              "entity_id": "T752",
              "entity": "CKD 1~3期",
              "entity_type": "Disease",
              "start_idx": 264,
              "end_idx": 272,
              "entity_en": "CKD Stages 1-3"
            },
            {
              "entity_id": "T753",
              "entity": "1~3期",
              "entity_type": "Class",
              "start_idx": 268,
              "end_idx": 272,
              "entity_en": "Phase 1~3"
            },
            {
              "entity_id": "T754",
              "entity": "CKD4~5期",
              "entity_type": "Disease",
              "start_idx": 278,
              "end_idx": 285,
              "entity_en": "CKD stage 4-5"
            },
            {
              "entity_id": "T755",
              "entity": "4~5期",
              "entity_type": "Class",
              "start_idx": 281,
              "end_idx": 285,
              "entity_en": "4~5th period"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R380",
              "head_entity_id": "T742",
              "tail_entity_id": "T745"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R381",
              "head_entity_id": "T742",
              "tail_entity_id": "T746"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R382",
              "head_entity_id": "T743",
              "tail_entity_id": "T745"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R383",
              "head_entity_id": "T743",
              "tail_entity_id": "T746"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R384",
              "head_entity_id": "T744",
              "tail_entity_id": "T745"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R385",
              "head_entity_id": "T744",
              "tail_entity_id": "T746"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R386",
              "head_entity_id": "T751",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R387",
              "head_entity_id": "T755",
              "tail_entity_id": "T754"
            }
          ],
          "sentence_en": "(5) α-Glucosidase inhibitors: α-Glucosidase inhibitors are suitable for patients whose diet is mainly composed of carbohydrates and whose postprandial blood sugar is elevated. They can reduce HbA1c by 0.5%~0.8%. Their main pharmacological action is to inhibit the absorption of carbohydrates in the upper small intestine and reduce postprandial blood sugar. They do not increase body weight and tend to reduce body weight. Less than 1% of this type of drug is absorbed by the gastrointestinal tract after oral administration, so systemic adverse reactions are rare. The main adverse reactions are gastrointestinal discomfort, manifested as abdominal distension, diarrhea, etc. Its main representative drugs include acarbose and voglibose. With the decline of renal function, the blood concentration of acarbose and its metabolites increases significantly. It is contraindicated for patients with Ccr lower than 25ml·min-1·1.73m-2. Voglibose is only absorbed in trace amounts and distributed in the intestinal mucosa and kidneys. It can be used for patients with CKD stages 1~3, and should be used with caution in patients with CKD stages 4~5. No dosage adjustment is required."
        }
      ],
      "paragraph_en": "(5) α-Glucosidase inhibitors: α-Glucosidase inhibitors are suitable for patients whose diet is mainly composed of carbohydrates and whose postprandial blood sugar is elevated. They can reduce HbA1c by 0.5%~0.8%. Their main pharmacological action is to inhibit the absorption of carbohydrates in the upper small intestine and reduce postprandial blood sugar. They do not increase body weight and tend to reduce body weight. Less than 1% of this type of drug is absorbed by the gastrointestinal tract after oral administration, so systemic adverse reactions are rare. The main adverse reactions are gastrointestinal discomfort, manifested as abdominal distension, diarrhea, etc. Its main representative drugs include acarbose and voglibose. With the decline of renal function, the blood concentration of acarbose and its metabolites increases significantly. It is contraindicated for patients with Ccr lower than 25ml·min-1·1.73m-2. Voglibose is only absorbed in trace amounts and distributed in the intestinal mucosa and kidneys. It can be used for patients with CKD stages 1~3, and should be used with caution in patients with CKD stages 4~5. No dosage adjustment is required."
    },
    {
      "paragraph_id": "37",
      "paragraph": "(6)GLP-1：GLP-1半衰期短，GLP-1类似物的半衰期延长，其代表药物有艾塞那肽、利拉鲁肽等。艾塞那肽经肾排泄，GFR低于45ml·min-1·1.73m-2时，其清除率下降36%，GFR低于30ml·min-1·1.73m-2时，其清除率下降64%且透析患者不能耐受胃肠道不良反应，因此艾塞那肽不推荐用于CKD4~5期的患者。利拉鲁肽也仅可用于CKD1~2期患者，在中度肾功能损害患者中的治疗经验有限，不推荐用于包括ESRD患者在内的重度肾功能损害患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(6)GLP-1：GLP-1半衰期短，GLP-1类似物的半衰期延长，其代表药物有艾塞那肽、利拉鲁肽等。艾塞那肽经肾排泄，GFR低于45ml·min-1·1.73m-2时，其清除率下降36%，GFR低于30ml·min-1·1.73m-2时，其清除率下降64%且透析患者不能耐受胃肠道不良反应，因此艾塞那肽不推荐用于CKD4~5期的患者。利拉鲁肽也仅可用于CKD1~2期患者，在中度肾功能损害患者中的治疗经验有限，不推荐用于包括ESRD患者在内的重度肾功能损害患者。",
          "start_idx": 0,
          "end_idx": 232,
          "entities": [
            {
              "entity_id": "T756",
              "entity": "GLP-1",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "GLP-1"
            },
            {
              "entity_id": "T757",
              "entity": "GLP-1",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "GLP-1"
            },
            {
              "entity_id": "T758",
              "entity": "GLP-1",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "GLP-1"
            },
            {
              "entity_id": "T759",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T760",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T761",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T762",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T763",
              "entity": "低于45ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 63,
              "end_idx": 83,
              "entity_en": "Less than 45ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T764",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 95,
              "end_idx": 98,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T765",
              "entity": "低于30ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 98,
              "end_idx": 118,
              "entity_en": "Less than 30ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T766",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 130,
              "end_idx": 132,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T767",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 138,
              "end_idx": 145,
              "entity_en": "Gastrointestinal adverse reactions"
            },
            {
              "entity_id": "T768",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 148,
              "end_idx": 152,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T769",
              "entity": "CKD4~5期",
              "entity_type": "Disease",
              "start_idx": 157,
              "end_idx": 164,
              "entity_en": "CKD stage 4-5"
            },
            {
              "entity_id": "T770",
              "entity": "4~5期",
              "entity_type": "Class",
              "start_idx": 160,
              "end_idx": 164,
              "entity_en": "4~5th period"
            },
            {
              "entity_id": "T771",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 168,
              "end_idx": 172,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T772",
              "entity": "CKD1~2期",
              "entity_type": "Disease",
              "start_idx": 177,
              "end_idx": 184,
              "entity_en": "CKD stage 1-2"
            },
            {
              "entity_id": "T773",
              "entity": "1~2期",
              "entity_type": "Class",
              "start_idx": 180,
              "end_idx": 184,
              "entity_en": "Phase 1~2"
            },
            {
              "entity_id": "T774",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 188,
              "end_idx": 190,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T775",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 190,
              "end_idx": 195,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T776",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 190,
              "end_idx": 191,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T777",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 213,
              "end_idx": 217,
              "entity_en": "ESRD"
            },
            {
              "entity_id": "T778",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 222,
              "end_idx": 224,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T779",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 229,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T780",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 224,
              "end_idx": 225,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R388",
              "head_entity_id": "T767",
              "tail_entity_id": "T761"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R389",
              "head_entity_id": "T761",
              "tail_entity_id": "T769"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R390",
              "head_entity_id": "T762",
              "tail_entity_id": "T769"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R391",
              "head_entity_id": "T764",
              "tail_entity_id": "T769"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R392",
              "head_entity_id": "T766",
              "tail_entity_id": "T769"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R393",
              "head_entity_id": "T770",
              "tail_entity_id": "T769"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R394",
              "head_entity_id": "T771",
              "tail_entity_id": "T772"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R395",
              "head_entity_id": "T773",
              "tail_entity_id": "T772"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R396",
              "head_entity_id": "T776",
              "tail_entity_id": "T775"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R397",
              "head_entity_id": "T780",
              "tail_entity_id": "T779"
            }
          ],
          "sentence_en": "(6) GLP-1: GLP-1 has a short half-life, while GLP-1 analogs have a longer half-life. Representative drugs include exenatide and liraglutide. Exenatide is excreted through the kidneys. When GFR is lower than 45 ml·min-1·1.73 m-2, its clearance rate decreases by 36%. When GFR is lower than 30 ml·min-1·1.73 m-2, its clearance rate decreases by 64%. In addition, dialysis patients cannot tolerate gastrointestinal adverse reactions. Therefore, exenatide is not recommended for patients with CKD stage 4~5. Liraglutide can only be used for patients with CKD stage 1~2. There is limited experience in treating patients with moderate renal impairment, and it is not recommended for patients with severe renal impairment, including ESRD patients."
        }
      ],
      "paragraph_en": "(6) GLP-1: GLP-1 has a short half-life, while GLP-1 analogs have a longer half-life. Representative drugs include exenatide and liraglutide. Exenatide is excreted through the kidneys. When GFR is lower than 45 ml·min-1·1.73 m-2, its clearance rate decreases by 36%. When GFR is lower than 30 ml·min-1·1.73 m-2, its clearance rate decreases by 64%. In addition, dialysis patients cannot tolerate gastrointestinal adverse reactions. Therefore, exenatide is not recommended for patients with CKD stage 4~5. Liraglutide can only be used for patients with CKD stage 1~2. There is limited experience in treating patients with moderate renal impairment, and it is not recommended for patients with severe renal impairment, including ESRD patients."
    },
    {
      "paragraph_id": "38",
      "paragraph": "包括ESRD患者在内的重度肾功能损害患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "包括ESRD患者在内的重度肾功能损害患者。",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T781",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "ESRD"
            },
            {
              "entity_id": "T782",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T783",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T784",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 14,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R398",
              "head_entity_id": "T784",
              "tail_entity_id": "T783"
            }
          ],
          "sentence_en": "Patients with severe renal impairment including ESRD patients."
        }
      ],
      "paragraph_en": "Patients with severe renal impairment including ESRD patients."
    },
    {
      "paragraph_id": "39",
      "paragraph": "(7)DPP-4抑制剂：DPP-4是GLP-1降解酶，DDP-4抑剂通过减少GLP-1在体内的降解，增加体内GLP-1的水平。这一类降糖药由于上市较晚，缺乏临床用药经验，因此用于糖尿病肾病患者时应酌情减量。DPP-4抑制剂降低HbA1c弱于其他胰岛素促泌剂。目前在国内上市的DPP-4抑制剂为西格列汀、沙格列汀、维格列汀和利格列汀。西格列汀用于GFR>50ml·min-1·1.73m-2的CKD患者时无需调整剂量，当GFR在30~50ml·min-1·1.73m-2时减量至50mg每日1次，GFR<30ml·min-1·1.73m-2或透析的患者可减量至每日25mg，但相关的临床经验尚不丰富。沙格列汀和维格列汀可用于CKD 1~2期患者，用于中重度肾功能不全患者的临床试验数据有限，不推荐用于3~5期患者，仅有利格列汀在CKD 4~5期时无需减量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(7)DPP-4抑制剂：DPP-4是GLP-1降解酶，DDP-4抑剂通过减少GLP-1在体内的降解，增加体内GLP-1的水平。这一类降糖药由于上市较晚，缺乏临床用药经验，因此用于糖尿病肾病患者时应酌情减量。DPP-4抑制剂降低HbA1c弱于其他胰岛素促泌剂。目前在国内上市的DPP-4抑制剂为西格列汀、沙格列汀、维格列汀和利格列汀。西格列汀用于GFR>50ml·min-1·1.73m-2的CKD患者时无需调整剂量，当GFR在30~50ml·min-1·1.73m-2时减量至50mg每日1次，GFR<30ml·min-1·1.73m-2或透析的患者可减量至每日25mg，但相关的临床经验尚不丰富。沙格列汀和维格列汀可用于CKD 1~2期患者，用于中重度肾功能不全患者的临床试验数据有限，不推荐用于3~5期患者，仅有利格列汀在CKD 4~5期时无需减量。",
          "start_idx": 0,
          "end_idx": 377,
          "entities": [
            {
              "entity_id": "T785",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 11,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T786",
              "entity": "DDP-4抑剂",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 34,
              "entity_en": "DDP-4 inhibitor"
            },
            {
              "entity_id": "T787",
              "entity": "GLP-1",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": "GLP-1"
            },
            {
              "entity_id": "T788",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 94,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T789",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 92,
              "end_idx": 93,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T790",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 111,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T791",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 113,
              "end_idx": 118,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T792",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 122,
              "end_idx": 128,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T793",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 145,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T794",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T795",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 155,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T796",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 156,
              "end_idx": 160,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T797",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 161,
              "end_idx": 165,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T798",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 170,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T799",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 172,
              "end_idx": 175,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T800",
              "entity": ">50ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 175,
              "end_idx": 194,
              "entity_en": ">50ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T801",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 195,
              "end_idx": 198,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T802",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 209,
              "end_idx": 212,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T803",
              "entity": "30~50ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 213,
              "end_idx": 234,
              "entity_en": "30~50ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T804",
              "entity": "50mg",
              "entity_type": "Amount",
              "start_idx": 238,
              "end_idx": 242,
              "entity_en": "50mg"
            },
            {
              "entity_id": "T805",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 242,
              "end_idx": 246,
              "entity_en": "1 time per day"
            },
            {
              "entity_id": "T806",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 247,
              "end_idx": 250,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T807",
              "entity": "<30ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 250,
              "end_idx": 269,
              "entity_en": "<30ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T808",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 270,
              "end_idx": 272,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T809",
              "entity": "25mg",
              "entity_type": "Amount",
              "start_idx": 281,
              "end_idx": 285,
              "entity_en": "25mg"
            },
            {
              "entity_id": "T810",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 299,
              "end_idx": 303,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T811",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 304,
              "end_idx": 308,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T812",
              "entity": "CKD 1~2期",
              "entity_type": "Disease",
              "start_idx": 311,
              "end_idx": 319,
              "entity_en": "CKD stage 1-2"
            },
            {
              "entity_id": "T813",
              "entity": "1~2期",
              "entity_type": "Class",
              "start_idx": 315,
              "end_idx": 319,
              "entity_en": "Phase 1~2"
            },
            {
              "entity_id": "T814",
              "entity": "中重度",
              "entity_type": "Level",
              "start_idx": 324,
              "end_idx": 327,
              "entity_en": "Moderate to severe"
            },
            {
              "entity_id": "T815",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 327,
              "end_idx": 332,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T816",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 327,
              "end_idx": 328,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T817",
              "entity": "3~5期",
              "entity_type": "Class",
              "start_idx": 349,
              "end_idx": 353,
              "entity_en": "3~5th period"
            },
            {
              "entity_id": "T818",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 358,
              "end_idx": 362,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T819",
              "entity": "CKD 4~5期",
              "entity_type": "Disease",
              "start_idx": 363,
              "end_idx": 371,
              "entity_en": "CKD stage 4-5"
            },
            {
              "entity_id": "T820",
              "entity": "4~5期",
              "entity_type": "Class",
              "start_idx": 367,
              "end_idx": 371,
              "entity_en": "4~5th period"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R399",
              "head_entity_id": "T789",
              "tail_entity_id": "T788"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R400",
              "head_entity_id": "T798",
              "tail_entity_id": "T801"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R401",
              "head_entity_id": "T804",
              "tail_entity_id": "T798"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R402",
              "head_entity_id": "T809",
              "tail_entity_id": "T798"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R403",
              "head_entity_id": "T805",
              "tail_entity_id": "T798"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R404",
              "head_entity_id": "T799",
              "tail_entity_id": "T801"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R405",
              "head_entity_id": "T802",
              "tail_entity_id": "T801"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R406",
              "head_entity_id": "T806",
              "tail_entity_id": "T801"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R407",
              "head_entity_id": "T808",
              "tail_entity_id": "T801"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R408",
              "head_entity_id": "T810",
              "tail_entity_id": "T812"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R409",
              "head_entity_id": "T811",
              "tail_entity_id": "T812"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R410",
              "head_entity_id": "T813",
              "tail_entity_id": "T812"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R411",
              "head_entity_id": "T817",
              "tail_entity_id": "T812"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R412",
              "head_entity_id": "T816",
              "tail_entity_id": "T815"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R413",
              "head_entity_id": "T818",
              "tail_entity_id": "T819"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R414",
              "head_entity_id": "T820",
              "tail_entity_id": "T819"
            }
          ],
          "sentence_en": "(7) DPP-4 inhibitors: DPP-4 is a GLP-1 degrading enzyme. DPP-4 inhibitors increase the level of GLP-1 in the body by reducing the degradation of GLP-1 in the body. This type of hypoglycemic drug was launched relatively late and there is a lack of clinical experience. Therefore, the dose should be reduced as appropriate when used in patients with diabetic nephropathy. DPP-4 inhibitors are less effective in reducing HbA1c than other insulin secretagogues. Currently, the DPP-4 inhibitors available in China are sitagliptin, saxagliptin, vildagliptin, and linagliptin. Sitagliptin does not require dose adjustment for CKD patients with GFR>50ml·min-1·1.73m-2. When the GFR is between 30 and 50ml·min-1·1.73m-2, the dose can be reduced to 50mg once a day. Patients with GFR<30ml·min-1·1.73m-2 or on dialysis can reduce the dose to 25mg per day, but relevant clinical experience is not yet abundant. Saxagliptin and vildagliptin can be used for patients with CKD stage 1-2. There are limited clinical trial data for their use in patients with moderate to severe renal insufficiency, and they are not recommended for patients with stages 3-5. Only linagliptin does not require a dose reduction in patients with CKD stage 4-5."
        }
      ],
      "paragraph_en": "(7) DPP-4 inhibitors: DPP-4 is a GLP-1 degrading enzyme. DPP-4 inhibitors increase the level of GLP-1 in the body by reducing the degradation of GLP-1 in the body. This type of hypoglycemic drug was launched relatively late and there is a lack of clinical experience. Therefore, the dose should be reduced as appropriate when used in patients with diabetic nephropathy. DPP-4 inhibitors are less effective in reducing HbA1c than other insulin secretagogues. Currently, the DPP-4 inhibitors available in China are sitagliptin, saxagliptin, vildagliptin, and linagliptin. Sitagliptin does not require dose adjustment for CKD patients with GFR>50ml·min-1·1.73m-2. When the GFR is between 30 and 50ml·min-1·1.73m-2, the dose can be reduced to 50mg once a day. Patients with GFR<30ml·min-1·1.73m-2 or on dialysis can reduce the dose to 25mg per day, but relevant clinical experience is not yet abundant. Saxagliptin and vildagliptin can be used for patients with CKD stage 1-2. There are limited clinical trial data for their use in patients with moderate to severe renal insufficiency, and they are not recommended for patients with stages 3-5. Only linagliptin does not require a dose reduction in patients with CKD stage 4-5."
    },
    {
      "paragraph_id": "40",
      "paragraph": "(8)胰岛素：胰岛素是糖尿病的基础用药，适用于1型糖尿病、有急性并发症或严重合并症或处于应激状态或口服降糖药物疗效不佳或有口服降糖药禁忌的2型糖尿病、妊娠糖尿病、继发于严重胰腺疾病的糖尿病、严重营养不良等。不良反应主要有低血糖发作、体重增加、治疗初期的外周组织水肿、过敏反应等。肾功能受损者胰岛素的排泄减少，故CKD3期以上的患者胰岛素用量需减少。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(8)胰岛素：胰岛素是糖尿病的基础用药，适用于1型糖尿病、有急性并发症或严重合并症或处于应激状态或口服降糖药物疗效不佳或有口服降糖药禁忌的2型糖尿病、妊娠糖尿病、继发于严重胰腺疾病的糖尿病、严重营养不良等。不良反应主要有低血糖发作、体重增加、治疗初期的外周组织水肿、过敏反应等。肾功能受损者胰岛素的排泄减少，故CKD3期以上的患者胰岛素用量需减少。",
          "start_idx": 0,
          "end_idx": 174,
          "entities": [
            {
              "entity_id": "T821",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T822",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T823",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T824",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T825",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T826",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "oral"
            },
            {
              "entity_id": "T827",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "oral"
            },
            {
              "entity_id": "T828",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 74,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T829",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 69,
              "end_idx": 71,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T830",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T831",
              "entity": "严重胰腺疾病",
              "entity_type": "Reason",
              "start_idx": 84,
              "end_idx": 90,
              "entity_en": "Severe pancreatic disease"
            },
            {
              "entity_id": "T832",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 94,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T833",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "serious"
            },
            {
              "entity_id": "T834",
              "entity": "营养不良",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "Malnutrition"
            },
            {
              "entity_id": "T835",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 113,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T836",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 116,
              "end_idx": 120,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T837",
              "entity": "治疗初期的外周组织水肿",
              "entity_type": "ADE",
              "start_idx": 121,
              "end_idx": 132,
              "entity_en": "Peripheral tissue edema during the initial treatment period"
            },
            {
              "entity_id": "T838",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 133,
              "end_idx": 137,
              "entity_en": "Allergic reactions"
            },
            {
              "entity_id": "T839",
              "entity": "肾功能受损者胰岛素的排泄减少",
              "entity_type": "Pathogenesis",
              "start_idx": 139,
              "end_idx": 153,
              "entity_en": "Insulin excretion is reduced in patients with impaired renal function"
            },
            {
              "entity_id": "T840",
              "entity": "CKD3期",
              "entity_type": "Disease",
              "start_idx": 155,
              "end_idx": 160,
              "entity_en": "CKD stage 3"
            },
            {
              "entity_id": "T841",
              "entity": "3期",
              "entity_type": "Class",
              "start_idx": 158,
              "end_idx": 160,
              "entity_en": "Phase 3"
            },
            {
              "entity_id": "T842",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 168,
              "entity_en": "insulin"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R415",
              "head_entity_id": "T822",
              "tail_entity_id": "T823"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R416",
              "head_entity_id": "T825",
              "tail_entity_id": "T824"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R417",
              "head_entity_id": "T829",
              "tail_entity_id": "T828"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R418",
              "head_entity_id": "T831",
              "tail_entity_id": "T832"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R419",
              "head_entity_id": "T839",
              "tail_entity_id": "T840"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R420",
              "head_entity_id": "T841",
              "tail_entity_id": "T840"
            }
          ],
          "sentence_en": "(8) Insulin: Insulin is the basic medication for diabetes. It is suitable for type 1 diabetes, type 2 diabetes with acute complications or severe comorbidities, or in a state of stress, or with poor efficacy or contraindications to oral hypoglycemic drugs, gestational diabetes, diabetes secondary to severe pancreatic disease, severe malnutrition, etc. Adverse reactions mainly include hypoglycemia, weight gain, peripheral tissue edema in the early stage of treatment, allergic reactions, etc. The excretion of insulin is reduced in patients with impaired renal function, so the insulin dosage needs to be reduced in patients with CKD stage 3 or above."
        }
      ],
      "paragraph_en": "(8) Insulin: Insulin is the basic medication for diabetes. It is suitable for type 1 diabetes, type 2 diabetes with acute complications or severe comorbidities, or in a state of stress, or with poor efficacy or contraindications to oral hypoglycemic drugs, gestational diabetes, diabetes secondary to severe pancreatic disease, severe malnutrition, etc. Adverse reactions mainly include hypoglycemia, weight gain, peripheral tissue edema in the early stage of treatment, allergic reactions, etc. The excretion of insulin is reduced in patients with impaired renal function, so the insulin dosage needs to be reduced in patients with CKD stage 3 or above."
    },
    {
      "paragraph_id": "41",
      "paragraph": "(三)控制血压",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)控制血压",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T843",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "blood pressure"
            }
          ],
          "relations": [],
          "sentence_en": "3. Control blood pressure"
        }
      ],
      "paragraph_en": "3. Control blood pressure"
    },
    {
      "paragraph_id": "42",
      "paragraph": "血压升高不仅是加速糖尿病肾病进展的重要因素，也是决定患者心血管病预后的主要风险因素。在2型糖尿病肾病患者中，血压对肾功能的影响更加突出，收缩压超过140mmHg(1mmHg=0.133kPa)的患者，其肾功能下降速度为每年13.5%，而收缩压<140mmHg者每年肾功能下降的速度是1%。UKPDS研究显示，在处于糖尿病早期的糖尿病患者中采用强化的血压控制，不但可以显著减少糖尿病大血管病变发生的风险，还显著减少了微血管病变发生的风险。大量临床观察也证实，严格控制高血压能明显减少糖尿病肾病患者尿蛋白水平，延缓肾功能损害的进展。强化血压控制还可使心血管病终点事件的风险下降20%~30%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "血压升高不仅是加速糖尿病肾病进展的重要因素，也是决定患者心血管病预后的主要风险因素。在2型糖尿病肾病患者中，血压对肾功能的影响更加突出，收缩压超过140mmHg(1mmHg=0.133kPa)的患者，其肾功能下降速度为每年13.5%，而收缩压<140mmHg者每年肾功能下降的速度是1%。UKPDS研究显示，在处于糖尿病早期的糖尿病患者中采用强化的血压控制，不但可以显著减少糖尿病大血管病变发生的风险，还显著减少了微血管病变发生的风险。大量临床观察也证实，严格控制高血压能明显减少糖尿病肾病患者尿蛋白水平，延缓肾功能损害的进展。",
          "start_idx": 0,
          "end_idx": 264,
          "entities": [
            {
              "entity_id": "T844",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T845",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T846",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T847",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T848",
              "entity": "2型糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 50,
              "entity_en": "Type 2 diabetic nephropathy"
            },
            {
              "entity_id": "T849",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T850",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 49,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T851",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T852",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T853",
              "entity": "收缩压",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 71,
              "entity_en": "Systolic blood pressure"
            },
            {
              "entity_id": "T854",
              "entity": "超过140mmHg(1mmHg=0.133kPa)",
              "entity_type": "Test_Value",
              "start_idx": 71,
              "end_idx": 96,
              "entity_en": "More than 140 mmHg (1 mmHg = 0.133 kPa)"
            },
            {
              "entity_id": "T855",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 101,
              "end_idx": 104,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T856",
              "entity": "收缩压",
              "entity_type": "Test_items",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "Systolic blood pressure"
            },
            {
              "entity_id": "T857",
              "entity": "<140mmHg",
              "entity_type": "Test_Value",
              "start_idx": 121,
              "end_idx": 129,
              "entity_en": "<140 mmHg"
            },
            {
              "entity_id": "T858",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 132,
              "end_idx": 135,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T859",
              "entity": "下降的速度是1%",
              "entity_type": "Test_Value",
              "start_idx": 135,
              "end_idx": 143,
              "entity_en": "The rate of decline is 1%"
            },
            {
              "entity_id": "T860",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 157,
              "end_idx": 160,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T861",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T862",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 174,
              "end_idx": 176,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T863",
              "entity": "糖尿病大血管病变",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 195,
              "entity_en": "Diabetic macroangiopathy"
            },
            {
              "entity_id": "T864",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 190,
              "end_idx": 193,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T865",
              "entity": "微血管病变",
              "entity_type": "Disease",
              "start_idx": 207,
              "end_idx": 212,
              "entity_en": "Microangiopathy"
            },
            {
              "entity_id": "T866",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 207,
              "end_idx": 210,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T867",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 232,
              "end_idx": 235,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T868",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 240,
              "end_idx": 245,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T869",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 243,
              "end_idx": 244,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T870",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 247,
              "end_idx": 250,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T871",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 255,
              "end_idx": 260,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T872",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 255,
              "end_idx": 256,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T876",
              "entity": "心血管病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T877",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R421",
              "head_entity_id": "T844",
              "tail_entity_id": "T846"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R422",
              "head_entity_id": "T844",
              "tail_entity_id": "T876"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R423",
              "head_entity_id": "T847",
              "tail_entity_id": "T846"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R424",
              "head_entity_id": "T850",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R425",
              "head_entity_id": "T851",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R426",
              "head_entity_id": "T852",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R427",
              "head_entity_id": "T855",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R428",
              "head_entity_id": "T858",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R429",
              "head_entity_id": "T853",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R430",
              "head_entity_id": "T856",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R431",
              "head_entity_id": "T849",
              "tail_entity_id": "T848"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R432",
              "head_entity_id": "T862",
              "tail_entity_id": "T861"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R433",
              "head_entity_id": "T864",
              "tail_entity_id": "T863"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R434",
              "head_entity_id": "T866",
              "tail_entity_id": "T865"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R435",
              "head_entity_id": "T869",
              "tail_entity_id": "T868"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R436",
              "head_entity_id": "T870",
              "tail_entity_id": "T868"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R437",
              "head_entity_id": "T872",
              "tail_entity_id": "T871"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R440",
              "head_entity_id": "T877",
              "tail_entity_id": "T876"
            }
          ],
          "sentence_en": "Increased blood pressure is not only an important factor that accelerates the progression of diabetic nephropathy, but also a major risk factor that determines the prognosis of cardiovascular disease in patients. In patients with type 2 diabetic nephropathy, the impact of blood pressure on renal function is more prominent. For patients with systolic blood pressure exceeding 140 mmHg (1 mmHg = 0.133 kPa), the rate of renal function decline is 13.5% per year, while for those with systolic blood pressure <140 mmHg, the rate of renal function decline is 1% per year. The UKPDS study showed that the use of intensive blood pressure control in diabetic patients in the early stages of diabetes can not only significantly reduce the risk of diabetic macrovascular disease, but also significantly reduce the risk of microvascular disease. A large number of clinical observations have also confirmed that strict control of hypertension can significantly reduce the level of urine protein in patients with diabetic nephropathy and delay the progression of renal damage."
        },
        {
          "sentence_id": "1",
          "sentence": "强化血压控制还可使心血管病终点事件的风险下降20%~30%。",
          "start_idx": 264,
          "end_idx": 294,
          "entities": [
            {
              "entity_id": "T873",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T874",
              "entity": "心血管病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T875",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R438",
              "head_entity_id": "T873",
              "tail_entity_id": "T874"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R439",
              "head_entity_id": "T875",
              "tail_entity_id": "T874"
            }
          ],
          "sentence_en": "Strengthening blood pressure control can also reduce the risk of cardiovascular disease endpoint events by 20% to 30%."
        }
      ],
      "paragraph_en": "Increased blood pressure is not only an important factor that accelerates the progression of diabetic nephropathy, but also a major risk factor that determines the prognosis of cardiovascular disease in patients. In patients with type 2 diabetic nephropathy, the impact of blood pressure on renal function is more prominent. For patients with systolic blood pressure exceeding 140 mmHg (1 mmHg = 0.133 kPa), the rate of renal function decline is 13.5% per year, while for those with systolic blood pressure <140 mmHg, the rate of renal function decline is 1% per year. The UKPDS study showed that the use of intensive blood pressure control in diabetic patients in the early stages of diabetes can not only significantly reduce the risk of diabetic macrovascular disease, but also significantly reduce the risk of microvascular disease. A large number of clinical observations have also confirmed that strict control of hypertension can significantly reduce the level of urine protein in patients with diabetic nephropathy and delay the progression of renal damage. Intensive blood pressure control can also reduce the risk of cardiovascular endpoint events by 20% to 30%."
    },
    {
      "paragraph_id": "43",
      "paragraph": "1.血压控制目标：糖尿病患者的血压控制目标为140/90mmHg，对年轻患者或合并肾病者的血压控制目标为130/80mmHg。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.血压控制目标：糖尿病患者的血压控制目标为140/90mmHg，对年轻患者或合并肾病者的血压控制目标为130/80mmHg。",
          "start_idx": 0,
          "end_idx": 63,
          "entities": [
            {
              "entity_id": "T878",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T879",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T880",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T881",
              "entity": "140/90mmHg",
              "entity_type": "Test_Value",
              "start_idx": 22,
              "end_idx": 32,
              "entity_en": "140/90 mmHg"
            },
            {
              "entity_id": "T882",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T883",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 41,
              "end_idx": 42,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T884",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T885",
              "entity": "130/80mmHg",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 62,
              "entity_en": "130/80 mmHg"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R441",
              "head_entity_id": "T878",
              "tail_entity_id": "T879"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R442",
              "head_entity_id": "T880",
              "tail_entity_id": "T879"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R443",
              "head_entity_id": "T883",
              "tail_entity_id": "T882"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R444",
              "head_entity_id": "T884",
              "tail_entity_id": "T882"
            }
          ],
          "sentence_en": "1. Blood pressure control target: The blood pressure control target for diabetic patients is 140/90 mmHg, and the blood pressure control target for young patients or those with concomitant kidney disease is 130/80 mmHg."
        }
      ],
      "paragraph_en": "1. Blood pressure control target: The blood pressure control target for diabetic patients is 140/90 mmHg, and the blood pressure control target for young patients or those with concomitant kidney disease is 130/80 mmHg."
    },
    {
      "paragraph_id": "44",
      "paragraph": "2.降压药物的选择：ACEI或ARB在糖尿病肾病中有控制血压、减少蛋白尿、延缓肾功能进展的作用，是目前治疗糖尿病肾病的药物中临床证据最多的，被推荐作为治疗糖尿病肾病的一线药物。糖尿病肾病或糖尿病合并高血压的患者首选使用其中一种，不能耐受时以另一种替代，使用期间应监测血清肌酐及血钾水平。ACEI或ARB降压效果不理想时，可联合使用钙通道阻滞剂(CCB)、噻嗪类或袢利尿剂、β受体阻滞剂等降压药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.降压药物的选择：ACEI或ARB在糖尿病肾病中有控制血压、减少蛋白尿、延缓肾功能进展的作用，是目前治疗糖尿病肾病的药物中临床证据最多的，被推荐作为治疗糖尿病肾病的一线药物。糖尿病肾病或糖尿病合并高血压的患者首选使用其中一种，不能耐受时以另一种替代，使用期间应监测血清肌酐及血钾水平。",
          "start_idx": 0,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T886",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T887",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T888",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T889",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 22,
              "end_idx": 23,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T890",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T891",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T892",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T893",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 56,
              "end_idx": 57,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T894",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 77,
              "end_idx": 82,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T895",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 80,
              "end_idx": 81,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T896",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 93,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T897",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 91,
              "end_idx": 92,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T898",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 94,
              "end_idx": 97,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T899",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 102,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T900",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 133,
              "end_idx": 137,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T901",
              "entity": "血钾水平",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 142,
              "entity_en": "Potassium level"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R445",
              "head_entity_id": "T886",
              "tail_entity_id": "T888"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R446",
              "head_entity_id": "T887",
              "tail_entity_id": "T888"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R447",
              "head_entity_id": "T889",
              "tail_entity_id": "T888"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R448",
              "head_entity_id": "T890",
              "tail_entity_id": "T888"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R449",
              "head_entity_id": "T893",
              "tail_entity_id": "T892"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R450",
              "head_entity_id": "T895",
              "tail_entity_id": "T894"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R451",
              "head_entity_id": "T900",
              "tail_entity_id": "T896"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R452",
              "head_entity_id": "T901",
              "tail_entity_id": "T896"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R453",
              "head_entity_id": "T897",
              "tail_entity_id": "T896"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R454",
              "head_entity_id": "T900",
              "tail_entity_id": "T898"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R455",
              "head_entity_id": "T901",
              "tail_entity_id": "T898"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R456",
              "head_entity_id": "T900",
              "tail_entity_id": "T899"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R457",
              "head_entity_id": "T901",
              "tail_entity_id": "T899"
            }
          ],
          "sentence_en": "2. Choice of antihypertensive drugs: ACEI or ARB can control blood pressure, reduce proteinuria, and slow the progression of renal function in diabetic nephropathy. They are the drugs with the most clinical evidence for treating diabetic nephropathy and are recommended as first-line drugs for treating diabetic nephropathy. Patients with diabetic nephropathy or diabetes combined with hypertension should first use one of them. If they cannot tolerate it, they can be replaced with another one. Serum creatinine and blood potassium levels should be monitored during use."
        },
        {
          "sentence_id": "1",
          "sentence": "ACEI或ARB降压效果不理想时，可联合使用钙通道阻滞剂(CCB)、噻嗪类或袢利尿剂、β受体阻滞剂等降压药物。",
          "start_idx": 143,
          "end_idx": 198,
          "entities": [
            {
              "entity_id": "T902",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T903",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T904",
              "entity": "钙通道阻滞剂(CCB)",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 33,
              "entity_en": "Calcium channel blockers (CCBs)"
            },
            {
              "entity_id": "T905",
              "entity": "噻嗪类",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "Thiazides"
            },
            {
              "entity_id": "T906",
              "entity": "袢利尿剂",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Loop diuretics"
            },
            {
              "entity_id": "T907",
              "entity": "β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 49,
              "entity_en": "Beta-blockers"
            }
          ],
          "relations": [],
          "sentence_en": "When the antihypertensive effect of ACEI or ARB is not ideal, antihypertensive drugs such as calcium channel blockers (CCB), thiazide or loop diuretics, and beta-blockers can be used in combination."
        }
      ],
      "paragraph_en": "2. Choice of antihypertensive drugs: ACEI or ARB can control blood pressure, reduce proteinuria, and slow the progression of renal function in diabetic nephropathy. They are the drugs with the most clinical evidence for the treatment of diabetic nephropathy and are recommended as first-line drugs for the treatment of diabetic nephropathy. Patients with diabetic nephropathy or diabetes combined with hypertension should first use one of them. If they cannot tolerate it, they can be replaced with another one. Serum creatinine and blood potassium levels should be monitored during use. When the antihypertensive effect of ACEI or ARB is not ideal, antihypertensive drugs such as calcium channel blockers (CCB), thiazide or loop diuretics, and beta-blockers can be used in combination."
    },
    {
      "paragraph_id": "45",
      "paragraph": "ACEI及ARB应用于糖尿病肾病的一级预防治疗存在争议。一项临床试验研究将伴有高血压的2型DM患者分为群多普利组、维拉帕米组、群多普利联合维拉帕米组及安慰剂组，发现群多普利组及群多普利+维拉帕米组两组患者微量白蛋白尿的出现明显延迟，提示ARB对2型糖尿病患者微量白蛋白尿的发生可能具有一级预防作用。糖尿病视网膜坎地沙坦临床试验-肾脏研究(DIRECT-Renal)和肾素-血管紧张素系统研究(RASS)的结果却表明ACEI或ARB改善微量白蛋白尿、保护肾脏的作用并不明显。因此，本共识暂不推荐应用该类药物作为糖尿病肾病的一级预防。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "ACEI及ARB应用于糖尿病肾病的一级预防治疗存在争议。一项临床试验研究将伴有高血压的2型DM患者分为群多普利组、维拉帕米组、群多普利联合维拉帕米组及安慰剂组，发现群多普利组及群多普利+维拉帕米组两组患者微量白蛋白尿的出现明显延迟，提示ARB对2型糖尿病患者微量白蛋白尿的发生可能具有一级预防作用。糖尿病视网膜坎地沙坦临床试验-肾脏研究(DIRECT-Renal)和肾素-血管紧张素系统研究(RASS)的结果却表明ACEI或ARB改善微量白蛋白尿、保护肾脏的作用并不明显。",
          "start_idx": 0,
          "end_idx": 236,
          "entities": [
            {
              "entity_id": "T908",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T909",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T910",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T911",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 42,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T912",
              "entity": "2型DM",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Type 2 DM"
            },
            {
              "entity_id": "T913",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T914",
              "entity": "群多普利",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 67,
              "entity_en": "Trandolapril"
            },
            {
              "entity_id": "T915",
              "entity": "维拉帕米",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "Verapamil"
            },
            {
              "entity_id": "T916",
              "entity": "群多普利",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Trandolapril"
            },
            {
              "entity_id": "T917",
              "entity": "维拉帕米",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Verapamil"
            },
            {
              "entity_id": "T918",
              "entity": "群多普利",
              "entity_type": "Drug",
              "start_idx": 82,
              "end_idx": 86,
              "entity_en": "Trandolapril"
            },
            {
              "entity_id": "T919",
              "entity": "群多普利",
              "entity_type": "Drug",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "Trandolapril"
            },
            {
              "entity_id": "T920",
              "entity": "维拉帕米",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 97,
              "entity_en": "Verapamil"
            },
            {
              "entity_id": "T921",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T922",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T923",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 122,
              "end_idx": 127,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T924",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 122,
              "end_idx": 124,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T925",
              "entity": "白蛋白尿",
              "entity_type": "Symptom",
              "start_idx": 131,
              "end_idx": 135,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T926",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 149,
              "end_idx": 152,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T927",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 152,
              "end_idx": 155,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T928",
              "entity": "坎地沙坦",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Candesartan"
            },
            {
              "entity_id": "T929",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 211,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T930",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 212,
              "end_idx": 215,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T931",
              "entity": "微量",
              "entity_type": "Level",
              "start_idx": 217,
              "end_idx": 219,
              "entity_en": "Trace"
            },
            {
              "entity_id": "T932",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 223,
              "entity_en": "Albuminuria"
            },
            {
              "entity_id": "T935",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 15,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R458",
              "head_entity_id": "T908",
              "tail_entity_id": "T910"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R459",
              "head_entity_id": "T909",
              "tail_entity_id": "T910"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R460",
              "head_entity_id": "T935",
              "tail_entity_id": "T910"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R461",
              "head_entity_id": "T916",
              "tail_entity_id": "T911"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R462",
              "head_entity_id": "T917",
              "tail_entity_id": "T911"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R463",
              "head_entity_id": "T914",
              "tail_entity_id": "T911"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R464",
              "head_entity_id": "T915",
              "tail_entity_id": "T911"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R465",
              "head_entity_id": "T916",
              "tail_entity_id": "T912"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R466",
              "head_entity_id": "T917",
              "tail_entity_id": "T912"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R467",
              "head_entity_id": "T914",
              "tail_entity_id": "T912"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R468",
              "head_entity_id": "T915",
              "tail_entity_id": "T912"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R469",
              "head_entity_id": "T913",
              "tail_entity_id": "T912"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R470",
              "head_entity_id": "T922",
              "tail_entity_id": "T923"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R471",
              "head_entity_id": "T924",
              "tail_entity_id": "T923"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R472",
              "head_entity_id": "T927",
              "tail_entity_id": "T926"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R473",
              "head_entity_id": "T928",
              "tail_entity_id": "T926"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R474",
              "head_entity_id": "T929",
              "tail_entity_id": "T932"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R475",
              "head_entity_id": "T930",
              "tail_entity_id": "T932"
            }
          ],
          "sentence_en": "There is controversy over the use of ACEI and ARB in the primary prevention of diabetic nephropathy. A clinical trial divided patients with type 2 DM accompanied by hypertension into trandolapril group, verapamil group, trandolapril combined with verapamil group and placebo group, and found that the onset of microalbuminuria in the trandolapril group and the trandolapril + verapamil group was significantly delayed, suggesting that ARB may have a primary preventive effect on the occurrence of microalbuminuria in patients with type 2 diabetes. However, the results of the Diabetic Retinal Candesartan Clinical Trial-Renal Study (DIRECT-Renal) and the Renin-Angiotensin System Study (RASS) showed that the effects of ACEI or ARB in improving microalbuminuria and protecting the kidneys were not obvious."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，本共识暂不推荐应用该类药物作为糖尿病肾病的一级预防。",
          "start_idx": 236,
          "end_idx": 265,
          "entities": [
            {
              "entity_id": "T933",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T934",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 21,
              "end_idx": 22,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R476",
              "head_entity_id": "T934",
              "tail_entity_id": "T933"
            }
          ],
          "sentence_en": "Therefore, this consensus does not recommend the use of this type of drug as the primary prevention of diabetic nephropathy."
        }
      ],
      "paragraph_en": "There is controversy over the use of ACEI and ARB for the primary prevention of diabetic nephropathy. A clinical trial divided patients with type 2 DM accompanied by hypertension into the trandolapril group, the verapamil group, the trandolapril combined with verapamil group, and the placebo group. It was found that the onset of microalbuminuria in the trandolapril group and the trandolapril + verapamil group was significantly delayed, suggesting that ARB may have a primary preventive effect on the occurrence of microalbuminuria in patients with type 2 diabetes. However, the results of the Diabetic Retinal Candesartan Clinical Trial-Renal Study (DIRECT-Renal) and the Renin-Angiotensin System Study (RASS) showed that the effects of ACEI or ARB in improving microalbuminuria and protecting the kidneys were not obvious. Therefore, this consensus does not recommend the use of such drugs as the primary prevention of diabetic nephropathy."
    },
    {
      "paragraph_id": "46",
      "paragraph": "(1)ACEI：ACEI主要药理作用是抑制血浆及组织中的血管紧张素转换酶，减少血管紧张素II的生成，减少血管收缩和醛固酮的分泌。在用药过程中需要注意观察患者肾功能及血钾的变化，对伴有肾动脉狭窄的患者要慎用或禁用。有报道显示该药物在妊娠早期可能对胎儿有害(新生儿急性肾损伤、肺毒性作用、先天心血管系统畸形、中枢神经系统畸形、肾脏畸形、头颅发育不全等)。培哚普利在糖尿病及肾功能减退患者中无不良代谢作用，但在透析中可被清除，中重度肾功能损害患者应根据肾小球滤过率变化调整剂量，起始剂量2mg/d，最大剂量不超过8mg/d，在透析患者中培哚普利清除率同肾功能正常患者。卡托普利在肾功能严重减退患者中应谨慎使用。贝那普利的药代动力学和生物利用度在轻中度肾功能不全中不受影响，重度肾功能不全患者需减量，透析对贝那普利的浓度无影响，透析后无需补充药物。雷米普利在中度肾功能不全患者中需减量，且不能应用于聚丙烯腈或甲基烯丙基硫化钠高通量滤膜或血液透析。福辛普利在肾功能不全患者中应减量或停药，它在透析中不可清除，但在高流量透析膜进行血液透析时较易引起类过敏反应。赖诺普利在严重的肾功能不全患者中半衰期可达40h以上，可在体内发生蓄积，蓄积的原药可在透析中去除。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)ACEI：ACEI主要药理作用是抑制血浆及组织中的血管紧张素转换酶，减少血管紧张素II的生成，减少血管收缩和醛固酮的分泌。在用药过程中需要注意观察患者肾功能及血钾的变化，对伴有肾动脉狭窄的患者要慎用或禁用。有报道显示该药物在妊娠早期可能对胎儿有害(新生儿急性肾损伤、肺毒性作用、先天心血管系统畸形、中枢神经系统畸形、肾脏畸形、头颅发育不全等)。培哚普利在糖尿病及肾功能减退患者中无不良代谢作用，但在透析中可被清除，中重度肾功能损害患者应根据肾小球滤过率变化调整剂量，起始剂量2mg/d，最大剂量不超过8mg/d，在透析患者中培哚普利清除率同肾功能正常患者。卡托普利在肾功能严重减退患者中应谨慎使用。",
          "start_idx": 0,
          "end_idx": 302,
          "entities": [
            {
              "entity_id": "T936",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T937",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T938",
              "entity": "血管紧张素II",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 46,
              "entity_en": "Angiotensin II"
            },
            {
              "entity_id": "T939",
              "entity": "醛固酮",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "Aldosterone"
            },
            {
              "entity_id": "T940",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 78,
              "end_idx": 81,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T941",
              "entity": "血钾",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 84,
              "entity_en": "Serum potassium"
            },
            {
              "entity_id": "T942",
              "entity": "肾动脉狭窄",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 96,
              "entity_en": "Renal artery stenosis"
            },
            {
              "entity_id": "T943",
              "entity": "肾动脉",
              "entity_type": "Anatomy",
              "start_idx": 91,
              "end_idx": 94,
              "entity_en": "Renal artery"
            },
            {
              "entity_id": "T944",
              "entity": "新生儿急性肾损伤",
              "entity_type": "ADE",
              "start_idx": 127,
              "end_idx": 135,
              "entity_en": "Acute kidney injury in newborns"
            },
            {
              "entity_id": "T945",
              "entity": "肺毒性作用",
              "entity_type": "ADE",
              "start_idx": 136,
              "end_idx": 141,
              "entity_en": "Pulmonary toxicity"
            },
            {
              "entity_id": "T946",
              "entity": "先天心血管系统畸形",
              "entity_type": "ADE",
              "start_idx": 142,
              "end_idx": 151,
              "entity_en": "Congenital malformations of the cardiovascular system"
            },
            {
              "entity_id": "T947",
              "entity": "中枢神经系统畸形",
              "entity_type": "ADE",
              "start_idx": 152,
              "end_idx": 160,
              "entity_en": "Central nervous system malformations"
            },
            {
              "entity_id": "T948",
              "entity": "肾脏畸形",
              "entity_type": "ADE",
              "start_idx": 161,
              "end_idx": 165,
              "entity_en": "Kidney malformations"
            },
            {
              "entity_id": "T949",
              "entity": "头颅发育不全",
              "entity_type": "ADE",
              "start_idx": 166,
              "end_idx": 172,
              "entity_en": "Hypoplasia of the head"
            },
            {
              "entity_id": "T950",
              "entity": "培哚普利",
              "entity_type": "Drug",
              "start_idx": 175,
              "end_idx": 179,
              "entity_en": "Perindopril"
            },
            {
              "entity_id": "T951",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 180,
              "end_idx": 183,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T952",
              "entity": "肾功能减退",
              "entity_type": "Disease",
              "start_idx": 184,
              "end_idx": 189,
              "entity_en": "Decreased kidney function"
            },
            {
              "entity_id": "T953",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 185,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T954",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 202,
              "end_idx": 204,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T955",
              "entity": "中重度",
              "entity_type": "Level",
              "start_idx": 210,
              "end_idx": 213,
              "entity_en": "Moderate to severe"
            },
            {
              "entity_id": "T956",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 213,
              "end_idx": 218,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T957",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 213,
              "end_idx": 214,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T958",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 223,
              "end_idx": 229,
              "entity_en": "Glomerular filtration rate"
            },
            {
              "entity_id": "T959",
              "entity": "2mg/d",
              "entity_type": "Amount",
              "start_idx": 240,
              "end_idx": 245,
              "entity_en": "2 mg/day"
            },
            {
              "entity_id": "T960",
              "entity": "8mg/d",
              "entity_type": "Amount",
              "start_idx": 253,
              "end_idx": 258,
              "entity_en": "8 mg/day"
            },
            {
              "entity_id": "T961",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 260,
              "end_idx": 262,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T962",
              "entity": "培哚普利",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "Perindopril"
            },
            {
              "entity_id": "T963",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 273,
              "end_idx": 276,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T964",
              "entity": "正常",
              "entity_type": "Test_Value",
              "start_idx": 276,
              "end_idx": 278,
              "entity_en": "normal"
            },
            {
              "entity_id": "T965",
              "entity": "卡托普利",
              "entity_type": "Drug",
              "start_idx": 281,
              "end_idx": 285,
              "entity_en": "Captopril"
            },
            {
              "entity_id": "T966",
              "entity": "肾功能严重减退",
              "entity_type": "Disease",
              "start_idx": 286,
              "end_idx": 293,
              "entity_en": "Severe renal impairment"
            },
            {
              "entity_id": "T967",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 286,
              "end_idx": 287,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R477",
              "head_entity_id": "T943",
              "tail_entity_id": "T942"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R478",
              "head_entity_id": "T950",
              "tail_entity_id": "T951"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R479",
              "head_entity_id": "T950",
              "tail_entity_id": "T952"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R480",
              "head_entity_id": "T953",
              "tail_entity_id": "T952"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R481",
              "head_entity_id": "T958",
              "tail_entity_id": "T956"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R482",
              "head_entity_id": "T957",
              "tail_entity_id": "T956"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R483",
              "head_entity_id": "T965",
              "tail_entity_id": "T966"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R484",
              "head_entity_id": "T967",
              "tail_entity_id": "T966"
            }
          ],
          "sentence_en": "(1) ACEI: The main pharmacological action of ACEI is to inhibit angiotensin converting enzyme in plasma and tissues, reduce the production of angiotensin II, reduce vasoconstriction and aldosterone secretion. During medication, it is necessary to observe the changes in the patient's renal function and blood potassium. It should be used with caution or prohibited for patients with renal artery stenosis. There are reports that this drug may be harmful to the fetus in early pregnancy (neonatal acute kidney injury, pulmonary toxicity, congenital cardiovascular system malformations, central nervous system malformations, kidney malformations, and cranial hypoplasia). Perindopril has no adverse metabolic effects in patients with diabetes and renal impairment, but it can be cleared during dialysis. Patients with moderate to severe renal impairment should adjust the dose according to changes in glomerular filtration rate. The initial dose is 2 mg/d and the maximum dose does not exceed 8 mg/d. The clearance rate of perindopril in dialysis patients is the same as that in patients with normal renal function. Captopril should be used with caution in patients with severe renal impairment."
        },
        {
          "sentence_id": "1",
          "sentence": "贝那普利的药代动力学和生物利用度在轻中度肾功能不全中不受影响，重度肾功能不全患者需减量，透析对贝那普利的浓度无影响，透析后无需补充药物。",
          "start_idx": 302,
          "end_idx": 370,
          "entities": [
            {
              "entity_id": "T968",
              "entity": "贝那普利",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Benazepril"
            },
            {
              "entity_id": "T969",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T970",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T971",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 21,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T972",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T973",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T974",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 34,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T975",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 44,
              "end_idx": 46,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T976",
              "entity": "贝那普利",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Benazepril"
            },
            {
              "entity_id": "T977",
              "entity": "透析",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "Dialysis"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R485",
              "head_entity_id": "T968",
              "tail_entity_id": "T970"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R486",
              "head_entity_id": "T971",
              "tail_entity_id": "T970"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R487",
              "head_entity_id": "T974",
              "tail_entity_id": "T973"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R488",
              "head_entity_id": "T976",
              "tail_entity_id": "T973"
            }
          ],
          "sentence_en": "The pharmacokinetics and bioavailability of benazepril are not affected in mild to moderate renal insufficiency. Patients with severe renal insufficiency need to reduce the dose. Dialysis has no effect on the concentration of benazepril, and no additional medication is required after dialysis."
        },
        {
          "sentence_id": "2",
          "sentence": "雷米普利在中度肾功能不全患者中需减量，且不能应用于聚丙烯腈或甲基烯丙基硫化钠高通量滤膜或血液透析。",
          "start_idx": 370,
          "end_idx": 419,
          "entities": [
            {
              "entity_id": "T978",
              "entity": "雷米普利",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Ramipril"
            },
            {
              "entity_id": "T979",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T980",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T981",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 8,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T982",
              "entity": "聚丙烯腈",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 29,
              "entity_en": "Polyacrylonitrile"
            },
            {
              "entity_id": "T983",
              "entity": "甲基烯丙基硫化钠",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 38,
              "entity_en": "Sodium Methyl Allyl Sulfide"
            },
            {
              "entity_id": "T984",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Hemodialysis"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R489",
              "head_entity_id": "T978",
              "tail_entity_id": "T980"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R490",
              "head_entity_id": "T981",
              "tail_entity_id": "T980"
            }
          ],
          "sentence_en": "Ramipril should be used at a reduced dose in patients with moderate renal impairment and should not be used with polyacrylonitrile or sodium methyl allyl sulfide high-flux membrane filters or in hemodialysis."
        },
        {
          "sentence_id": "3",
          "sentence": "福辛普利在肾功能不全患者中应减量或停药，它在透析中不可清除，但在高流量透析膜进行血液透析时较易引起类过敏反应。",
          "start_idx": 419,
          "end_idx": 474,
          "entities": [
            {
              "entity_id": "T985",
              "entity": "福辛普利",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Fosinopril"
            },
            {
              "entity_id": "T986",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T987",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 6,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T988",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T989",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Hemodialysis"
            },
            {
              "entity_id": "T990",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "Allergic reactions"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R491",
              "head_entity_id": "T985",
              "tail_entity_id": "T986"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R492",
              "head_entity_id": "T987",
              "tail_entity_id": "T986"
            }
          ],
          "sentence_en": "Fosinopril should be reduced or discontinued in patients with renal insufficiency. It cannot be removed during dialysis, but is more likely to cause anaphylactoid reactions during hemodialysis with high-flow dialysis membranes."
        },
        {
          "sentence_id": "4",
          "sentence": "赖诺普利在严重的肾功能不全患者中半衰期可达40h以上，可在体内发生蓄积，蓄积的原药可在透析中去除。",
          "start_idx": 474,
          "end_idx": 523,
          "entities": [
            {
              "entity_id": "T991",
              "entity": "赖诺普利",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Lisinopril"
            },
            {
              "entity_id": "T992",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "serious"
            },
            {
              "entity_id": "T993",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T994",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 8,
              "end_idx": 9,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R493",
              "head_entity_id": "T991",
              "tail_entity_id": "T993"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R494",
              "head_entity_id": "T994",
              "tail_entity_id": "T993"
            }
          ],
          "sentence_en": "The half-life of lisinopril can reach more than 40 hours in patients with severe renal insufficiency, and it can accumulate in the body. The accumulated original drug can be removed during dialysis."
        }
      ],
      "paragraph_en": "(1) ACEI: The main pharmacological action of ACEI is to inhibit angiotensin converting enzyme in plasma and tissues, reduce the production of angiotensin II, reduce vasoconstriction and aldosterone secretion. During medication, it is necessary to observe the changes in the patient's renal function and blood potassium. It should be used with caution or prohibited for patients with renal artery stenosis. There are reports that this drug may be harmful to the fetus in early pregnancy (neonatal acute kidney injury, pulmonary toxicity, congenital cardiovascular system malformations, central nervous system malformations, kidney malformations, and cranial hypoplasia). Perindopril has no adverse metabolic effects in patients with diabetes and renal impairment, but it can be cleared during dialysis. Patients with moderate to severe renal impairment should adjust the dose according to changes in glomerular filtration rate. The initial dose is 2 mg/d and the maximum dose does not exceed 8 mg/d. The clearance rate of perindopril in dialysis patients is the same as that in patients with normal renal function. Captopril should be used with caution in patients with severe renal impairment. The pharmacokinetics and bioavailability of benazepril are not affected in mild to moderate renal insufficiency. Patients with severe renal insufficiency need to reduce the dose. Dialysis has no effect on the concentration of benazepril, and no additional medication is required after dialysis. Ramipril needs to be reduced in patients with moderate renal insufficiency, and cannot be used in polyacrylonitrile or sodium methyl allyl sulfide high-flux membranes or hemodialysis. Fosinopril should be reduced or discontinued in patients with renal insufficiency. It cannot be removed during dialysis, but it is more likely to cause allergic reactions during hemodialysis with high-flux dialysis membranes. The half-life of lisinopril can reach more than 40 hours in patients with severe renal insufficiency, and it can accumulate in the body. The accumulated original drug can be removed during dialysis."
    },
    {
      "paragraph_id": "47",
      "paragraph": "(2)ARB：ARB通过双重方式降低血压：其一是阻断血管紧张素Ⅱ(AngⅡ)与血管紧张素II 1型受体(AT1R)结合，从而直接或间接抑制血管收缩，减少血管加压素和醛固酮释放，减少肾脏水钠重吸收；其二是促使AngⅡ与AT2R结合，使血管舒张，抑制细胞分化生长，抑制钠水重吸收和交感神经活性。氯沙坦在肾功能不全患者中无需调整剂量，缬沙坦在肾功能减退的大部分患者中都无需调整用药，但在严重肾功能不全患者中用药经验不足，应谨慎用药。替米沙坦及坎地沙坦在轻中度。肾功能不全患者中无需调整用量，重度肾功能不全患者禁用。厄贝沙坦在肾功能不全及血液透析的患者中可能需要调整剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)ARB：ARB通过双重方式降低血压：其一是阻断血管紧张素Ⅱ(AngⅡ)与血管紧张素II 1型受体(AT1R)结合，从而直接或间接抑制血管收缩，减少血管加压素和醛固酮释放，减少肾脏水钠重吸收；其二是促使AngⅡ与AT2R结合，使血管舒张，抑制细胞分化生长，抑制钠水重吸收和交感神经活性。氯沙坦在肾功能不全患者中无需调整剂量，缬沙坦在肾功能减退的大部分患者中都无需调整用药，但在严重肾功能不全患者中用药经验不足，应谨慎用药。替米沙坦及坎地沙坦在轻中度。肾功能不全患者中无需调整用量，重度肾功能不全患者禁用。厄贝沙坦在肾功能不全及血液透析的患者中可能需要调整剂量。",
          "start_idx": 0,
          "end_idx": 282,
          "entities": [
            {
              "entity_id": "T995",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T996",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T997",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T998",
              "entity": "血管紧张素Ⅱ(AngⅡ)",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 38,
              "entity_en": "Angiotensin II (Ang II)"
            },
            {
              "entity_id": "T999",
              "entity": "醛固酮",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 85,
              "entity_en": "Aldosterone"
            },
            {
              "entity_id": "T1000",
              "entity": "氯沙坦",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 148,
              "entity_en": "Losartan"
            },
            {
              "entity_id": "T1001",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 149,
              "end_idx": 154,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1002",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 149,
              "end_idx": 150,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1003",
              "entity": "缬沙坦",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 167,
              "entity_en": "Valsartan"
            },
            {
              "entity_id": "T1004",
              "entity": "肾功能减退",
              "entity_type": "Disease",
              "start_idx": 168,
              "end_idx": 173,
              "entity_en": "Decreased kidney function"
            },
            {
              "entity_id": "T1005",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 168,
              "end_idx": 169,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1006",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 190,
              "end_idx": 192,
              "entity_en": "serious"
            },
            {
              "entity_id": "T1007",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 192,
              "end_idx": 197,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1008",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 192,
              "end_idx": 193,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1009",
              "entity": "替米沙坦",
              "entity_type": "Drug",
              "start_idx": 213,
              "end_idx": 217,
              "entity_en": "Telmisartan"
            },
            {
              "entity_id": "T1010",
              "entity": "坎地沙坦",
              "entity_type": "Drug",
              "start_idx": 218,
              "end_idx": 222,
              "entity_en": "Candesartan"
            },
            {
              "entity_id": "T1011",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 223,
              "end_idx": 226,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T1012",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 227,
              "end_idx": 232,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1013",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 227,
              "end_idx": 228,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1014",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 242,
              "end_idx": 244,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T1015",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 244,
              "end_idx": 249,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1016",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 244,
              "end_idx": 245,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1017",
              "entity": "厄贝沙坦",
              "entity_type": "Drug",
              "start_idx": 254,
              "end_idx": 258,
              "entity_en": "Irbesartan"
            },
            {
              "entity_id": "T1018",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 259,
              "end_idx": 264,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1019",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 259,
              "end_idx": 260,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1020",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "Hemodialysis"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R495",
              "head_entity_id": "T1000",
              "tail_entity_id": "T1001"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R496",
              "head_entity_id": "T1002",
              "tail_entity_id": "T1001"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R497",
              "head_entity_id": "T1003",
              "tail_entity_id": "T1004"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R498",
              "head_entity_id": "T1005",
              "tail_entity_id": "T1004"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R499",
              "head_entity_id": "T1008",
              "tail_entity_id": "T1007"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R500",
              "head_entity_id": "T1013",
              "tail_entity_id": "T1012"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R501",
              "head_entity_id": "T1016",
              "tail_entity_id": "T1015"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R502",
              "head_entity_id": "T1017",
              "tail_entity_id": "T1018"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R503",
              "head_entity_id": "T1019",
              "tail_entity_id": "T1018"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R504",
              "head_entity_id": "T1020",
              "tail_entity_id": "T1018"
            }
          ],
          "sentence_en": "(2) ARB: ARB lowers blood pressure in two ways: first, it blocks the binding of angiotensin II (Ang II) to angiotensin II type 1 receptor (AT1R), thereby directly or indirectly inhibiting vasoconstriction, reducing the release of vasopressin and aldosterone, and reducing renal sodium and water reabsorption; second, it promotes the binding of Ang II to AT2R, causing vasodilation, inhibiting cell differentiation and growth, and inhibiting sodium and water reabsorption and sympathetic nerve activity. Losartan does not require dose adjustment in patients with renal insufficiency, and valsartan does not require medication adjustment in most patients with renal impairment, but there is insufficient experience in using it in patients with severe renal insufficiency, so it should be used with caution. Telmisartan and candesartan do not require dose adjustment in patients with mild to moderate renal insufficiency, but are contraindicated in patients with severe renal insufficiency. Irbesartan may require dose adjustment in patients with renal insufficiency and hemodialysis."
        }
      ],
      "paragraph_en": "(2) ARB: ARB lowers blood pressure in two ways: first, it blocks the binding of angiotensin II (Ang II) to angiotensin II type 1 receptor (AT1R), thereby directly or indirectly inhibiting vasoconstriction, reducing the release of vasopressin and aldosterone, and reducing renal sodium and water reabsorption; second, it promotes the binding of Ang II to AT2R, causing vasodilation, inhibiting cell differentiation and growth, and inhibiting sodium and water reabsorption and sympathetic nerve activity. Losartan does not require dose adjustment in patients with renal insufficiency, and valsartan does not require medication adjustment in most patients with renal impairment, but there is insufficient experience in using it in patients with severe renal insufficiency, so it should be used with caution. Telmisartan and candesartan do not require dose adjustment in patients with mild to moderate renal insufficiency, but are contraindicated in patients with severe renal insufficiency. Irbesartan may require dose adjustment in patients with renal insufficiency and hemodialysis."
    },
    {
      "paragraph_id": "48",
      "paragraph": "(3)CCB：非二氢吡啶类钙拮抗剂地尔硫?和维拉帕米能够减少蛋白尿；二氢吡啶类钙拮抗剂能维持和增加肾血流量，改善Ccr和GFR；可以抑制内皮素对肾脏的影响以及预防肾脏肥大。国际拜新同抗高血压干预研究(INSIGHT)证明，与利尿剂相比，硝苯地平胃肠控释系统能显著提高肾小球滤过率，保护肾功能。一般认为，CCB延缓高血压患者的肾功能进展的机制，主要是通过降低血压减轻了体循环对肾小球内压力的传导，从而改善肾小球内高滤过、高灌注状态。在肾功能受损时，长效钙通道阻滞剂无需减低剂量，尤其适用于合并冠心病、肾动脉狭窄、重度肾功能不全、存在ACEI或ARB使用禁忌的患者。CCB是治疗CKD合并高血压最常用的选择之一，但若尿蛋白持续增多，需加用ACEI或ARB药物才能达到保护肾功能的作用。有临床研究表明，二氢吡啶类CCB氨氯地平联合贝那普利在降低糖尿病患者心血管事件及延缓肾病进展方面优于贝那普利与噻嗪类利尿剂组合，非二氢吡啶CCB类药物在降低糖尿病肾病患者尿蛋白水平，延缓肾病进程方面明显优于ACEI及β受体阻滞剂，且不受血压控制的影响。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)CCB：非二氢吡啶类钙拮抗剂地尔硫?和维拉帕米能够减少蛋白尿；二氢吡啶类钙拮抗剂能维持和增加肾血流量，改善Ccr和GFR；可以抑制内皮素对肾脏的影响以及预防肾脏肥大。国际拜新同抗高血压干预研究(INSIGHT)证明，与利尿剂相比，硝苯地平胃肠控释系统能显著提高肾小球滤过率，保护肾功能。一般认为，CCB延缓高血压患者的肾功能进展的机制，主要是通过降低血压减轻了体循环对肾小球内压力的传导，从而改善肾小球内高滤过、高灌注状态。在肾功能受损时，长效钙通道阻滞剂无需减低剂量，尤其适用于合并冠心病、肾动脉狭窄、重度肾功能不全、存在ACEI或ARB使用禁忌的患者。CCB是治疗CKD合并高血压最常用的选择之一，但若尿蛋白持续增多，需加用ACEI或ARB药物才能达到保护肾功能的作用。有临床研究表明，二氢吡啶类CCB氨氯地平联合贝那普利在降低糖尿病患者心血管事件及延缓肾病进展方面优于贝那普利与噻嗪类利尿剂组合，非二氢吡啶CCB类药物在降低糖尿病肾病患者尿蛋白水平，延缓肾病进程方面明显优于ACEI及β受体阻滞剂，且不受血压控制的影响。",
          "start_idx": 0,
          "end_idx": 466,
          "entities": [
            {
              "entity_id": "T1021",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1022",
              "entity": "非二氢吡啶类钙拮抗剂",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 17,
              "entity_en": "Non-dihydropyridine calcium antagonists"
            },
            {
              "entity_id": "T1023",
              "entity": "地尔硫?",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Diltiazem?"
            },
            {
              "entity_id": "T1024",
              "entity": "维拉帕米",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Verapamil"
            },
            {
              "entity_id": "T1025",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T1026",
              "entity": "二氢吡啶类钙拮抗剂",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 43,
              "entity_en": "Dihydropyridine calcium antagonists"
            },
            {
              "entity_id": "T1027",
              "entity": "Ccr",
              "entity_type": "Test_items",
              "start_idx": 56,
              "end_idx": 59,
              "entity_en": "Ccr"
            },
            {
              "entity_id": "T1028",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1029",
              "entity": "肾脏肥大",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85,
              "entity_en": "Kidney hypertrophy"
            },
            {
              "entity_id": "T1030",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1031",
              "entity": "拜新同",
              "entity_type": "Drug",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "Bai Xintong"
            },
            {
              "entity_id": "T1032",
              "entity": "利尿剂",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "Diuretics"
            },
            {
              "entity_id": "T1033",
              "entity": "硝苯地平",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 122,
              "entity_en": "Nifedipine"
            },
            {
              "entity_id": "T1034",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 133,
              "end_idx": 139,
              "entity_en": "Glomerular filtration rate"
            },
            {
              "entity_id": "T1035",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 95,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T1036",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 154,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1037",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 156,
              "end_idx": 159,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T1038",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 178,
              "end_idx": 180,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T1039",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 216,
              "end_idx": 221,
              "entity_en": "Impaired renal function"
            },
            {
              "entity_id": "T1040",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 216,
              "end_idx": 217,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1041",
              "entity": "长效钙通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 231,
              "entity_en": "Long-acting calcium channel blockers"
            },
            {
              "entity_id": "T1042",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 245,
              "end_idx": 248,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T1043",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 246,
              "end_idx": 247,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T1044",
              "entity": "肾动脉狭窄",
              "entity_type": "Disease",
              "start_idx": 249,
              "end_idx": 254,
              "entity_en": "Renal artery stenosis"
            },
            {
              "entity_id": "T1045",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 255,
              "end_idx": 257,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T1046",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 257,
              "end_idx": 262,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1047",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 257,
              "end_idx": 258,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1048",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1049",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 270,
              "end_idx": 273,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1050",
              "entity": "肾动脉",
              "entity_type": "Anatomy",
              "start_idx": 249,
              "end_idx": 252,
              "entity_en": "Renal artery"
            },
            {
              "entity_id": "T1051",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 281,
              "end_idx": 284,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1052",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 287,
              "end_idx": 290,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T1053",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 292,
              "end_idx": 295,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T1054",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 306,
              "end_idx": 309,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T1055",
              "entity": "持续增多",
              "entity_type": "Test_Value",
              "start_idx": 309,
              "end_idx": 313,
              "entity_en": "Continue to increase"
            },
            {
              "entity_id": "T1056",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 317,
              "end_idx": 321,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1057",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 322,
              "end_idx": 325,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1058",
              "entity": "二氢吡啶类",
              "entity_type": "Drug",
              "start_idx": 348,
              "end_idx": 353,
              "entity_en": "Dihydropyridines"
            },
            {
              "entity_id": "T1059",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 353,
              "end_idx": 356,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1060",
              "entity": "氨氯地平",
              "entity_type": "Drug",
              "start_idx": 356,
              "end_idx": 360,
              "entity_en": "Amlodipine"
            },
            {
              "entity_id": "T1061",
              "entity": "贝那普利",
              "entity_type": "Drug",
              "start_idx": 362,
              "end_idx": 366,
              "entity_en": "Benazepril"
            },
            {
              "entity_id": "T1062",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 369,
              "end_idx": 372,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1063",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 374,
              "end_idx": 379,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T1064",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 374,
              "end_idx": 377,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T1065",
              "entity": "贝那普利",
              "entity_type": "Drug",
              "start_idx": 390,
              "end_idx": 394,
              "entity_en": "Benazepril"
            },
            {
              "entity_id": "T1066",
              "entity": "噻嗪类利尿剂",
              "entity_type": "Drug",
              "start_idx": 395,
              "end_idx": 401,
              "entity_en": "Thiazide diuretics"
            },
            {
              "entity_id": "T1067",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 418,
              "end_idx": 423,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1068",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 421,
              "end_idx": 422,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1069",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 425,
              "end_idx": 428,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T1070",
              "entity": "非二氢吡啶CCB类药物",
              "entity_type": "Drug",
              "start_idx": 404,
              "end_idx": 415,
              "entity_en": "Non-dihydropyridine CCBs"
            },
            {
              "entity_id": "T1071",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 443,
              "end_idx": 447,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1072",
              "entity": "β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 448,
              "end_idx": 454,
              "entity_en": "Beta-blockers"
            },
            {
              "entity_id": "T1073",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 458,
              "end_idx": 460,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T1074",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 433,
              "end_idx": 435,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T1075",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 433,
              "end_idx": 434,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R505",
              "head_entity_id": "T1022",
              "tail_entity_id": "T1025"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R506",
              "head_entity_id": "T1023",
              "tail_entity_id": "T1025"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R507",
              "head_entity_id": "T1024",
              "tail_entity_id": "T1025"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R508",
              "head_entity_id": "T1026",
              "tail_entity_id": "T1029"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R509",
              "head_entity_id": "T1030",
              "tail_entity_id": "T1029"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R510",
              "head_entity_id": "T1031",
              "tail_entity_id": "T1035"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R511",
              "head_entity_id": "T1032",
              "tail_entity_id": "T1035"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R512",
              "head_entity_id": "T1033",
              "tail_entity_id": "T1035"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R513",
              "head_entity_id": "T1034",
              "tail_entity_id": "T1035"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R514",
              "head_entity_id": "T1036",
              "tail_entity_id": "T1037"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R515",
              "head_entity_id": "T1038",
              "tail_entity_id": "T1037"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R516",
              "head_entity_id": "T1041",
              "tail_entity_id": "T1039"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R517",
              "head_entity_id": "T1040",
              "tail_entity_id": "T1039"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R518",
              "head_entity_id": "T1041",
              "tail_entity_id": "T1042"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R519",
              "head_entity_id": "T1041",
              "tail_entity_id": "T1044"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R520",
              "head_entity_id": "T1041",
              "tail_entity_id": "T1046"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R521",
              "head_entity_id": "T1043",
              "tail_entity_id": "T1042"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R522",
              "head_entity_id": "T1050",
              "tail_entity_id": "T1044"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R523",
              "head_entity_id": "T1047",
              "tail_entity_id": "T1046"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R524",
              "head_entity_id": "T1051",
              "tail_entity_id": "T1052"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R525",
              "head_entity_id": "T1051",
              "tail_entity_id": "T1053"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R526",
              "head_entity_id": "T1056",
              "tail_entity_id": "T1052"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R527",
              "head_entity_id": "T1057",
              "tail_entity_id": "T1052"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R528",
              "head_entity_id": "T1054",
              "tail_entity_id": "T1052"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R529",
              "head_entity_id": "T1056",
              "tail_entity_id": "T1053"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R530",
              "head_entity_id": "T1057",
              "tail_entity_id": "T1053"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R531",
              "head_entity_id": "T1054",
              "tail_entity_id": "T1053"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R532",
              "head_entity_id": "T1058",
              "tail_entity_id": "T1062"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R533",
              "head_entity_id": "T1059",
              "tail_entity_id": "T1062"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R534",
              "head_entity_id": "T1060",
              "tail_entity_id": "T1062"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R535",
              "head_entity_id": "T1061",
              "tail_entity_id": "T1062"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R536",
              "head_entity_id": "T1065",
              "tail_entity_id": "T1062"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R537",
              "head_entity_id": "T1066",
              "tail_entity_id": "T1062"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R538",
              "head_entity_id": "T1064",
              "tail_entity_id": "T1063"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R539",
              "head_entity_id": "T1070",
              "tail_entity_id": "T1067"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R540",
              "head_entity_id": "T1071",
              "tail_entity_id": "T1067"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R541",
              "head_entity_id": "T1072",
              "tail_entity_id": "T1067"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R542",
              "head_entity_id": "T1068",
              "tail_entity_id": "T1067"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R543",
              "head_entity_id": "T1069",
              "tail_entity_id": "T1067"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R544",
              "head_entity_id": "T1073",
              "tail_entity_id": "T1067"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R545",
              "head_entity_id": "T1075",
              "tail_entity_id": "T1074"
            }
          ],
          "sentence_en": "(3) CCB: Non-dihydropyridine calcium antagonists diltiazem and verapamil can reduce proteinuria; dihydropyridine calcium antagonists can maintain and increase renal blood flow, improve Ccr and GFR; inhibit the effects of endothelin on the kidney and prevent renal hypertrophy. The International Bayxintong Antihypertensive Intervention Study (INSIGHT) has shown that compared with diuretics, nifedipine gastrointestinal controlled release system can significantly increase glomerular filtration rate and protect renal function. It is generally believed that the mechanism by which CCB delays the progression of renal function in hypertensive patients is mainly to reduce the transmission of systemic circulation to glomerular pressure by lowering blood pressure, thereby improving the high filtration and high perfusion state in the glomerulus. When renal function is impaired, long-acting calcium channel blockers do not need to be reduced in dose, especially for patients with coronary heart disease, renal artery stenosis, severe renal insufficiency, and contraindications to ACEI or ARB. CCB is one of the most commonly used options for the treatment of CKD with hypertension, but if urine protein continues to increase, ACEI or ARB drugs must be added to achieve the effect of protecting renal function. Clinical studies have shown that the dihydropyridine CCB amlodipine combined with benazepril is superior to the combination of benazepril and thiazide diuretics in reducing cardiovascular events and delaying the progression of kidney disease in diabetic patients. Non-dihydropyridine CCB drugs are significantly superior to ACEI and beta-blockers in reducing urine protein levels and delaying the progression of kidney disease in patients with diabetic nephropathy, and are not affected by blood pressure control."
        }
      ],
      "paragraph_en": "(3) CCB: Non-dihydropyridine calcium antagonists diltiazem and verapamil can reduce proteinuria; dihydropyridine calcium antagonists can maintain and increase renal blood flow, improve Ccr and GFR; inhibit the effects of endothelin on the kidney and prevent renal hypertrophy. The International Bayxintong Antihypertensive Intervention Study (INSIGHT) has shown that compared with diuretics, nifedipine gastrointestinal controlled release system can significantly increase glomerular filtration rate and protect renal function. It is generally believed that the mechanism by which CCB delays the progression of renal function in hypertensive patients is mainly to reduce the transmission of systemic circulation to glomerular pressure by lowering blood pressure, thereby improving the high filtration and high perfusion state in the glomerulus. When renal function is impaired, long-acting calcium channel blockers do not need to be reduced in dose, especially for patients with coronary heart disease, renal artery stenosis, severe renal insufficiency, and contraindications to ACEI or ARB. CCB is one of the most commonly used options for the treatment of CKD with hypertension, but if urine protein continues to increase, ACEI or ARB drugs must be added to achieve the effect of protecting renal function. Clinical studies have shown that the dihydropyridine CCB amlodipine combined with benazepril is superior to the combination of benazepril and thiazide diuretics in reducing cardiovascular events and delaying the progression of kidney disease in diabetic patients. Non-dihydropyridine CCB drugs are significantly superior to ACEI and beta-blockers in reducing urine protein levels and delaying the progression of kidney disease in patients with diabetic nephropathy, and are not affected by blood pressure control."
    },
    {
      "paragraph_id": "49",
      "paragraph": "(4)利尿剂：60%~90%糖尿病肾病合并高血压的患者使用噻嗪类或袢利尿剂。GUARD临床研究表明ACEI与氢氯噻嗪联合用药在降低患者尿蛋白水平方面优于ACEI与CCB组合。对收缩期高血压患者应用联合治疗以预防心血管事件(ACCOMPLISH)临床研究的结果却表明，在糖尿病高血压高危患者中，ACEI与氢氯噻嗪联合用药对减缓患者肾小球滤过率下降的作用不及ACEI与CCB组合。虽然噻嗪类或袢利尿剂作为联合用药是否强于CCB存在争议，多数糖尿病肾病合并高血压的患者，尤其血压高于130/80mmHg者需要一种以上药物控制血压，故推荐噻嗪类或袢利尿剂作为联合用药。氢氯噻嗪促进钾钠排泄，造成低钠血症时可引起反射性肾素和醛固酮分泌，在无尿或肾功能损害患者的效果差，大剂量使用易导致药物蓄积，增加毒性，故其慎用于该类患者，应从小剂量每日25mg开始。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)利尿剂：60%~90%糖尿病肾病合并高血压的患者使用噻嗪类或袢利尿剂。GUARD临床研究表明ACEI与氢氯噻嗪联合用药在降低患者尿蛋白水平方面优于ACEI与CCB组合。对收缩期高血压患者应用联合治疗以预防心血管事件(ACCOMPLISH)临床研究的结果却表明，在糖尿病高血压高危患者中，ACEI与氢氯噻嗪联合用药对减缓患者肾小球滤过率下降的作用不及ACEI与CCB组合。虽然噻嗪类或袢利尿剂作为联合用药是否强于CCB存在争议，多数糖尿病肾病合并高血压的患者，尤其血压高于130/80mmHg者需要一种以上药物控制血压，故推荐噻嗪类或袢利尿剂作为联合用药。氢氯噻嗪促进钾钠排泄，造成低钠血症时可引起反射性肾素和醛固酮分泌，在无尿或肾功能损害患者的效果差，大剂量使用易导致药物蓄积，增加毒性，故其慎用于该类患者，应从小剂量每日25mg开始。",
          "start_idx": 0,
          "end_idx": 371,
          "entities": [
            {
              "entity_id": "T1076",
              "entity": "利尿剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Diuretics"
            },
            {
              "entity_id": "T1077",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1078",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 18,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1079",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 24,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T1080",
              "entity": "噻嗪类",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "Thiazides"
            },
            {
              "entity_id": "T1081",
              "entity": "袢利尿剂",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Loop diuretics"
            },
            {
              "entity_id": "T1082",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1083",
              "entity": "氢氯噻嗪",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Hydrochlorothiazide"
            },
            {
              "entity_id": "T1084",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 80,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1085",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 84,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1086",
              "entity": "收缩期高血压",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 94,
              "entity_en": "Systolic hypertension"
            },
            {
              "entity_id": "T1087",
              "entity": "收缩期",
              "entity_type": "Class",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "Systole"
            },
            {
              "entity_id": "T1088",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 110,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T1089",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 108,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T1090",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 134,
              "end_idx": 137,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1091",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 137,
              "end_idx": 140,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T1092",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1093",
              "entity": "氢氯噻嗪",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 155,
              "entity_en": "Hydrochlorothiazide"
            },
            {
              "entity_id": "T1094",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 164,
              "end_idx": 170,
              "entity_en": "Glomerular filtration rate"
            },
            {
              "entity_id": "T1095",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 170,
              "end_idx": 172,
              "entity_en": "decline"
            },
            {
              "entity_id": "T1096",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 177,
              "end_idx": 181,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1097",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 185,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1098",
              "entity": "噻嗪类",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 193,
              "entity_en": "Thiazides"
            },
            {
              "entity_id": "T1099",
              "entity": "袢利尿剂",
              "entity_type": "Drug",
              "start_idx": 194,
              "end_idx": 198,
              "entity_en": "Loop diuretics"
            },
            {
              "entity_id": "T1100",
              "entity": "CCB",
              "entity_type": "Drug",
              "start_idx": 208,
              "end_idx": 211,
              "entity_en": "CCB"
            },
            {
              "entity_id": "T1101",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 218,
              "end_idx": 223,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1102",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 221,
              "end_idx": 222,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1103",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 225,
              "end_idx": 228,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T1104",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 234,
              "end_idx": 236,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T1105",
              "entity": "高于130/80mmHg",
              "entity_type": "Test_Value",
              "start_idx": 236,
              "end_idx": 248,
              "entity_en": "Above 130/80 mmHg"
            },
            {
              "entity_id": "T1106",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 259,
              "end_idx": 261,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T1107",
              "entity": "噻嗪类",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 268,
              "entity_en": "Thiazides"
            },
            {
              "entity_id": "T1108",
              "entity": "袢利尿剂",
              "entity_type": "Drug",
              "start_idx": 269,
              "end_idx": 273,
              "entity_en": "Loop diuretics"
            },
            {
              "entity_id": "T1109",
              "entity": "无尿",
              "entity_type": "Symptom",
              "start_idx": 314,
              "end_idx": 316,
              "entity_en": "Anuria"
            },
            {
              "entity_id": "T1110",
              "entity": "氢氯噻嗪",
              "entity_type": "Drug",
              "start_idx": 280,
              "end_idx": 284,
              "entity_en": "Hydrochlorothiazide"
            },
            {
              "entity_id": "T1111",
              "entity": "低钠血症",
              "entity_type": "ADE",
              "start_idx": 293,
              "end_idx": 297,
              "entity_en": "Hyponatremia"
            },
            {
              "entity_id": "T1112",
              "entity": "25mg",
              "entity_type": "Amount",
              "start_idx": 364,
              "end_idx": 368,
              "entity_en": "25mg"
            },
            {
              "entity_id": "T1113",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 317,
              "end_idx": 322,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T1114",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 317,
              "end_idx": 318,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R546",
              "head_entity_id": "T1078",
              "tail_entity_id": "T1077"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R547",
              "head_entity_id": "T1080",
              "tail_entity_id": "T1077"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R548",
              "head_entity_id": "T1081",
              "tail_entity_id": "T1077"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R549",
              "head_entity_id": "T1080",
              "tail_entity_id": "T1079"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R550",
              "head_entity_id": "T1081",
              "tail_entity_id": "T1079"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R551",
              "head_entity_id": "T1087",
              "tail_entity_id": "T1086"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R552",
              "head_entity_id": "T1089",
              "tail_entity_id": "T1088"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R553",
              "head_entity_id": "T1092",
              "tail_entity_id": "T1090"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R554",
              "head_entity_id": "T1093",
              "tail_entity_id": "T1090"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R555",
              "head_entity_id": "T1096",
              "tail_entity_id": "T1090"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R556",
              "head_entity_id": "T1097",
              "tail_entity_id": "T1090"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R557",
              "head_entity_id": "T1094",
              "tail_entity_id": "T1090"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R558",
              "head_entity_id": "T1092",
              "tail_entity_id": "T1091"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R559",
              "head_entity_id": "T1093",
              "tail_entity_id": "T1091"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R560",
              "head_entity_id": "T1096",
              "tail_entity_id": "T1091"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R561",
              "head_entity_id": "T1097",
              "tail_entity_id": "T1091"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R562",
              "head_entity_id": "T1094",
              "tail_entity_id": "T1091"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R563",
              "head_entity_id": "T1102",
              "tail_entity_id": "T1101"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R564",
              "head_entity_id": "T1104",
              "tail_entity_id": "T1101"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R565",
              "head_entity_id": "T1107",
              "tail_entity_id": "T1101"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R566",
              "head_entity_id": "T1108",
              "tail_entity_id": "T1101"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R567",
              "head_entity_id": "T1106",
              "tail_entity_id": "T1101"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R568",
              "head_entity_id": "T1104",
              "tail_entity_id": "T1103"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R569",
              "head_entity_id": "T1106",
              "tail_entity_id": "T1103"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R570",
              "head_entity_id": "T1107",
              "tail_entity_id": "T1103"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R571",
              "head_entity_id": "T1108",
              "tail_entity_id": "T1103"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R572",
              "head_entity_id": "T1111",
              "tail_entity_id": "T1110"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R573",
              "head_entity_id": "T1112",
              "tail_entity_id": "T1110"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R574",
              "head_entity_id": "T1110",
              "tail_entity_id": "T1113"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R575",
              "head_entity_id": "T1114",
              "tail_entity_id": "T1113"
            }
          ],
          "sentence_en": "(4) Diuretics: 60% to 90% of patients with diabetic nephropathy and hypertension use thiazides or loop diuretics. The GUARD clinical study showed that the combination of ACEI and hydrochlorothiazide is superior to the combination of ACEI and CCB in reducing the patient's urine protein level. The results of the ACCOMPLISH clinical study showed that in high-risk diabetic hypertensive patients, the combination of ACEI and hydrochlorothiazide was less effective than the combination of ACEI and CCB in slowing the decline in the patient's glomerular filtration rate. Although there is controversy over whether thiazides or loop diuretics are better than CCBs as a combination drug, most patients with diabetic nephropathy and hypertension, especially those with blood pressure above 130/80 mmHg, need more than one drug to control their blood pressure. Therefore, thiazides or loop diuretics are recommended as a combination drug. Hydrochlorothiazide promotes potassium and sodium excretion, which can cause reflex renin and aldosterone secretion when causing hyponatremia. It has poor effects in patients with anuria or renal impairment. High-dose use can easily lead to drug accumulation and increase toxicity. Therefore, it should be used with caution in such patients and should start with a small dose of 25 mg per day."
        }
      ],
      "paragraph_en": "(4) Diuretics: 60% to 90% of patients with diabetic nephropathy and hypertension use thiazides or loop diuretics. The GUARD clinical study showed that the combination of ACEI and hydrochlorothiazide is superior to the combination of ACEI and CCB in reducing the patient's urine protein level. The results of the ACCOMPLISH clinical study showed that in high-risk diabetic hypertensive patients, the combination of ACEI and hydrochlorothiazide is less effective than the combination of ACEI and CCB in slowing the decline in the patient's glomerular filtration rate. Although there is controversy over whether thiazides or loop diuretics are better than CCBs as a combination drug, most patients with diabetic nephropathy and hypertension, especially those with blood pressure above 130/80 mmHg, need more than one drug to control their blood pressure. Therefore, thiazides or loop diuretics are recommended as a combination drug. Hydrochlorothiazide promotes potassium and sodium excretion, which can cause reflex renin and aldosterone secretion when causing hyponatremia. It has poor effects in patients with anuria or renal impairment. High-dose use can easily lead to drug accumulation and increase toxicity. Therefore, it should be used with caution in such patients and should start with a small dose of 25 mg per day."
    },
    {
      "paragraph_id": "50",
      "paragraph": "(5)β受体阻滞剂：尽管ACEI在降低糖尿病患者蛋白尿方面较β受体阻滞剂更有优势，但两种药物均可延缓患者肾功能的衰退。UKPDS研究亦认为ACEI与β受体阻滞剂在降低2型糖尿病患者微血管和大血管并发症方面临床价值相当。β受体阻滞剂可作为降压治疗的联合用药。第一类为非选择性β受体阻滞剂，主要代表药物是普萘洛尔，目前已较少使用。第二类主要作用于β1受体，代表药物有美托洛尔、比索洛尔。美托洛尔主要经肝脏代谢，5%以原型经肾排泄，用于肾功能损害者剂量无需调整。比索洛尔50%通过肝脏代谢为无活性的代谢产物然后从肾脏排出，剩余50%以原形药的形式从肾脏排出，轻中度肾功能不全患者剂量不需调整，当GFR<20ml·min-1·1.73m-2时每日剂量不超过10mg，肾透析患者使用经验较少。第三类主要作用于β和α1受体，代表药物有卡维地洛、拉贝洛尔。拉贝洛尔55%~60%的原形药物和代谢产物由尿排f也，血液透析和腹膜透析均不易清除，应慎用于肾功能不全者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)β受体阻滞剂：尽管ACEI在降低糖尿病患者蛋白尿方面较β受体阻滞剂更有优势，但两种药物均可延缓患者肾功能的衰退。UKPDS研究亦认为ACEI与β受体阻滞剂在降低2型糖尿病患者微血管和大血管并发症方面临床价值相当。β受体阻滞剂可作为降压治疗的联合用药。第一类为非选择性β受体阻滞剂，主要代表药物是普萘洛尔，目前已较少使用。第二类主要作用于β1受体，代表药物有美托洛尔、比索洛尔。美托洛尔主要经肝脏代谢，5%以原型经肾排泄，用于肾功能损害者剂量无需调整。比索洛尔50%通过肝脏代谢为无活性的代谢产物然后从肾脏排出，剩余50%以原形药的形式从肾脏排出，轻中度肾功能不全患者剂量不需调整，当GFR<20ml·min-1·1.73m-2时每日剂量不超过10mg，肾透析患者使用经验较少。第三类主要作用于β和α1受体，代表药物有卡维地洛、拉贝洛尔。拉贝洛尔55%~60%的原形药物和代谢产物由尿排f也，血液透析和腹膜透析均不易清除，应慎用于肾功能不全者。",
          "start_idx": 0,
          "end_idx": 424,
          "entities": [
            {
              "entity_id": "T1115",
              "entity": "β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Beta-blockers"
            },
            {
              "entity_id": "T1116",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1117",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1118",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T1119",
              "entity": "β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 36,
              "entity_en": "Beta-blockers"
            },
            {
              "entity_id": "T1120",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1121",
              "entity": "β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 80,
              "entity_en": "Beta-blockers"
            },
            {
              "entity_id": "T1122",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 88,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1123",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 83,
              "end_idx": 85,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T1124",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T1125",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 94,
              "end_idx": 97,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T1126",
              "entity": "β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 115,
              "entity_en": "Beta-blockers"
            },
            {
              "entity_id": "T1127",
              "entity": "非选择性β受体阻滞剂",
              "entity_type": "Drug",
              "start_idx": 132,
              "end_idx": 142,
              "entity_en": "Nonselective beta-blockers"
            },
            {
              "entity_id": "T1128",
              "entity": "普萘洛尔",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Propranolol"
            },
            {
              "entity_id": "T1129",
              "entity": "美托洛尔",
              "entity_type": "Drug",
              "start_idx": 181,
              "end_idx": 185,
              "entity_en": "Metoprolol"
            },
            {
              "entity_id": "T1130",
              "entity": "比索洛尔",
              "entity_type": "Drug",
              "start_idx": 186,
              "end_idx": 190,
              "entity_en": "Bisoprolol"
            },
            {
              "entity_id": "T1131",
              "entity": "美托洛尔",
              "entity_type": "Drug",
              "start_idx": 191,
              "end_idx": 195,
              "entity_en": "Metoprolol"
            },
            {
              "entity_id": "T1132",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 215,
              "end_idx": 220,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T1133",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 215,
              "end_idx": 216,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1134",
              "entity": "比索洛尔",
              "entity_type": "Drug",
              "start_idx": 228,
              "end_idx": 232,
              "entity_en": "Bisoprolol"
            },
            {
              "entity_id": "T1135",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 279,
              "end_idx": 284,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1136",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 276,
              "end_idx": 279,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T1137",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 279,
              "end_idx": 280,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1138",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 294,
              "end_idx": 297,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1139",
              "entity": "<20ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 297,
              "end_idx": 316,
              "entity_en": "<20ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T1140",
              "entity": "不超过10mg",
              "entity_type": "Amount",
              "start_idx": 321,
              "end_idx": 328,
              "entity_en": "Not more than 10 mg"
            },
            {
              "entity_id": "T1141",
              "entity": "肾透析",
              "entity_type": "Treatment",
              "start_idx": 329,
              "end_idx": 332,
              "entity_en": "Kidney dialysis"
            },
            {
              "entity_id": "T1142",
              "entity": "卡维地洛",
              "entity_type": "Drug",
              "start_idx": 361,
              "end_idx": 365,
              "entity_en": "Carvedilol"
            },
            {
              "entity_id": "T1143",
              "entity": "拉贝洛尔",
              "entity_type": "Drug",
              "start_idx": 366,
              "end_idx": 370,
              "entity_en": "Labetalol"
            },
            {
              "entity_id": "T1144",
              "entity": "拉贝洛尔",
              "entity_type": "Drug",
              "start_idx": 371,
              "end_idx": 375,
              "entity_en": "Labetalol"
            },
            {
              "entity_id": "T1145",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 398,
              "end_idx": 402,
              "entity_en": "Hemodialysis"
            },
            {
              "entity_id": "T1146",
              "entity": "腹膜透析",
              "entity_type": "Treatment",
              "start_idx": 403,
              "end_idx": 407,
              "entity_en": "Peritoneal dialysis"
            },
            {
              "entity_id": "T1147",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 417,
              "end_idx": 422,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1148",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 417,
              "end_idx": 418,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R576",
              "head_entity_id": "T1116",
              "tail_entity_id": "T1117"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R577",
              "head_entity_id": "T1119",
              "tail_entity_id": "T1117"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R578",
              "head_entity_id": "T1120",
              "tail_entity_id": "T1122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R579",
              "head_entity_id": "T1121",
              "tail_entity_id": "T1122"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R580",
              "head_entity_id": "T1123",
              "tail_entity_id": "T1122"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R581",
              "head_entity_id": "T1124",
              "tail_entity_id": "T1122"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R582",
              "head_entity_id": "T1125",
              "tail_entity_id": "T1122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R583",
              "head_entity_id": "T1131",
              "tail_entity_id": "T1132"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R584",
              "head_entity_id": "T1133",
              "tail_entity_id": "T1132"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R585",
              "head_entity_id": "T1134",
              "tail_entity_id": "T1135"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R586",
              "head_entity_id": "T1140",
              "tail_entity_id": "T1134"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R587",
              "head_entity_id": "T1137",
              "tail_entity_id": "T1135"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R588",
              "head_entity_id": "T1138",
              "tail_entity_id": "T1135"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R589",
              "head_entity_id": "T1141",
              "tail_entity_id": "T1135"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R590",
              "head_entity_id": "T1144",
              "tail_entity_id": "T1147"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R591",
              "head_entity_id": "T1145",
              "tail_entity_id": "T1147"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R592",
              "head_entity_id": "T1146",
              "tail_entity_id": "T1147"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R593",
              "head_entity_id": "T1148",
              "tail_entity_id": "T1147"
            }
          ],
          "sentence_en": "(5) β-blockers: Although ACEI is more advantageous than β-blockers in reducing proteinuria in diabetic patients, both drugs can delay the decline of renal function in patients. The UKPDS study also believes that ACEI and β-blockers have equivalent clinical value in reducing microvascular and macrovascular complications in patients with type 2 diabetes. β-blockers can be used as a combination drug for antihypertensive treatment. The first category is non-selective β-blockers, the main representative drug is propranolol, which is rarely used now. The second category mainly acts on β1 receptors, and the representative drugs are metoprolol and bisoprolol. Metoprolol is mainly metabolized by the liver, and 5% is excreted as the original drug by the kidney. No dosage adjustment is required for patients with renal impairment. 50% of bisoprolol is metabolized by the liver into inactive metabolites and then excreted from the kidneys, and the remaining 50% is excreted from the kidneys in the form of the original drug. No dosage adjustment is required for patients with mild to moderate renal insufficiency. When GFR < 20 ml·min-1·1.73 m-2, the daily dose should not exceed 10 mg. There is little experience in using it in patients undergoing renal dialysis. The third category mainly acts on β and α1 receptors, and its representative drugs include carvedilol and labetalol. 55% to 60% of the original drug and metabolites of labetalol are excreted in urine, which is not easily removed by hemodialysis and peritoneal dialysis, so it should be used with caution in patients with renal insufficiency."
        }
      ],
      "paragraph_en": "(5) β-blockers: Although ACEI is more advantageous than β-blockers in reducing proteinuria in diabetic patients, both drugs can delay the decline of renal function in patients. The UKPDS study also believes that ACEI and β-blockers have equivalent clinical value in reducing microvascular and macrovascular complications in patients with type 2 diabetes. β-blockers can be used as a combination drug for antihypertensive treatment. The first category is non-selective β-blockers, the main representative drug is propranolol, which is rarely used now. The second category mainly acts on β1 receptors, and the representative drugs are metoprolol and bisoprolol. Metoprolol is mainly metabolized by the liver, and 5% is excreted as the original drug by the kidney. No dosage adjustment is required for patients with renal impairment. 50% of bisoprolol is metabolized by the liver into inactive metabolites and then excreted from the kidneys, and the remaining 50% is excreted from the kidneys in the form of the original drug. No dosage adjustment is required for patients with mild to moderate renal insufficiency. When GFR < 20 ml·min-1·1.73 m-2, the daily dose should not exceed 10 mg. There is little experience in using it in patients undergoing renal dialysis. The third category mainly acts on β and α1 receptors, and its representative drugs include carvedilol and labetalol. 55% to 60% of the original drug and metabolites of labetalol are excreted in urine, which is not easily removed by hemodialysis and peritoneal dialysis, so it should be used with caution in patients with renal insufficiency."
    },
    {
      "paragraph_id": "51",
      "paragraph": "(6)其他肾素-血管紧张素系统(RAS)阻断剂：ACEI或ARB类药物可以降低患者血浆醛固酮水平，但有研究发现有40%服用上述药物的患者其血浆醛固酮水平并未下降，反而升高到了其治疗前的浓度水平，称之为“醛固酮逃避”现象，这可能与肾病进展过程有关，具体机制尚不明确。早期一些短期临床研究表明，ACEI/ARB与醛固酮受体拮抗剂(MRA)联合治疗在降低1型DN患者尿白蛋白水平方面的益处，但是需要更多临床研究证实。赖诺普利联合螺内酯组与赖诺普利+安慰剂组患者相比，其尿白蛋白水平明显降低。因螺内酯可使血钾升高的风险增高，应用时需监测血钾。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(6)其他肾素-血管紧张素系统(RAS)阻断剂：ACEI或ARB类药物可以降低患者血浆醛固酮水平，但有研究发现有40%服用上述药物的患者其血浆醛固酮水平并未下降，反而升高到了其治疗前的浓度水平，称之为“醛固酮逃避”现象，这可能与肾病进展过程有关，具体机制尚不明确。早期一些短期临床研究表明，ACEI/ARB与醛固酮受体拮抗剂(MRA)联合治疗在降低1型DN患者尿白蛋白水平方面的益处，但是需要更多临床研究证实。赖诺普利联合螺内酯组与赖诺普利+安慰剂组患者相比，其尿白蛋白水平明显降低。因螺内酯可使血钾升高的风险增高，应用时需监测血钾。",
          "start_idx": 0,
          "end_idx": 267,
          "entities": [
            {
              "entity_id": "T1149",
              "entity": "肾素-血管紧张素系统(RAS)阻断剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 23,
              "entity_en": "Renin-angiotensin system (RAS) blockers"
            },
            {
              "entity_id": "T1150",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1151",
              "entity": "ARB类药物",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 35,
              "entity_en": "ARBs"
            },
            {
              "entity_id": "T1152",
              "entity": "血浆醛固酮",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "Plasma aldosterone"
            },
            {
              "entity_id": "T1153",
              "entity": "血浆醛固酮水平",
              "entity_type": "Test_items",
              "start_idx": 69,
              "end_idx": 76,
              "entity_en": "Plasma aldosterone level"
            },
            {
              "entity_id": "T1154",
              "entity": "未下降",
              "entity_type": "Test_Value",
              "start_idx": 77,
              "end_idx": 80,
              "entity_en": "Not decreased"
            },
            {
              "entity_id": "T1155",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 83,
              "end_idx": 85,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T1156",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 116,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T1157",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 114,
              "end_idx": 115,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1158",
              "entity": "ACEI/ARB",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 153,
              "entity_en": "ACEI/ARB"
            },
            {
              "entity_id": "T1159",
              "entity": "醛固酮受体拮抗剂(MRA)",
              "entity_type": "Drug",
              "start_idx": 154,
              "end_idx": 167,
              "entity_en": "Aldosterone receptor antagonists (MRA)"
            },
            {
              "entity_id": "T1160",
              "entity": "1型DN",
              "entity_type": "Disease",
              "start_idx": 174,
              "end_idx": 178,
              "entity_en": "Type 1DN"
            },
            {
              "entity_id": "T1161",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 174,
              "end_idx": 176,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T1162",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 180,
              "end_idx": 184,
              "entity_en": "Urine albumin"
            },
            {
              "entity_id": "T1163",
              "entity": "赖诺普利",
              "entity_type": "Drug",
              "start_idx": 205,
              "end_idx": 209,
              "entity_en": "Lisinopril"
            },
            {
              "entity_id": "T1164",
              "entity": "螺内酯",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 214,
              "entity_en": "Spironolactone"
            },
            {
              "entity_id": "T1165",
              "entity": "赖诺普利",
              "entity_type": "Drug",
              "start_idx": 216,
              "end_idx": 220,
              "entity_en": "Lisinopril"
            },
            {
              "entity_id": "T1166",
              "entity": "尿白蛋白水平",
              "entity_type": "Test_items",
              "start_idx": 231,
              "end_idx": 237,
              "entity_en": "Urine albumin level"
            },
            {
              "entity_id": "T1167",
              "entity": "明显降低",
              "entity_type": "Test_Value",
              "start_idx": 237,
              "end_idx": 241,
              "entity_en": "Significantly reduced"
            },
            {
              "entity_id": "T1168",
              "entity": "螺内酯",
              "entity_type": "Drug",
              "start_idx": 243,
              "end_idx": 246,
              "entity_en": "Spironolactone"
            },
            {
              "entity_id": "T1169",
              "entity": "血钾升高",
              "entity_type": "ADE",
              "start_idx": 248,
              "end_idx": 252,
              "entity_en": "Increased potassium levels"
            },
            {
              "entity_id": "T1170",
              "entity": "血钾",
              "entity_type": "Test_items",
              "start_idx": 264,
              "end_idx": 266,
              "entity_en": "Serum potassium"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R594",
              "head_entity_id": "T1150",
              "tail_entity_id": "T1156"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R595",
              "head_entity_id": "T1151",
              "tail_entity_id": "T1156"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R596",
              "head_entity_id": "T1152",
              "tail_entity_id": "T1156"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R597",
              "head_entity_id": "T1153",
              "tail_entity_id": "T1156"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R598",
              "head_entity_id": "T1157",
              "tail_entity_id": "T1156"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R599",
              "head_entity_id": "T1158",
              "tail_entity_id": "T1160"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R600",
              "head_entity_id": "T1159",
              "tail_entity_id": "T1160"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R601",
              "head_entity_id": "T1161",
              "tail_entity_id": "T1160"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R602",
              "head_entity_id": "T1162",
              "tail_entity_id": "T1160"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R603",
              "head_entity_id": "T1169",
              "tail_entity_id": "T1168"
            }
          ],
          "sentence_en": "(6) Other renin-angiotensin system (RAS) blockers: ACEI or ARB drugs can reduce the patient's plasma aldosterone level, but studies have found that 40% of patients taking the above drugs did not have a decrease in plasma aldosterone levels, but instead increased to the concentration level before treatment, which is called the \"aldosterone escape\" phenomenon. This may be related to the progression of kidney disease, and the specific mechanism is still unclear. Some early short-term clinical studies have shown the benefits of combined treatment with ACEI/ARB and aldosterone receptor antagonists (MRA) in reducing the urine albumin level of patients with type 1 DN, but more clinical studies are needed to confirm this. Compared with the patients in the lisinopril combined with spironolactone group, the urine albumin level was significantly lower. Because spironolactone can increase the risk of elevated blood potassium, blood potassium needs to be monitored during its use."
        }
      ],
      "paragraph_en": "(6) Other renin-angiotensin system (RAS) blockers: ACEI or ARB drugs can reduce the patient's plasma aldosterone level, but studies have found that 40% of patients taking the above drugs did not have a decrease in plasma aldosterone levels, but instead increased to the concentration level before treatment, which is called the \"aldosterone escape\" phenomenon. This may be related to the progression of kidney disease, and the specific mechanism is still unclear. Some early short-term clinical studies have shown the benefits of combined treatment with ACEI/ARB and aldosterone receptor antagonist (MRA) in reducing the urine albumin level of patients with type 1 DN, but more clinical studies are needed to confirm this. Compared with the lisinopril + placebo group, the urine albumin level of patients in the lisinopril combined with spironolactone group was significantly lower. Because spironolactone can increase the risk of elevated blood potassium, blood potassium needs to be monitored during its use."
    },
    {
      "paragraph_id": "52",
      "paragraph": "抑制糖尿病肾病患者体内的肾素活性，可显著降低其血压和蛋白尿水平。2型糖尿病患者中，肾素抑制剂阿利吉仑联合氯沙坦与单用氯沙坦相比，尿蛋白更低。然而，近期一项在2型糖尿病患者中进行的阿利吉仑临床试验却因阿利吉仑与ACEI/ARB的联合应用所导致的严重不良事件所终止，不良反应包括肾功能衰竭、高血钾及低血压等。因此FDA仍将阿利吉仑禁用于已使用ACEI/ARB的糖尿病患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "抑制糖尿病肾病患者体内的肾素活性，可显著降低其血压和蛋白尿水平。2型糖尿病患者中，肾素抑制剂阿利吉仑联合氯沙坦与单用氯沙坦相比，尿蛋白更低。然而，近期一项在2型糖尿病患者中进行的阿利吉仑临床试验却因阿利吉仑与ACEI/ARB的联合应用所导致的严重不良事件所终止，不良反应包括肾功能衰竭、高血钾及低血压等。",
          "start_idx": 0,
          "end_idx": 152,
          "entities": [
            {
              "entity_id": "T1171",
              "entity": "肾功能衰竭",
              "entity_type": "ADE",
              "start_idx": 137,
              "end_idx": 142,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T1172",
              "entity": "高血钾",
              "entity_type": "ADE",
              "start_idx": 143,
              "end_idx": 146,
              "entity_en": "Hyperkalemia"
            },
            {
              "entity_id": "T1173",
              "entity": "低血压",
              "entity_type": "ADE",
              "start_idx": 147,
              "end_idx": 150,
              "entity_en": "Low blood pressure"
            },
            {
              "entity_id": "T1178",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1179",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 6,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1180",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T1181",
              "entity": "蛋白尿",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T1182",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1183",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T1184",
              "entity": "肾素抑制剂",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "Renin inhibitors"
            },
            {
              "entity_id": "T1185",
              "entity": "阿利吉仑",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "Aliskiren"
            },
            {
              "entity_id": "T1186",
              "entity": "氯沙坦",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "Losartan"
            },
            {
              "entity_id": "T1187",
              "entity": "氯沙坦",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "Losartan"
            },
            {
              "entity_id": "T1188",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T1189",
              "entity": "更低",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "Lower"
            },
            {
              "entity_id": "T1190",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1191",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T1192",
              "entity": "阿利吉仑",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Aliskiren"
            },
            {
              "entity_id": "T1193",
              "entity": "阿利吉仑",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "Aliskiren"
            },
            {
              "entity_id": "T1194",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1195",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 112,
              "entity_en": "ARB"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R604",
              "head_entity_id": "T1171",
              "tail_entity_id": "T1193"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R605",
              "head_entity_id": "T1171",
              "tail_entity_id": "T1194"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R606",
              "head_entity_id": "T1171",
              "tail_entity_id": "T1195"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R607",
              "head_entity_id": "T1172",
              "tail_entity_id": "T1193"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R608",
              "head_entity_id": "T1172",
              "tail_entity_id": "T1194"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R609",
              "head_entity_id": "T1172",
              "tail_entity_id": "T1195"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R610",
              "head_entity_id": "T1173",
              "tail_entity_id": "T1193"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R611",
              "head_entity_id": "T1173",
              "tail_entity_id": "T1194"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R612",
              "head_entity_id": "T1173",
              "tail_entity_id": "T1195"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R613",
              "head_entity_id": "T1179",
              "tail_entity_id": "T1178"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R614",
              "head_entity_id": "T1180",
              "tail_entity_id": "T1178"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R615",
              "head_entity_id": "T1181",
              "tail_entity_id": "T1178"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R616",
              "head_entity_id": "T1183",
              "tail_entity_id": "T1182"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R617",
              "head_entity_id": "T1184",
              "tail_entity_id": "T1182"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R618",
              "head_entity_id": "T1185",
              "tail_entity_id": "T1182"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R619",
              "head_entity_id": "T1186",
              "tail_entity_id": "T1182"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R620",
              "head_entity_id": "T1187",
              "tail_entity_id": "T1182"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R621",
              "head_entity_id": "T1188",
              "tail_entity_id": "T1182"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R622",
              "head_entity_id": "T1191",
              "tail_entity_id": "T1190"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R623",
              "head_entity_id": "T1192",
              "tail_entity_id": "T1190"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R624",
              "head_entity_id": "T1193",
              "tail_entity_id": "T1190"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R625",
              "head_entity_id": "T1194",
              "tail_entity_id": "T1190"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R626",
              "head_entity_id": "T1195",
              "tail_entity_id": "T1190"
            }
          ],
          "sentence_en": "Inhibiting renin activity in patients with diabetic nephropathy can significantly reduce their blood pressure and proteinuria levels. In patients with type 2 diabetes, the renin inhibitor aliskiren combined with losartan has lower urine protein than losartan alone. However, a recent clinical trial of aliskiren in patients with type 2 diabetes was terminated due to serious adverse events caused by the combined use of aliskiren and ACEI/ARB, including renal failure, hyperkalemia, and hypotension."
        },
        {
          "sentence_id": "1",
          "sentence": "因此FDA仍将阿利吉仑禁用于已使用ACEI/ARB的糖尿病患者。",
          "start_idx": 152,
          "end_idx": 184,
          "entities": [
            {
              "entity_id": "T1174",
              "entity": "阿利吉仑",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Aliskiren"
            },
            {
              "entity_id": "T1175",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1176",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1177",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, the FDA still prohibits the use of aliskiren in diabetic patients who are already using ACEI/ARB."
        }
      ],
      "paragraph_en": "Inhibiting renin activity in patients with diabetic nephropathy can significantly reduce their blood pressure and proteinuria levels. In patients with type 2 diabetes, the renin inhibitor aliskiren combined with losartan has lower urine protein than losartan alone. However, a recent clinical trial of aliskiren in patients with type 2 diabetes was terminated due to serious adverse events caused by the combined use of aliskiren and ACEI/ARB, including renal failure, hyperkalemia, and hypotension. Therefore, the FDA still prohibits aliskiren from being used in diabetic patients who are already using ACEI/ARB."
    },
    {
      "paragraph_id": "53",
      "paragraph": "(7)联合用药：糖尿病肾病患者在血压控制不佳时，可在ACEI/ARB的基础上选择其他降压药物联合使用。一些早期小型临床研究结果表明，ACEI联合ARB在糖尿病肾病患者中具有较高的耐受性和有效率，可使糖尿病患者的尿蛋白水平显著降低，有效降低了患者舒张压。然而，较新的研究表明ACEI与ARB联合治疗疗效并不优于单药治疗，联合ARB及ACEI后，糖尿病患者血清肌酐水平、ESRD发生及死亡率方面并无明显差异。本共识不推荐联合使用ACEI和ARB。如果已在联合使用ACEI和ARB，则需要检测和随访血钾和肾功能。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(7)联合用药：糖尿病肾病患者在血压控制不佳时，可在ACEI/ARB的基础上选择其他降压药物联合使用。一些早期小型临床研究结果表明，ACEI联合ARB在糖尿病肾病患者中具有较高的耐受性和有效率，可使糖尿病患者的尿蛋白水平显著降低，有效降低了患者舒张压。然而，较新的研究表明ACEI与ARB联合治疗疗效并不优于单药治疗，联合ARB及ACEI后，糖尿病患者血清肌酐水平、ESRD发生及死亡率方面并无明显差异。",
          "start_idx": 0,
          "end_idx": 202,
          "entities": [
            {
              "entity_id": "T1196",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1197",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 12,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1198",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T1199",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T1200",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1201",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1202",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1203",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1204",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 81,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1205",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 80,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1206",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 102,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1207",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 105,
              "end_idx": 108,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T1208",
              "entity": "显著降低",
              "entity_type": "Test_Value",
              "start_idx": 110,
              "end_idx": 114,
              "entity_en": "Significantly reduce"
            },
            {
              "entity_id": "T1209",
              "entity": "舒张压",
              "entity_type": "Test",
              "start_idx": 122,
              "end_idx": 125,
              "entity_en": "Diastolic blood pressure"
            },
            {
              "entity_id": "T1210",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 140,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1211",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 144,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1212",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 161,
              "end_idx": 164,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1213",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 169,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1214",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 171,
              "end_idx": 174,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1215",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 176,
              "end_idx": 180,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T1216",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 183,
              "end_idx": 187,
              "entity_en": "ESRD"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R627",
              "head_entity_id": "T1197",
              "tail_entity_id": "T1196"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R628",
              "head_entity_id": "T1198",
              "tail_entity_id": "T1196"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R629",
              "head_entity_id": "T1200",
              "tail_entity_id": "T1196"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R630",
              "head_entity_id": "T1201",
              "tail_entity_id": "T1196"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R631",
              "head_entity_id": "T1202",
              "tail_entity_id": "T1204"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R632",
              "head_entity_id": "T1203",
              "tail_entity_id": "T1204"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R633",
              "head_entity_id": "T1205",
              "tail_entity_id": "T1204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R634",
              "head_entity_id": "T1207",
              "tail_entity_id": "T1206"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R635",
              "head_entity_id": "T1209",
              "tail_entity_id": "T1206"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R636",
              "head_entity_id": "T1210",
              "tail_entity_id": "T1214"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R637",
              "head_entity_id": "T1211",
              "tail_entity_id": "T1214"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R638",
              "head_entity_id": "T1212",
              "tail_entity_id": "T1214"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R639",
              "head_entity_id": "T1213",
              "tail_entity_id": "T1214"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R640",
              "head_entity_id": "T1215",
              "tail_entity_id": "T1214"
            }
          ],
          "sentence_en": "(7) Combination therapy: When blood pressure in patients with diabetic nephropathy is poorly controlled, other antihypertensive drugs can be used in combination with ACEI/ARB. The results of some early small-scale clinical studies have shown that ACEI combined with ARB has high tolerance and efficacy in patients with diabetic nephropathy, and can significantly reduce the urine protein level of diabetic patients and effectively reduce the diastolic blood pressure of patients. However, newer studies have shown that the efficacy of ACEI and ARB combination therapy is not better than monotherapy. After combining ARB and ACEI, there is no significant difference in serum creatinine levels, ESRD incidence and mortality in diabetic patients."
        },
        {
          "sentence_id": "1",
          "sentence": "本共识不推荐联合使用ACEI和ARB。",
          "start_idx": 202,
          "end_idx": 221,
          "entities": [
            {
              "entity_id": "T1217",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1218",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "ARB"
            }
          ],
          "relations": [],
          "sentence_en": "This consensus does not recommend the combined use of ACEI and ARB."
        },
        {
          "sentence_id": "2",
          "sentence": "如果已在联合使用ACEI和ARB，则需要检测和随访血钾和肾功能。",
          "start_idx": 221,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T1219",
              "entity": "ACEI",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "ACEI"
            },
            {
              "entity_id": "T1220",
              "entity": "ARB",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "ARB"
            },
            {
              "entity_id": "T1221",
              "entity": "血钾",
              "entity_type": "Test_items",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "Serum potassium"
            },
            {
              "entity_id": "T1222",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Renal function"
            }
          ],
          "relations": [],
          "sentence_en": "If ACEI and ARB are used in combination, serum potassium and renal function need to be tested and followed up."
        }
      ],
      "paragraph_en": "(7) Combination therapy: When blood pressure in patients with diabetic nephropathy is poorly controlled, other antihypertensive drugs can be used in combination with ACEI/ARB. The results of some early small clinical studies have shown that ACEI combined with ARB has high tolerability and efficacy in patients with diabetic nephropathy, and can significantly reduce the urine protein level of diabetic patients and effectively reduce the diastolic blood pressure of patients. However, newer studies have shown that the efficacy of ACEI and ARB combination therapy is not better than monotherapy. After combining ARB and ACEI, there is no significant difference in serum creatinine levels, ESRD incidence and mortality in diabetic patients. This consensus does not recommend the combined use of ACEI and ARB. If ACEI and ARB are already being used in combination, blood potassium and renal function need to be tested and followed up."
    },
    {
      "paragraph_id": "54",
      "paragraph": "(四)纠正脂质代谢紊乱",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)纠正脂质代谢紊乱",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [
            {
              "entity_id": "T1223",
              "entity": "脂质代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 11,
              "entity_en": "Lipid metabolism disorders"
            }
          ],
          "relations": [],
          "sentence_en": "(IV) Correction of lipid metabolism disorders"
        }
      ],
      "paragraph_en": "(IV) Correction of lipid metabolism disorders"
    },
    {
      "paragraph_id": "55",
      "paragraph": "高脂血症不仅直接参与糖尿病胰岛素抵抗和心血管并发症的发生，低密度脂蛋白胆固醇(LDL-C)还可以通过作用于肾小球系膜细胞上的LDL受体，导致系膜细胞和足细胞的损伤，加重蛋白尿和肾小球及肾小管间质纤维化的进展。糖尿病患者出现肾病综合征和肾功能不全，又会进一步加重高脂血症。因此，积极纠正糖尿病肾病患者体内脂代谢紊乱，亦对糖尿病肾病具有重要意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "高脂血症不仅直接参与糖尿病胰岛素抵抗和心血管并发症的发生，低密度脂蛋白胆固醇(LDL-C)还可以通过作用于肾小球系膜细胞上的LDL受体，导致系膜细胞和足细胞的损伤，加重蛋白尿和肾小球及肾小管间质纤维化的进展。糖尿病患者出现肾病综合征和肾功能不全，又会进一步加重高脂血症。因此，积极纠正糖尿病肾病患者体内脂代谢紊乱，亦对糖尿病肾病具有重要意义。",
          "start_idx": 0,
          "end_idx": 171,
          "entities": [
            {
              "entity_id": "T1224",
              "entity": "高脂血症",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Hyperlipidemia"
            },
            {
              "entity_id": "T1225",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1226",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T1227",
              "entity": "心血管并发症",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 25,
              "entity_en": "Cardiovascular complications"
            },
            {
              "entity_id": "T1228",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T1229",
              "entity": "低密度脂蛋白胆固醇(LDL-C)还可以通过作用于肾小球系膜细胞上的LDL受体",
              "entity_type": "Pathogenesis",
              "start_idx": 29,
              "end_idx": 67,
              "entity_en": "Low-density lipoprotein cholesterol (LDL-C) can also act on LDL receptors on glomerular mesangial cells"
            },
            {
              "entity_id": "T1230",
              "entity": "系膜细胞和足细胞的损伤",
              "entity_type": "Pathogenesis",
              "start_idx": 70,
              "end_idx": 81,
              "entity_en": "Damage to mesangial cells and podocytes"
            },
            {
              "entity_id": "T1231",
              "entity": "加重蛋白尿和肾小球及肾小管间质纤维化的进展",
              "entity_type": "Pathogenesis",
              "start_idx": 82,
              "end_idx": 103,
              "entity_en": "Aggravated proteinuria and progression of glomerular and tubulointerstitial fibrosis"
            },
            {
              "entity_id": "T1232",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 107,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1233",
              "entity": "肾病综合征",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Nephrotic syndrome"
            },
            {
              "entity_id": "T1234",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 111,
              "end_idx": 112,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1235",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 122,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1236",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 117,
              "end_idx": 118,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1237",
              "entity": "高脂血症",
              "entity_type": "Disease",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Hyperlipidemia"
            },
            {
              "entity_id": "T1238",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 147,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1239",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 145,
              "end_idx": 146,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1240",
              "entity": "脂代谢紊乱",
              "entity_type": "Disease",
              "start_idx": 151,
              "end_idx": 156,
              "entity_en": "Lipid metabolism disorders"
            },
            {
              "entity_id": "T1241",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 164,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1242",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 162,
              "end_idx": 163,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R641",
              "head_entity_id": "T1229",
              "tail_entity_id": "T1224"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R642",
              "head_entity_id": "T1230",
              "tail_entity_id": "T1224"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R643",
              "head_entity_id": "T1231",
              "tail_entity_id": "T1224"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R644",
              "head_entity_id": "T1226",
              "tail_entity_id": "T1225"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R645",
              "head_entity_id": "T1228",
              "tail_entity_id": "T1227"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R646",
              "head_entity_id": "T1234",
              "tail_entity_id": "T1233"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R647",
              "head_entity_id": "T1236",
              "tail_entity_id": "T1235"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R648",
              "head_entity_id": "T1239",
              "tail_entity_id": "T1238"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R649",
              "head_entity_id": "T1242",
              "tail_entity_id": "T1241"
            }
          ],
          "sentence_en": "Hyperlipidemia is not only directly involved in the occurrence of insulin resistance and cardiovascular complications of diabetes, but low-density lipoprotein cholesterol (LDL-C) can also act on LDL receptors on glomerular mesangial cells, leading to damage to mesangial cells and podocytes, aggravating the progression of proteinuria and glomerular and tubular interstitial fibrosis. The occurrence of nephrotic syndrome and renal insufficiency in diabetic patients will further aggravate hyperlipidemia. Therefore, actively correcting lipid metabolism disorders in patients with diabetic nephropathy is also of great significance for diabetic nephropathy."
        }
      ],
      "paragraph_en": "Hyperlipidemia is not only directly involved in the occurrence of insulin resistance and cardiovascular complications in diabetes, but low-density lipoprotein cholesterol (LDL-C) can also act on LDL receptors on mesangial cells, leading to damage to mesangial cells and podocytes, aggravating the progression of proteinuria and glomerular and tubulointerstitial fibrosis. The occurrence of nephrotic syndrome and renal insufficiency in diabetic patients will further aggravate hyperlipidemia. Therefore, actively correcting lipid metabolism disorders in patients with diabetic nephropathy is also of great significance for diabetic nephropathy."
    },
    {
      "paragraph_id": "56",
      "paragraph": "1.血脂控制目标值：糖尿病肾病患者血脂干预治疗切点：血LDL-C>3.38mmol/L(130mg/d1)，甘油三酯(TG)>2.26(200mg/d1)。治疗目标：LDL-C水平降至2.6mmol/L以下(并发冠心病将至1.86mmol/L以下)，TG降至1.5mmol/L以下。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.血脂控制目标值：糖尿病肾病患者血脂干预治疗切点：血LDL-C>3.38mmol/L(130mg/d1)，甘油三酯(TG)>2.26(200mg/d1)。治疗目标：LDL-C水平降至2.6mmol/L以下(并发冠心病将至1.86mmol/L以下)，TG降至1.5mmol/L以下。",
          "start_idx": 0,
          "end_idx": 141,
          "entities": [
            {
              "entity_id": "T1243",
              "entity": ".血脂",
              "entity_type": "Test",
              "start_idx": 1,
              "end_idx": 4,
              "entity_en": ".Blood lipids"
            },
            {
              "entity_id": "T1244",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1245",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 14,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1246",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "Blood lipids"
            },
            {
              "entity_id": "T1247",
              "entity": "血LDL-C",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 32,
              "entity_en": "Blood LDL-C"
            },
            {
              "entity_id": "T1248",
              "entity": ">3.38mmol/L(130mg/d1)",
              "entity_type": "Test_Value",
              "start_idx": 32,
              "end_idx": 53,
              "entity_en": ">3.38mmol/L (130mg/d1)"
            },
            {
              "entity_id": "T1249",
              "entity": "甘油三酯(TG)",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 62,
              "entity_en": "Triglyceride (TG)"
            },
            {
              "entity_id": "T1250",
              "entity": ">2.26(200mg/d1)",
              "entity_type": "Test_Value",
              "start_idx": 62,
              "end_idx": 77,
              "entity_en": ">2.26 (200 mg/d1)"
            },
            {
              "entity_id": "T1251",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 88,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T1252",
              "entity": "降至2.6mmol/L以下",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 103,
              "entity_en": "Drop to below 2.6mmol/L"
            },
            {
              "entity_id": "T1253",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 109,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T1254",
              "entity": "将至1.86mmol/L以下",
              "entity_type": "Test_Value",
              "start_idx": 109,
              "end_idx": 123,
              "entity_en": "Will be below 1.86mmol/L"
            },
            {
              "entity_id": "T1255",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 127,
              "entity_en": "TG"
            },
            {
              "entity_id": "T1256",
              "entity": "降至1.5mmol/L以下",
              "entity_type": "Test_Value",
              "start_idx": 127,
              "end_idx": 140,
              "entity_en": "Drop to below 1.5mmol/L"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R650",
              "head_entity_id": "T1245",
              "tail_entity_id": "T1244"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R651",
              "head_entity_id": "T1246",
              "tail_entity_id": "T1244"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R652",
              "head_entity_id": "T1247",
              "tail_entity_id": "T1244"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R653",
              "head_entity_id": "T1249",
              "tail_entity_id": "T1244"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R654",
              "head_entity_id": "T1251",
              "tail_entity_id": "T1253"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R655",
              "head_entity_id": "T1255",
              "tail_entity_id": "T1253"
            }
          ],
          "sentence_en": "1. Blood lipid control target value: The cut-off point for blood lipid intervention treatment in patients with diabetic nephropathy: blood LDL-C>3.38mmol/L (130mg/d1), triglyceride (TG)>2.26 (200mg/d1). Treatment goal: LDL-C level drops to below 2.6mmol/L (below 1.86mmol/L for patients with coronary heart disease), and TG drops to below 1.5mmol/L."
        }
      ],
      "paragraph_en": "1. Blood lipid control target value: The cut-off point for blood lipid intervention treatment in patients with diabetic nephropathy: blood LDL-C>3.38mmol/L (130mg/d1), triglyceride (TG)>2.26 (200mg/d1). Treatment goal: LDL-C level drops to below 2.6mmol/L (below 1.86mmol/L for patients with coronary heart disease), and TG drops to below 1.5mmol/L."
    },
    {
      "paragraph_id": "57",
      "paragraph": "2.降脂药物的选择：研究表明他汀类药物可减少糖尿病血管疾病的发生率和肾功能减退，建议所有糖尿病患者均应首选口服他汀类药物，以TG升高为主时可首选贝特类降脂药。2型糖尿病患者常见混合性高脂血症。单一降脂药大剂量时不良反应增加，为了提高调脂治疗的达标率，往往需不同类别调脂药联合应用。他汀类和贝特类联用：混合性高脂血症经单用他汀类或贝特类未达标者，可考虑两药联合治疗。尽管目前有证据表明两药合理联用是安全的(ACCORD已经证明是安全的)，但除非特别严重的混合性血脂异常，一般应单药治疗；必要时谨慎联合，但剂量应小；两药分开时间服用；他汀类和贝特类联用时，首选非诺贝特。有以下特殊情况者慎用，包括老年、严重肝肾疾病、甲状腺功能减退等，并严密监测和随访，一旦发现异常，及时停药。他汀类和依折麦布联用：单用他汀类调脂药治疗后LDL-C仍未达标者，可考虑他汀类和依折麦布联用。现有证据表明依折麦布和小剂量他汀类联合应用比单独增加他汀类剂量能更好地改善血脂紊乱，且安全性好。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.降脂药物的选择：研究表明他汀类药物可减少糖尿病血管疾病的发生率和肾功能减退，建议所有糖尿病患者均应首选口服他汀类药物，以TG升高为主时可首选贝特类降脂药。2型糖尿病患者常见混合性高脂血症。单一降脂药大剂量时不良反应增加，为了提高调脂治疗的达标率，往往需不同类别调脂药联合应用。他汀类和贝特类联用：混合性高脂血症经单用他汀类或贝特类未达标者，可考虑两药联合治疗。尽管目前有证据表明两药合理联用是安全的(ACCORD已经证明是安全的)，但除非特别严重的混合性血脂异常，一般应单药治疗；必要时谨慎联合，但剂量应小；两药分开时间服用；他汀类和贝特类联用时，首选非诺贝特。有以下特殊情况者慎用，包括老年、严重肝肾疾病、甲状腺功能减退等，并严密监测和随访，一旦发现异常，及时停药。他汀类和依折麦布联用：单用他汀类调脂药治疗后LDL-C仍未达标者，可考虑他汀类和依折麦布联用。现有证据表明依折麦布和小剂量他汀类联合应用比单独增加他汀类剂量能更好地改善血脂紊乱，且安全性好。",
          "start_idx": 0,
          "end_idx": 431,
          "entities": [
            {
              "entity_id": "T1257",
              "entity": "他汀类药物",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1258",
              "entity": "糖尿病血管疾病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 29,
              "entity_en": "Diabetic vascular disease"
            },
            {
              "entity_id": "T1259",
              "entity": "血管",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "Blood vessel"
            },
            {
              "entity_id": "T1260",
              "entity": "肾功能减退",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Decreased kidney function"
            },
            {
              "entity_id": "T1261",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 34,
              "end_idx": 35,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1262",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 47,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1263",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "oral"
            },
            {
              "entity_id": "T1264",
              "entity": "他汀类药物",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 60,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1265",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 64,
              "entity_en": "TG"
            },
            {
              "entity_id": "T1266",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T1267",
              "entity": "贝特类降脂药",
              "entity_type": "Drug",
              "start_idx": 72,
              "end_idx": 78,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T1268",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 84,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1269",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 79,
              "end_idx": 81,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T1270",
              "entity": "混合性高脂血症",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 95,
              "entity_en": "Combined hyperlipidemia"
            },
            {
              "entity_id": "T1271",
              "entity": "混合性",
              "entity_type": "Class",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "Mixed"
            },
            {
              "entity_id": "T1272",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1273",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 147,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T1274",
              "entity": "混合性高脂血症",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 157,
              "entity_en": "Combined hyperlipidemia"
            },
            {
              "entity_id": "T1275",
              "entity": "混合性",
              "entity_type": "Class",
              "start_idx": 150,
              "end_idx": 153,
              "entity_en": "Mixed"
            },
            {
              "entity_id": "T1276",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 163,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1277",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 167,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T1278",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 223,
              "end_idx": 225,
              "entity_en": "serious"
            },
            {
              "entity_id": "T1279",
              "entity": "混合性血脂异常",
              "entity_type": "Disease",
              "start_idx": 226,
              "end_idx": 233,
              "entity_en": "Mixed dyslipidemia"
            },
            {
              "entity_id": "T1280",
              "entity": "混合性",
              "entity_type": "Class",
              "start_idx": 226,
              "end_idx": 229,
              "entity_en": "Mixed"
            },
            {
              "entity_id": "T1281",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 268,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1282",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 269,
              "end_idx": 272,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T1283",
              "entity": "非诺贝特",
              "entity_type": "Drug",
              "start_idx": 278,
              "end_idx": 282,
              "entity_en": "Fenofibrate"
            },
            {
              "entity_id": "T1284",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 299,
              "end_idx": 301,
              "entity_en": "serious"
            },
            {
              "entity_id": "T1285",
              "entity": "肝肾疾病",
              "entity_type": "Disease",
              "start_idx": 301,
              "end_idx": 305,
              "entity_en": "Liver and kidney diseases"
            },
            {
              "entity_id": "T1286",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 301,
              "end_idx": 302,
              "entity_en": "liver"
            },
            {
              "entity_id": "T1287",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 302,
              "end_idx": 303,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1288",
              "entity": "甲状腺功能减退",
              "entity_type": "Disease",
              "start_idx": 306,
              "end_idx": 313,
              "entity_en": "Hypothyroidism"
            },
            {
              "entity_id": "T1289",
              "entity": "甲状腺",
              "entity_type": "Anatomy",
              "start_idx": 306,
              "end_idx": 309,
              "entity_en": "thyroid"
            },
            {
              "entity_id": "T1290",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 336,
              "end_idx": 339,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1291",
              "entity": "依折麦布",
              "entity_type": "Drug",
              "start_idx": 340,
              "end_idx": 344,
              "entity_en": "Ezetimibe"
            },
            {
              "entity_id": "T1292",
              "entity": "他汀类调脂药",
              "entity_type": "Drug",
              "start_idx": 349,
              "end_idx": 355,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1293",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 358,
              "end_idx": 363,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T1294",
              "entity": "未达标",
              "entity_type": "Test_Value",
              "start_idx": 364,
              "end_idx": 367,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T1295",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 372,
              "end_idx": 375,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1296",
              "entity": "依折麦布",
              "entity_type": "Drug",
              "start_idx": 376,
              "end_idx": 380,
              "entity_en": "Ezetimibe"
            },
            {
              "entity_id": "T1297",
              "entity": "依折麦布",
              "entity_type": "Drug",
              "start_idx": 389,
              "end_idx": 393,
              "entity_en": "Ezetimibe"
            },
            {
              "entity_id": "T1298",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 397,
              "end_idx": 400,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1299",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 409,
              "end_idx": 412,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1300",
              "entity": "血脂紊乱",
              "entity_type": "Disease",
              "start_idx": 420,
              "end_idx": 424,
              "entity_en": "Dyslipidemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R656",
              "head_entity_id": "T1257",
              "tail_entity_id": "T1258"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R657",
              "head_entity_id": "T1259",
              "tail_entity_id": "T1258"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R658",
              "head_entity_id": "T1261",
              "tail_entity_id": "T1260"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R659",
              "head_entity_id": "T1264",
              "tail_entity_id": "T1262"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R660",
              "head_entity_id": "T1265",
              "tail_entity_id": "T1262"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R661",
              "head_entity_id": "T1267",
              "tail_entity_id": "T1262"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R662",
              "head_entity_id": "T1269",
              "tail_entity_id": "T1268"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R663",
              "head_entity_id": "T1271",
              "tail_entity_id": "T1270"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R664",
              "head_entity_id": "T1275",
              "tail_entity_id": "T1274"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R665",
              "head_entity_id": "T1276",
              "tail_entity_id": "T1274"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R666",
              "head_entity_id": "T1277",
              "tail_entity_id": "T1274"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R667",
              "head_entity_id": "T1280",
              "tail_entity_id": "T1279"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R668",
              "head_entity_id": "T1281",
              "tail_entity_id": "T1279"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R669",
              "head_entity_id": "T1282",
              "tail_entity_id": "T1279"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R670",
              "head_entity_id": "T1283",
              "tail_entity_id": "T1279"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R671",
              "head_entity_id": "T1286",
              "tail_entity_id": "T1285"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R672",
              "head_entity_id": "T1287",
              "tail_entity_id": "T1285"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R673",
              "head_entity_id": "T1289",
              "tail_entity_id": "T1288"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R674",
              "head_entity_id": "T1297",
              "tail_entity_id": "T1300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R675",
              "head_entity_id": "T1298",
              "tail_entity_id": "T1300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R676",
              "head_entity_id": "T1299",
              "tail_entity_id": "T1300"
            }
          ],
          "sentence_en": "2. Choice of lipid-lowering drugs: Studies have shown that statins can reduce the incidence of diabetic vascular diseases and renal dysfunction. It is recommended that all diabetic patients should first choose oral statins. When TG is mainly elevated, fibrates can be the first choice. Mixed hyperlipidemia is common in patients with type 2 diabetes. Adverse reactions increase when a single lipid-lowering drug is taken in high doses. In order to improve the target rate of lipid-lowering treatment, different types of lipid-lowering drugs are often used in combination. Combination of statins and fibrates: For patients with mixed hyperlipidemia who have not reached the target after using statins or fibrates alone, the combination of the two drugs can be considered. Although there is evidence that the reasonable combination of the two drugs is safe (ACCORD has proven to be safe), unless the mixed dyslipidemia is particularly severe, it should generally be treated with a single drug; if necessary, it can be combined with caution, but the dose should be small; the two drugs should be taken at different times; when statins and fibrates are used in combination, fenofibrate is the first choice. Use with caution in the following special circumstances, including the elderly, severe liver and kidney diseases, hypothyroidism, etc., and monitor and follow up closely. Once abnormalities are found, stop the drug in time. Combination of statins and ezetimibe: For patients whose LDL-C level is still not up to standard after treatment with statins alone, combination of statins and ezetimibe may be considered. Existing evidence shows that the combination of ezetimibe and low-dose statins can better improve dyslipidemia than increasing the statin dose alone, and it is safer."
        }
      ],
      "paragraph_en": "2. Choice of lipid-lowering drugs: Studies have shown that statins can reduce the incidence of diabetic vascular diseases and renal dysfunction. It is recommended that all diabetic patients should first choose oral statins. When TG is mainly elevated, fibrates can be the first choice. Mixed hyperlipidemia is common in patients with type 2 diabetes. Adverse reactions increase when a single lipid-lowering drug is taken in high doses. In order to improve the target rate of lipid-lowering treatment, different types of lipid-lowering drugs are often used in combination. Combination of statins and fibrates: For patients with mixed hyperlipidemia who have not reached the target after using statins or fibrates alone, the combination of the two drugs can be considered. Although there is evidence that the reasonable combination of the two drugs is safe (ACCORD has proven to be safe), unless the mixed dyslipidemia is particularly severe, it should generally be treated with a single drug; if necessary, it can be combined with caution, but the dose should be small; the two drugs should be taken at different times; when statins and fibrates are used in combination, fenofibrate is the first choice. Use with caution in the following special circumstances, including the elderly, severe liver and kidney diseases, hypothyroidism, etc., and monitor and follow up closely. Once abnormalities are found, stop the drug in time. Combination of statins and ezetimibe: For patients whose LDL-C level is still not up to standard after treatment with statins alone, combination of statins and ezetimibe may be considered. Existing evidence shows that the combination of ezetimibe and low-dose statins can better improve dyslipidemia than increasing the statin dose alone, and it is safer."
    },
    {
      "paragraph_id": "58",
      "paragraph": "(1)三羟基三甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类)：抑制细胞内胆固醇合成早期阶段的限速酶即HMG-CoA还原酶，造成细胞内游离胆固醇减少，并通过反馈性上调细胞表面LDL受体的表达，因而使细胞LDL-C受体数目增多及活性增强，加速了循环极低密度脂蛋白(VLDL)残粒[或中间密度脂蛋白(IDL)]和LDL-C的清除。轻至中度肾功能患者无需调整辛伐他汀、氟伐他汀等他汀类的药物用量，但在重度肾功能不全(如Ccr<30ml/min)时需减量或禁用。肾脏疾病不影响阿托伐他汀的血浆浓度和其降低LDL-C的效果，故肾功能不全患者均无需调整其用药剂量，同时，由于阿托伐他汀与血浆蛋白的广泛结合，血液透析并不能显著提高其清除率，但目前由于缺乏其在透析患者中的用药经验，故仍需谨慎用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)三羟基三甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类)：抑制细胞内胆固醇合成早期阶段的限速酶即HMG-CoA还原酶，造成细胞内游离胆固醇减少，并通过反馈性上调细胞表面LDL受体的表达，因而使细胞LDL-C受体数目增多及活性增强，加速了循环极低密度脂蛋白(VLDL)残粒[或中间密度脂蛋白(IDL)]和LDL-C的清除。轻至中度肾功能患者无需调整辛伐他汀、氟伐他汀等他汀类的药物用量，但在重度肾功能不全(如Ccr<30ml/min)时需减量或禁用。肾脏疾病不影响阿托伐他汀的血浆浓度和其降低LDL-C的效果，故肾功能不全患者均无需调整其用药剂量，同时，由于阿托伐他汀与血浆蛋白的广泛结合，血液透析并不能显著提高其清除率，但目前由于缺乏其在透析患者中的用药经验，故仍需谨慎用药。",
          "start_idx": 0,
          "end_idx": 345,
          "entities": [
            {
              "entity_id": "T1301",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 262,
              "end_idx": 267,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1302",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 262,
              "end_idx": 263,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1303",
              "entity": "阿托伐他汀",
              "entity_type": "Drug",
              "start_idx": 285,
              "end_idx": 290,
              "entity_en": "Atorvastatin"
            },
            {
              "entity_id": "T1304",
              "entity": "血浆蛋白",
              "entity_type": "Test_items",
              "start_idx": 291,
              "end_idx": 295,
              "entity_en": "Plasma proteins"
            },
            {
              "entity_id": "T1305",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 301,
              "end_idx": 305,
              "entity_en": "Hemodialysis"
            },
            {
              "entity_id": "T1306",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 326,
              "end_idx": 328,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T1307",
              "entity": "三羟基三甲基戊二酰辅酶A(HMG-CoA)",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 24,
              "entity_en": "HMG-CoA"
            },
            {
              "entity_id": "T1308",
              "entity": "还原酶抑制剂(他汀类)",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 35,
              "entity_en": "Reductase inhibitors (statins)"
            },
            {
              "entity_id": "T1309",
              "entity": "游离胆固醇",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 76,
              "entity_en": "Free cholesterol"
            },
            {
              "entity_id": "T1310",
              "entity": "减少",
              "entity_type": "Test_Value",
              "start_idx": 76,
              "end_idx": 78,
              "entity_en": "reduce"
            },
            {
              "entity_id": "T1311",
              "entity": "极低密度脂蛋白(VLDL)",
              "entity_type": "Test_items",
              "start_idx": 127,
              "end_idx": 140,
              "entity_en": "Very low density lipoprotein (VLDL)"
            },
            {
              "entity_id": "T1312",
              "entity": "中间密度脂蛋白(IDL)",
              "entity_type": "Test_items",
              "start_idx": 144,
              "end_idx": 156,
              "entity_en": "Intermediate density lipoprotein (IDL)"
            },
            {
              "entity_id": "T1313",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T1314",
              "entity": "轻至中度",
              "entity_type": "Test_Value",
              "start_idx": 167,
              "end_idx": 171,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T1315",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 171,
              "end_idx": 174,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T1316",
              "entity": "辛伐他汀",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 184,
              "entity_en": "Simvastatin"
            },
            {
              "entity_id": "T1317",
              "entity": "氟伐他汀",
              "entity_type": "Drug",
              "start_idx": 185,
              "end_idx": 189,
              "entity_en": "Fluvastatin"
            },
            {
              "entity_id": "T1318",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 193,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T1319",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 208,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1320",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 203,
              "end_idx": 204,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1321",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 201,
              "end_idx": 203,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T1322",
              "entity": "Ccr",
              "entity_type": "Test_items",
              "start_idx": 210,
              "end_idx": 213,
              "entity_en": "Ccr"
            },
            {
              "entity_id": "T1323",
              "entity": "<30ml/min",
              "entity_type": "Test_Value",
              "start_idx": 213,
              "end_idx": 222,
              "entity_en": "<30ml/min"
            },
            {
              "entity_id": "T1324",
              "entity": "肾脏疾病",
              "entity_type": "Disease",
              "start_idx": 231,
              "end_idx": 235,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T1325",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 231,
              "end_idx": 233,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1326",
              "entity": "阿托伐他汀",
              "entity_type": "Drug",
              "start_idx": 238,
              "end_idx": 243,
              "entity_en": "Atorvastatin"
            },
            {
              "entity_id": "T1327",
              "entity": "血浆浓度",
              "entity_type": "Test_items",
              "start_idx": 244,
              "end_idx": 248,
              "entity_en": "Plasma concentration"
            },
            {
              "entity_id": "T1328",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 252,
              "end_idx": 257,
              "entity_en": "LDL-C"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R677",
              "head_entity_id": "T1302",
              "tail_entity_id": "T1301"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R678",
              "head_entity_id": "T1303",
              "tail_entity_id": "T1301"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R679",
              "head_entity_id": "T1304",
              "tail_entity_id": "T1301"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R680",
              "head_entity_id": "T1305",
              "tail_entity_id": "T1301"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R681",
              "head_entity_id": "T1306",
              "tail_entity_id": "T1301"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R682",
              "head_entity_id": "T1315",
              "tail_entity_id": "T1319"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R683",
              "head_entity_id": "T1316",
              "tail_entity_id": "T1319"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R684",
              "head_entity_id": "T1317",
              "tail_entity_id": "T1319"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R685",
              "head_entity_id": "T1318",
              "tail_entity_id": "T1319"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R686",
              "head_entity_id": "T1322",
              "tail_entity_id": "T1319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R687",
              "head_entity_id": "T1320",
              "tail_entity_id": "T1319"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R688",
              "head_entity_id": "T1325",
              "tail_entity_id": "T1324"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R689",
              "head_entity_id": "T1326",
              "tail_entity_id": "T1324"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R690",
              "head_entity_id": "T1327",
              "tail_entity_id": "T1324"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R691",
              "head_entity_id": "T1328",
              "tail_entity_id": "T1324"
            }
          ],
          "sentence_en": "(1) Trihydroxytrimethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins): inhibit HMG-CoA reductase, the rate-limiting enzyme in the early stages of intracellular cholesterol synthesis, resulting in a reduction in intracellular free cholesterol, and by feedback upregulating the expression of LDL receptors on the cell surface, thereby increasing the number and activity of cellular LDL-C receptors, accelerating the clearance of circulating very low-density lipoprotein (VLDL) remnants [or intermediate-density lipoprotein (IDL)] and LDL-C. Patients with mild to moderate renal function do not need to adjust the dosage of statins such as simvastatin and fluvastatin, but they need to be reduced or disabled in severe renal insufficiency (such as Ccr <30ml/min). Kidney disease does not affect the plasma concentration of atorvastatin and its effect on lowering LDL-C, so there is no need to adjust the dosage of atorvastatin for patients with renal insufficiency. At the same time, due to the extensive binding of atorvastatin to plasma proteins, hemodialysis cannot significantly increase its clearance rate. However, due to the lack of experience in its use in dialysis patients, it still needs to be used with caution."
        }
      ],
      "paragraph_en": "(1) Trihydroxytrimethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins): inhibit HMG-CoA reductase, the rate-limiting enzyme in the early stages of intracellular cholesterol synthesis, resulting in a reduction in intracellular free cholesterol, and by feedback upregulating the expression of LDL receptors on the cell surface, thereby increasing the number and activity of cellular LDL-C receptors, accelerating the clearance of circulating very low-density lipoprotein (VLDL) remnants [or intermediate-density lipoprotein (IDL)] and LDL-C. Patients with mild to moderate renal function do not need to adjust the dosage of statins such as simvastatin and fluvastatin, but they need to be reduced or disabled in severe renal insufficiency (such as Ccr <30ml/min). Kidney disease does not affect the plasma concentration of atorvastatin and its effect on lowering LDL-C, so there is no need to adjust the dosage of atorvastatin for patients with renal insufficiency. At the same time, due to the extensive binding of atorvastatin to plasma proteins, hemodialysis cannot significantly increase its clearance rate. However, due to the lack of experience in its use in dialysis patients, it still needs to be used with caution."
    },
    {
      "paragraph_id": "59",
      "paragraph": "(2)胆汁酸螯合剂：包括考来烯胺、考来替泊，主要为碱性阴离子交换树脂，在肠道内能与胆酸呈不可逆结合，因而阻断胆酸的肠肝循环，促进胆酸随大便排出体外，阻断胆汁酸中胆固醇的重吸收，能降低血总胆固醇(TC)及LDL-C水平，但对TG无降低作用。胆汁酸螯合剂在此肠道内不吸收，不参与肾脏代谢。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)胆汁酸螯合剂：包括考来烯胺、考来替泊，主要为碱性阴离子交换树脂，在肠道内能与胆酸呈不可逆结合，因而阻断胆酸的肠肝循环，促进胆酸随大便排出体外，阻断胆汁酸中胆固醇的重吸收，能降低血总胆固醇(TC)及LDL-C水平，但对TG无降低作用。",
          "start_idx": 0,
          "end_idx": 119,
          "entities": [
            {
              "entity_id": "T1329",
              "entity": "胆汁酸螯合剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Bile acid sequestrants"
            },
            {
              "entity_id": "T1330",
              "entity": "考来烯胺",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Cholestyramine"
            },
            {
              "entity_id": "T1331",
              "entity": "考来替泊",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Colestipol"
            },
            {
              "entity_id": "T1332",
              "entity": "总胆固醇(TC)",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 100,
              "entity_en": "Total cholesterol (TC)"
            },
            {
              "entity_id": "T1333",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 106,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T1334",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 111,
              "end_idx": 113,
              "entity_en": "TG"
            }
          ],
          "relations": [],
          "sentence_en": "(2) Bile acid sequestrants: including cholestyramine and colestipol, which are mainly alkaline anion exchange resins that can irreversibly bind to bile acid in the intestine, thereby blocking the enterohepatic circulation of bile acid, promoting the excretion of bile acid with feces, blocking the reabsorption of cholesterol in bile acid, and can lower blood total cholesterol (TC) and LDL-C levels, but have no effect on lowering TG."
        },
        {
          "sentence_id": "1",
          "sentence": "胆汁酸螯合剂在此肠道内不吸收，不参与肾脏代谢。",
          "start_idx": 119,
          "end_idx": 142,
          "entities": [
            {
              "entity_id": "T1335",
              "entity": "胆汁酸螯合剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Bile acid sequestrants"
            }
          ],
          "relations": [],
          "sentence_en": "Bile acid sequestrants are not absorbed in the intestine and are not metabolized by the kidneys."
        }
      ],
      "paragraph_en": "(2) Bile acid sequestrants: including cholestyramine and colestipol, which are mainly alkaline anion exchange resins that can irreversibly bind to bile acid in the intestine, thereby blocking the enterohepatic circulation of bile acid, promoting the excretion of bile acid with stool, blocking the reabsorption of cholesterol in bile acid, and can reduce blood total cholesterol (TC) and LDL-C levels, but have no effect on reducing TG. Bile acid sequestrants are not absorbed in the intestine and do not participate in renal metabolism."
    },
    {
      "paragraph_id": "60",
      "paragraph": "(3)烟酸：烟酸的降脂作用机制尚不明确，可能与抑制脂肪组织中的脂解和减少肝脏中VLDL合成和分泌有关，此外，烟酸还具有促进脂蛋白酶的活性，加速脂蛋白中TG的水解的作用，因而其降低TG的作用明显。但烟酸可导致糖代谢异常或糖耐量恶化，一般不推荐在糖尿病患者中使用，若必须使用，应该定期监测血糖水平。烟酸和阿昔莫司在。肾功能减退患者中应用证据有限，应谨慎或减量使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)烟酸：烟酸的降脂作用机制尚不明确，可能与抑制脂肪组织中的脂解和减少肝脏中VLDL合成和分泌有关，此外，烟酸还具有促进脂蛋白酶的活性，加速脂蛋白中TG的水解的作用，因而其降低TG的作用明显。但烟酸可导致糖代谢异常或糖耐量恶化，一般不推荐在糖尿病患者中使用，若必须使用，应该定期监测血糖水平。烟酸和阿昔莫司在。肾功能减退患者中应用证据有限，应谨慎或减量使用。",
          "start_idx": 0,
          "end_idx": 180,
          "entities": [
            {
              "entity_id": "T1336",
              "entity": "烟酸",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "niacin"
            },
            {
              "entity_id": "T1337",
              "entity": "烟酸",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "niacin"
            },
            {
              "entity_id": "T1338",
              "entity": "VLDL",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "VLDL"
            },
            {
              "entity_id": "T1339",
              "entity": "烟酸",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "niacin"
            },
            {
              "entity_id": "T1340",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "TG"
            },
            {
              "entity_id": "T1341",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 89,
              "end_idx": 91,
              "entity_en": "TG"
            },
            {
              "entity_id": "T1342",
              "entity": "烟酸",
              "entity_type": "Drug",
              "start_idx": 98,
              "end_idx": 100,
              "entity_en": "niacin"
            },
            {
              "entity_id": "T1343",
              "entity": "糖代谢异常",
              "entity_type": "ADE",
              "start_idx": 103,
              "end_idx": 108,
              "entity_en": "Abnormal glucose metabolism"
            },
            {
              "entity_id": "T1344",
              "entity": "糖耐量恶化",
              "entity_type": "ADE",
              "start_idx": 109,
              "end_idx": 114,
              "entity_en": "Worsening of glucose tolerance"
            },
            {
              "entity_id": "T1345",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1346",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T1347",
              "entity": "烟酸",
              "entity_type": "Drug",
              "start_idx": 147,
              "end_idx": 149,
              "entity_en": "niacin"
            },
            {
              "entity_id": "T1348",
              "entity": "阿昔莫司在",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 155,
              "entity_en": "Acipimox"
            },
            {
              "entity_id": "T1349",
              "entity": "肾功能减退",
              "entity_type": "Disease",
              "start_idx": 156,
              "end_idx": 161,
              "entity_en": "Decreased kidney function"
            },
            {
              "entity_id": "T1350",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 156,
              "end_idx": 157,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R692",
              "head_entity_id": "T1342",
              "tail_entity_id": "T1345"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R693",
              "head_entity_id": "T1343",
              "tail_entity_id": "T1342"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R694",
              "head_entity_id": "T1344",
              "tail_entity_id": "T1342"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R695",
              "head_entity_id": "T1346",
              "tail_entity_id": "T1345"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R696",
              "head_entity_id": "T1350",
              "tail_entity_id": "T1349"
            }
          ],
          "sentence_en": "(3) Niacin: The lipid-lowering mechanism of niacin is still unclear. It may be related to inhibiting lipolysis in adipose tissue and reducing VLDL synthesis and secretion in the liver. In addition, niacin can promote the activity of lipase and accelerate the hydrolysis of TG in lipoproteins, so its effect of reducing TG is obvious. However, niacin can cause abnormal glucose metabolism or worsen glucose tolerance. It is generally not recommended for use in diabetic patients. If it must be used, blood sugar levels should be monitored regularly. There is limited evidence for the use of niacin and acipimox in patients with renal impairment, so they should be used with caution or in reduced doses."
        }
      ],
      "paragraph_en": "(3) Niacin: The lipid-lowering mechanism of niacin is still unclear. It may be related to inhibiting lipolysis in adipose tissue and reducing VLDL synthesis and secretion in the liver. In addition, niacin can promote the activity of lipase and accelerate the hydrolysis of TG in lipoproteins, so its effect of reducing TG is obvious. However, niacin can cause abnormal glucose metabolism or worsen glucose tolerance. It is generally not recommended for use in diabetic patients. If it must be used, blood sugar levels should be monitored regularly. There is limited evidence for the use of niacin and acipimox in patients with renal impairment, so they should be used with caution or in reduced doses."
    },
    {
      "paragraph_id": "61",
      "paragraph": "(4)苯氧芳酸类：能增强脂蛋白酯酶的活性，加速VLDL分解代谢，并能抑制肝脏中VLDL的合成与分泌，可降低TG22%~43%、TC6%~15%，并有不同程度升高高密度脂蛋白胆固醇(HDL-C)的作用。有证据显示贝特类药物将会升高增加心血管事件风险的血清肌酐和同源半胱氨酸(Hcy)水平。肾功能减退的糖尿病患者应根据其GFR水平减少非诺贝特、吉非贝齐及苯扎贝特等贝特类药物，并在严重的肾功能不全患者中禁用。如非诺贝特不能用于透析，且当GFR<50ml·min-1·1.73m-2时禁用。当患者的GFR<60ml·min-1·1.73m-2时应将吉非贝齐的用量减至600mg/d，GFR<15ml·min-1·1.73m-2时禁用吉非贝齐。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)苯氧芳酸类：能增强脂蛋白酯酶的活性，加速VLDL分解代谢，并能抑制肝脏中VLDL的合成与分泌，可降低TG22%~43%、TC6%~15%，并有不同程度升高高密度脂蛋白胆固醇(HDL-C)的作用。有证据显示贝特类药物将会升高增加心血管事件风险的血清肌酐和同源半胱氨酸(Hcy)水平。肾功能减退的糖尿病患者应根据其GFR水平减少非诺贝特、吉非贝齐及苯扎贝特等贝特类药物，并在严重的肾功能不全患者中禁用。",
          "start_idx": 0,
          "end_idx": 202,
          "entities": [
            {
              "entity_id": "T1351",
              "entity": "苯氧芳酸类",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Phenoxy aromatic acids"
            },
            {
              "entity_id": "T1352",
              "entity": "VLDL",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "VLDL"
            },
            {
              "entity_id": "T1353",
              "entity": "VLDL",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "VLDL"
            },
            {
              "entity_id": "T1354",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "TG"
            },
            {
              "entity_id": "T1355",
              "entity": "22%~43%",
              "entity_type": "Test_Value",
              "start_idx": 55,
              "end_idx": 62,
              "entity_en": "22%~43%"
            },
            {
              "entity_id": "T1356",
              "entity": "TC",
              "entity_type": "Test_items",
              "start_idx": 63,
              "end_idx": 65,
              "entity_en": "TC"
            },
            {
              "entity_id": "T1357",
              "entity": "6%~15%",
              "entity_type": "Test_Value",
              "start_idx": 65,
              "end_idx": 71,
              "entity_en": "6%~15%"
            },
            {
              "entity_id": "T1358",
              "entity": "高密度脂蛋白胆固醇(HDL-C)",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 96,
              "entity_en": "High-density lipoprotein cholesterol (HDL-C)"
            },
            {
              "entity_id": "T1359",
              "entity": "贝特类药物",
              "entity_type": "Drug",
              "start_idx": 105,
              "end_idx": 110,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T1360",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 116,
              "end_idx": 121,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T1361",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 116,
              "end_idx": 119,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T1362",
              "entity": "血清肌酐",
              "entity_type": "Test_items",
              "start_idx": 124,
              "end_idx": 128,
              "entity_en": "Serum creatinine"
            },
            {
              "entity_id": "T1363",
              "entity": "同源半胱氨酸(Hcy)",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 140,
              "entity_en": "Homocysteine (Hcy)"
            },
            {
              "entity_id": "T1364",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 143,
              "end_idx": 146,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T1365",
              "entity": "减退",
              "entity_type": "Test_Value",
              "start_idx": 146,
              "end_idx": 148,
              "entity_en": "Decline"
            },
            {
              "entity_id": "T1366",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 149,
              "end_idx": 152,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1367",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 158,
              "end_idx": 161,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1368",
              "entity": "非诺贝特",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 169,
              "entity_en": "Fenofibrate"
            },
            {
              "entity_id": "T1369",
              "entity": "吉非贝齐",
              "entity_type": "Drug",
              "start_idx": 170,
              "end_idx": 174,
              "entity_en": "Gemfibrozil"
            },
            {
              "entity_id": "T1370",
              "entity": "苯扎贝特",
              "entity_type": "Drug",
              "start_idx": 175,
              "end_idx": 179,
              "entity_en": "Bezafibrate"
            },
            {
              "entity_id": "T1371",
              "entity": "贝特类药物",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 185,
              "entity_en": "Fibrates"
            },
            {
              "entity_id": "T1372",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 188,
              "end_idx": 190,
              "entity_en": "serious"
            },
            {
              "entity_id": "T1373",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 191,
              "end_idx": 196,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1374",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 191,
              "end_idx": 192,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R697",
              "head_entity_id": "T1359",
              "tail_entity_id": "T1360"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R698",
              "head_entity_id": "T1361",
              "tail_entity_id": "T1360"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R699",
              "head_entity_id": "T1362",
              "tail_entity_id": "T1360"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R700",
              "head_entity_id": "T1363",
              "tail_entity_id": "T1360"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R701",
              "head_entity_id": "T1364",
              "tail_entity_id": "T1366"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R702",
              "head_entity_id": "T1367",
              "tail_entity_id": "T1366"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R703",
              "head_entity_id": "T1368",
              "tail_entity_id": "T1366"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R704",
              "head_entity_id": "T1369",
              "tail_entity_id": "T1366"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R705",
              "head_entity_id": "T1370",
              "tail_entity_id": "T1366"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R706",
              "head_entity_id": "T1371",
              "tail_entity_id": "T1366"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R707",
              "head_entity_id": "T1374",
              "tail_entity_id": "T1373"
            }
          ],
          "sentence_en": "(4) Phenoxyaromatic acids: They can enhance the activity of lipoprotein esterase, accelerate the catabolism of VLDL, and inhibit the synthesis and secretion of VLDL in the liver. They can reduce TG by 22%~43% and TC by 6%~15%, and increase high-density lipoprotein cholesterol (HDL-C) to varying degrees. There is evidence that fibrates will increase serum creatinine and homocysteine (Hcy) levels, which increase the risk of cardiovascular events. Diabetic patients with impaired renal function should reduce the use of fibrates such as fenofibrate, gemfibrozil and bezafibrate according to their GFR levels, and they are prohibited in patients with severe renal insufficiency."
        },
        {
          "sentence_id": "1",
          "sentence": "如非诺贝特不能用于透析，且当GFR<50ml·min-1·1.73m-2时禁用。",
          "start_idx": 202,
          "end_idx": 242,
          "entities": [
            {
              "entity_id": "T1375",
              "entity": "非诺贝特",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Fenofibrate"
            },
            {
              "entity_id": "T1376",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T1377",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1378",
              "entity": "<50ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 17,
              "end_idx": 36,
              "entity_en": "<50ml·min-1·1.73m-2"
            }
          ],
          "relations": [],
          "sentence_en": "For example, fenofibrate cannot be used for dialysis and is contraindicated when GFR is <50ml·min-1·1.73m-2."
        },
        {
          "sentence_id": "2",
          "sentence": "当患者的GFR<60ml·min-1·1.73m-2时应将吉非贝齐的用量减至600mg/d，GFR<15ml·min-1·1.73m-2时禁用吉非贝齐。",
          "start_idx": 242,
          "end_idx": 318,
          "entities": [
            {
              "entity_id": "T1379",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1380",
              "entity": "<60ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 7,
              "end_idx": 26,
              "entity_en": "<60ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T1381",
              "entity": "吉非贝齐",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33,
              "entity_en": "Gemfibrozil"
            },
            {
              "entity_id": "T1382",
              "entity": "600mg/d",
              "entity_type": "Amount",
              "start_idx": 38,
              "end_idx": 45,
              "entity_en": "600 mg/day"
            },
            {
              "entity_id": "T1383",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1384",
              "entity": "<15ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 49,
              "end_idx": 68,
              "entity_en": "<15ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T1385",
              "entity": "吉非贝齐",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "Gemfibrozil"
            }
          ],
          "relations": [],
          "sentence_en": "When the patient's GFR is <60ml·min-1·1.73m-2, the dosage of gemfibrozil should be reduced to 600mg/d, and gemfibrozil is contraindicated when GFR is <15ml·min-1·1.73m-2."
        }
      ],
      "paragraph_en": "(4) Phenoxyaromatic acids: They can enhance the activity of lipoprotein esterase, accelerate the degradation of VLDL, inhibit the synthesis and secretion of VLDL in the liver, reduce TG by 22%~43%, TC by 6%~15%, and increase high-density lipoprotein cholesterol (HDL-C) to varying degrees. There is evidence that fibrates will increase serum creatinine and homocysteine (Hcy) levels, which increase the risk of cardiovascular events. Diabetic patients with impaired renal function should reduce the use of fibrates such as fenofibrate, gemfibrozil and bezafibrate according to their GFR levels, and they are contraindicated in patients with severe renal insufficiency. For example, fenofibrate cannot be used for dialysis and is contraindicated when GFR is <50ml·min-1·1.73m-2. When the patient's GFR is <60ml·min-1·1.73m-2, the dose of gemfibrozil should be reduced to 600mg/d, and gemfibrozil should be contraindicated when GFR is <15ml·min-1·1.73m-2."
    },
    {
      "paragraph_id": "62",
      "paragraph": "(5)胆固醇吸收抑制剂：依折麦布附着于小肠绒毛刷状缘，抑制胆固醇的吸收，从而降低小肠中的胆固醇向肝脏中的转运，使得肝脏胆固醇贮量降低从而增加血液中胆固醇的清除。本品不增加胆汁分泌(如胆酸螯合剂)，也不抑制胆固醇在肝脏中的合成(如他汀类)。依折麦布在不同肾功能水平下均无需调整剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)胆固醇吸收抑制剂：依折麦布附着于小肠绒毛刷状缘，抑制胆固醇的吸收，从而降低小肠中的胆固醇向肝脏中的转运，使得肝脏胆固醇贮量降低从而增加血液中胆固醇的清除。",
          "start_idx": 0,
          "end_idx": 80,
          "entities": [
            {
              "entity_id": "T1386",
              "entity": "固醇吸收抑制剂",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 11,
              "entity_en": "Steroid Absorption Inhibitors"
            },
            {
              "entity_id": "T1387",
              "entity": "依折麦布",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Ezetimibe"
            }
          ],
          "relations": [],
          "sentence_en": "(5) Cholesterol absorption inhibitor: Ezetimibe adheres to the brush border of the small intestinal villi, inhibiting the absorption of cholesterol, thereby reducing the transport of cholesterol in the small intestine to the liver, reducing the cholesterol storage in the liver and increasing the clearance of cholesterol in the blood."
        },
        {
          "sentence_id": "1",
          "sentence": "本品不增加胆汁分泌(如胆酸螯合剂)，也不抑制胆固醇在肝脏中的合成(如他汀类)。",
          "start_idx": 80,
          "end_idx": 119,
          "entities": [
            {
              "entity_id": "T1388",
              "entity": "胆酸螯合剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Bile acid sequestrants"
            },
            {
              "entity_id": "T1389",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "Statins"
            }
          ],
          "relations": [],
          "sentence_en": "This product does not increase bile secretion (like bile acid sequestrants) nor inhibit cholesterol synthesis in the liver (like statins)."
        },
        {
          "sentence_id": "2",
          "sentence": "依折麦布在不同肾功能水平下均无需调整剂量。",
          "start_idx": 119,
          "end_idx": 140,
          "entities": [
            {
              "entity_id": "T1390",
              "entity": "依折麦布",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Ezetimibe"
            },
            {
              "entity_id": "T1391",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "Renal function"
            }
          ],
          "relations": [],
          "sentence_en": "No dose adjustment is required for ezetimibe at different levels of renal function."
        }
      ],
      "paragraph_en": "(5) Cholesterol absorption inhibitor: Ezetimibe adheres to the brush border of the small intestine villi, inhibiting the absorption of cholesterol, thereby reducing the transport of cholesterol from the small intestine to the liver, reducing the cholesterol storage in the liver and increasing the clearance of cholesterol in the blood. This product does not increase bile secretion (such as bile acid sequestrants) nor inhibit the synthesis of cholesterol in the liver (such as statins). Ezetimibe does not require dosage adjustment at different levels of renal function."
    },
    {
      "paragraph_id": "63",
      "paragraph": "(五)肾脏替代治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(五)肾脏替代治疗",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "5. Renal replacement therapy"
        }
      ],
      "paragraph_en": "5. Renal replacement therapy"
    },
    {
      "paragraph_id": "64",
      "paragraph": "GFR低于15ml·min-1·1.73m-2的糖尿病肾病患者在条件允许的情况下可选择肾脏替代治疗，包括血液透析、腹膜透析和肾脏移植等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GFR低于15ml·min-1·1.73m-2的糖尿病肾病患者在条件允许的情况下可选择肾脏替代治疗，包括血液透析、腹膜透析和肾脏移植等。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T1392",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T1393",
              "entity": "低于15ml·min-1·1.73m-2",
              "entity_type": "Test_Value",
              "start_idx": 3,
              "end_idx": 23,
              "entity_en": "Less than 15ml·min-1·1.73m-2"
            },
            {
              "entity_id": "T1394",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1395",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 27,
              "end_idx": 28,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1396",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Hemodialysis"
            },
            {
              "entity_id": "T1397",
              "entity": "腹膜透析",
              "entity_type": "Treatment",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Peritoneal dialysis"
            },
            {
              "entity_id": "T1398",
              "entity": "肾脏移植",
              "entity_type": "Operation",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Kidney transplant"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R708",
              "head_entity_id": "T1392",
              "tail_entity_id": "T1394"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R709",
              "head_entity_id": "T1395",
              "tail_entity_id": "T1394"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R710",
              "head_entity_id": "T1396",
              "tail_entity_id": "T1394"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R711",
              "head_entity_id": "T1397",
              "tail_entity_id": "T1394"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R712",
              "head_entity_id": "T1398",
              "tail_entity_id": "T1394"
            }
          ],
          "sentence_en": "Patients with diabetic nephropathy whose GFR is lower than 15 ml·min-1·1.73 m-2 can choose renal replacement therapy, including hemodialysis, peritoneal dialysis and kidney transplantation, if conditions permit."
        }
      ],
      "paragraph_en": "Patients with diabetic nephropathy whose GFR is lower than 15 ml·min-1·1.73 m-2 can choose renal replacement therapy, including hemodialysis, peritoneal dialysis and kidney transplantation, if conditions permit."
    },
    {
      "paragraph_id": "65",
      "paragraph": "(六)其他治疗药物应用、研制及展望",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(六)其他治疗药物应用、研制及展望",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": [],
          "sentence_en": "(VI) Application, development and prospects of other therapeutic drugs"
        }
      ],
      "paragraph_en": "(VI) Application, development and prospects of other therapeutic drugs"
    },
    {
      "paragraph_id": "66",
      "paragraph": "1.微循环扩张剂：(1)胰激肽原酶肠溶片(怡开)：有改善微循环作用。主要用于微循环障碍性疾病，如糖尿病引起的肾病、周围神经病、视网膜病。脑出血及其他出血性疾病的急性期禁用。(2)羟苯磺酸钙(导升明)可用于糖尿病性微血管病变：视网膜病及肾小球硬化症(基·威氏综合征)，严重肾功能不全需透析的患者应减量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.微循环扩张剂：(1)胰激肽原酶肠溶片(怡开)：有改善微循环作用。主要用于微循环障碍性疾病，如糖尿病引起的肾病、周围神经病、视网膜病。脑出血及其他出血性疾病的急性期禁用。(2)羟苯磺酸钙(导升明)可用于糖尿病性微血管病变：视网膜病及肾小球硬化症(基·威氏综合征)，严重肾功能不全需透析的患者应减量。",
          "start_idx": 0,
          "end_idx": 150,
          "entities": [
            {
              "entity_id": "T1399",
              "entity": "微循环扩张剂",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "Microcirculatory dilators"
            },
            {
              "entity_id": "T1400",
              "entity": "胰激肽原酶肠溶片(怡开)",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 24,
              "entity_en": "Kallikrein enteric-coated tablets (Yikai)"
            },
            {
              "entity_id": "T1401",
              "entity": "微循环障碍性疾病",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 46,
              "entity_en": "Microcirculatory disorders"
            },
            {
              "entity_id": "T1402",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1403",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T1404",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 54,
              "end_idx": 55,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1405",
              "entity": "周围神经病",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Peripheral neuropathy"
            },
            {
              "entity_id": "T1406",
              "entity": "周围神经",
              "entity_type": "Anatomy",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Peripheral nerves"
            },
            {
              "entity_id": "T1407",
              "entity": "视网膜病",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 67,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T1408",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 63,
              "end_idx": 66,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T1409",
              "entity": "脑出血",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 71,
              "entity_en": "Cerebral hemorrhage"
            },
            {
              "entity_id": "T1410",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 68,
              "end_idx": 69,
              "entity_en": "brain"
            },
            {
              "entity_id": "T1411",
              "entity": "出血性疾病",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "Bleeding disorders"
            },
            {
              "entity_id": "T1412",
              "entity": "羟苯磺酸钙(导升明)",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 99,
              "entity_en": "Calcium dobesilate (Dosingmin)"
            },
            {
              "entity_id": "T1413",
              "entity": "糖尿病性微血管病变",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 111,
              "entity_en": "Diabetic microangiopathy"
            },
            {
              "entity_id": "T1414",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 109,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T1415",
              "entity": "视网膜病",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Retinopathy"
            },
            {
              "entity_id": "T1416",
              "entity": "视网膜",
              "entity_type": "Anatomy",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "Retina"
            },
            {
              "entity_id": "T1417",
              "entity": "肾小球硬化症(基·威氏综合征)",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 132,
              "entity_en": "Glomerulosclerosis (Kelly-Willi syndrome)"
            },
            {
              "entity_id": "T1418",
              "entity": "肾小球",
              "entity_type": "Anatomy",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "Glomerulus"
            },
            {
              "entity_id": "T1419",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 140,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T1420",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 133,
              "end_idx": 135,
              "entity_en": "serious"
            },
            {
              "entity_id": "T1421",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 135,
              "end_idx": 136,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1422",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 141,
              "end_idx": 143,
              "entity_en": "Dialysis"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R713",
              "head_entity_id": "T1404",
              "tail_entity_id": "T1403"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R714",
              "head_entity_id": "T1406",
              "tail_entity_id": "T1405"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R715",
              "head_entity_id": "T1408",
              "tail_entity_id": "T1407"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R716",
              "head_entity_id": "T1410",
              "tail_entity_id": "T1409"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R717",
              "head_entity_id": "T1412",
              "tail_entity_id": "T1413"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R718",
              "head_entity_id": "T1414",
              "tail_entity_id": "T1413"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R719",
              "head_entity_id": "T1416",
              "tail_entity_id": "T1415"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R720",
              "head_entity_id": "T1418",
              "tail_entity_id": "T1417"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R721",
              "head_entity_id": "T1421",
              "tail_entity_id": "T1419"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R722",
              "head_entity_id": "T1422",
              "tail_entity_id": "T1419"
            }
          ],
          "sentence_en": "1. Microcirculatory dilators: (1) Kallikrein enteric-coated tablets (Yikai): Improves microcirculation. Mainly used for microcirculatory disorders, such as diabetic nephropathy, peripheral neuropathy, and retinopathy. Contraindicated in the acute phase of cerebral hemorrhage and other hemorrhagic diseases. (2) Calcium dobesilate (Dushengming) can be used for diabetic microangiopathy: retinopathy and glomerulosclerosis (K-W syndrome). Patients with severe renal insufficiency who require dialysis should reduce the dose."
        }
      ],
      "paragraph_en": "1. Microcirculatory dilators: (1) Kallikrein enteric-coated tablets (Yikai): Improves microcirculation. Mainly used for microcirculatory disorders, such as diabetic nephropathy, peripheral neuropathy, and retinopathy. Contraindicated in the acute phase of cerebral hemorrhage and other hemorrhagic diseases. (2) Calcium dobesilate (Dushengming) can be used for diabetic microangiopathy: retinopathy and glomerulosclerosis (K-W syndrome). Patients with severe renal insufficiency who require dialysis should reduce the dose."
    },
    {
      "paragraph_id": "67",
      "paragraph": "2.探索中药和中西医结合治疗糖尿病肾病：中药抽提物(如大黄酸、雷公藤甲素等)及中成药(如复方血栓通胶囊、金水宝等)对降低尿白蛋白及改善肾功能有一定的疗效，目前正在积累更多循证医学的依据。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.探索中药和中西医结合治疗糖尿病肾病：中药抽提物(如大黄酸、雷公藤甲素等)及中成药(如复方血栓通胶囊、金水宝等)对降低尿白蛋白及改善肾功能有一定的疗效，目前正在积累更多循证医学的依据。",
          "start_idx": 0,
          "end_idx": 93,
          "entities": [
            {
              "entity_id": "T1423",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1424",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 18,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1425",
              "entity": "大黄酸",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Rhein"
            },
            {
              "entity_id": "T1426",
              "entity": "雷公藤甲素",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Triptolide"
            },
            {
              "entity_id": "T1427",
              "entity": "复方血栓通胶囊",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 51,
              "entity_en": "Fufang Xueshuantong Capsule"
            },
            {
              "entity_id": "T1428",
              "entity": "金水宝",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "Jinshuibao"
            },
            {
              "entity_id": "T1429",
              "entity": "尿白蛋白",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Urine albumin"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R723",
              "head_entity_id": "T1424",
              "tail_entity_id": "T1423"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R724",
              "head_entity_id": "T1426",
              "tail_entity_id": "T1423"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R725",
              "head_entity_id": "T1425",
              "tail_entity_id": "T1423"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R726",
              "head_entity_id": "T1427",
              "tail_entity_id": "T1423"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R727",
              "head_entity_id": "T1429",
              "tail_entity_id": "T1423"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R728",
              "head_entity_id": "T1428",
              "tail_entity_id": "T1423"
            }
          ],
          "sentence_en": "2. Explore the treatment of diabetic nephropathy with traditional Chinese medicine and the combination of traditional Chinese and Western medicine: Chinese herbal extracts (such as rhein, triptolide, etc.) and Chinese patent medicines (such as Compound Thrombolytic Capsules, Jinshuibao, etc.) have certain therapeutic effects on reducing urinary albumin and improving renal function, and more evidence-based medicine is currently being accumulated."
        }
      ],
      "paragraph_en": "2. Explore the treatment of diabetic nephropathy with traditional Chinese medicine and the combination of traditional Chinese and Western medicine: Chinese herbal extracts (such as rhein, triptolide, etc.) and Chinese patent medicines (such as Compound Thrombolytic Capsules, Jinshuibao, etc.) have certain therapeutic effects on reducing urinary albumin and improving renal function, and more evidence-based medicine is currently being accumulated."
    },
    {
      "paragraph_id": "68",
      "paragraph": "3.开发针对糖尿病肾病发病机制的药物：如抗AGE药物Pyridorin、抗纤维化类药物舒洛地昔，内皮受体拮抗剂阿曲生坦进入临床试验，但其应用尚缺乏经验。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.开发针对糖尿病肾病发病机制的药物：如抗AGE药物Pyridorin、抗纤维化类药物舒洛地昔，内皮受体拮抗剂阿曲生坦进入临床试验，但其应用尚缺乏经验。",
          "start_idx": 0,
          "end_idx": 76,
          "entities": [
            {
              "entity_id": "T1430",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T1431",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 10,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T1432",
              "entity": "抗AGE药物",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 26,
              "entity_en": "Anti-AGE drugs"
            },
            {
              "entity_id": "T1433",
              "entity": "Pyridorin",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 35,
              "entity_en": "Pyridorin"
            },
            {
              "entity_id": "T1434",
              "entity": "抗纤维化类药物",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 43,
              "entity_en": "Antifibrotic drugs"
            },
            {
              "entity_id": "T1435",
              "entity": "舒洛地昔",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Sulodex"
            },
            {
              "entity_id": "T1436",
              "entity": "内皮受体拮抗剂",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 55,
              "entity_en": "Endothelial receptor antagonists"
            },
            {
              "entity_id": "T1437",
              "entity": "阿曲生坦",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Atrasentan"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R729",
              "head_entity_id": "T1432",
              "tail_entity_id": "T1430"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R730",
              "head_entity_id": "T1433",
              "tail_entity_id": "T1430"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R731",
              "head_entity_id": "T1434",
              "tail_entity_id": "T1430"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R732",
              "head_entity_id": "T1435",
              "tail_entity_id": "T1430"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R733",
              "head_entity_id": "T1436",
              "tail_entity_id": "T1430"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R734",
              "head_entity_id": "T1437",
              "tail_entity_id": "T1430"
            }
          ],
          "sentence_en": "3. Develop drugs targeting the pathogenesis of diabetic nephropathy: For example, the anti-AGE drug Pyridorin, the anti-fibrosis drug Sulodexide, and the endothelial receptor antagonist Atrasentan have entered clinical trials, but there is still a lack of experience in their application."
        }
      ],
      "paragraph_en": "3. Develop drugs targeting the pathogenesis of diabetic nephropathy: For example, the anti-AGE drug Pyridorin, the anti-fibrosis drug Sulodexide, and the endothelial receptor antagonist Atrasentan have entered clinical trials, but there is still a lack of experience in their application."
    }
  ]
}